Page last updated: 2024-08-23

raloxifene hydrochloride and Breast Cancer

raloxifene hydrochloride has been researched along with Breast Cancer in 613 studies

Research

Studies (613)

Timeframe	Studies, this research(%)	All Research%
pre-1990	10 (1.63)	18.7374
1990's	72 (11.75)	18.2507
2000's	357 (58.24)	29.6817
2010's	142 (23.16)	24.3611
2020's	32 (5.22)	2.80

Authors

Authors	Studies
Bryant, HU; Cullinan, GJ; Glasebrook, AL; Hauser, KL; Muehl, BS; Palkowitz, AD; Pell, TR; Phillips, DL; Sato, M; Shetler, PK; Short, LL; Thrasher, KJ	1
Akileh, BM; AlHiary, AK; Bardaweel, SK; Dahabiyeh, LA; Dennis, JW; Pawling, J; Rahman, AMA; Shalabi, DD	1
Bender, SG; LaLonde, RL; Price, S; Till, NA; Varady, S; Yahn, R	1
Aljunidee, KA; Bardaweel, SK	1
Gong, S; Hong, K; Liang, JJ; Liu, TY; Qin, KM; Xie, BH; Yan, JJ; Yang, L; Yin, YP; Yu, WL; Zhou, HB	1
Choi, DY; Park, PH; Pham, DV; Tran, VT	1
Bychkovsky, B; Garber, JE; Hans, M; Katlin, F; King, TA; Knust Graichen, M; Laws, A; Pace, LE; Scheib, R	1
Bhatt, K; Jani, P; Patil, P; Sawant, K; Thakkar, P	1
Sinai Kunde, S; Wairkar, S	1
Castillo, AM; Couch, FJ; Jack, CR; Kantarci, K; Kara, F; Lesnick, TG; Lohse, CM; Mielke, MM; Olson, JE; Petersen, RC; Ruddy, KJ; Tosakulwong, N	1
Gandhi, S; Kavisri, M; Maddiboyina, B; Moovendhan, M; Nakkala, RK; Roy, H	1
Laws, A; Punglia, RS	1
Aeilts, A; Bordeleau, L; Cullinane, CA; Eisen, A; Eng, C; Foulkes, WD; Fruscio, R; Gronwald, J; Huzarski, T; Karlan, B; Kotsopoulos, J; Lubinski, J; Metcalfe, K; Narod, SA; Neuhausen, SL; Olopade, O; Pal, T; Randall Armel, S; Singer, CF; Sun, P; Tung, N	1
Madvar, RR; Taher, MA	1
Anderson, C; House, M; Nichols, HB; Sandler, DP	1
Fu, R; McDonagh, M; Nelson, HD; Pappas, M; Zakher, B	1
Barry, MJ; Cabana, M; Caughey, AB; Davidson, KW; Doubeni, CA; Epling, JW; Krist, AH; Kubik, M; Landefeld, CS; Mangione, CM; Owens, DK; Pbert, L; Silverstein, M; Tseng, CW; Wong, JB	1
Arevalo, M; Ball, S; Jones, C; Juarez, E; Payne, JD	1
DiNardo, D; Farkas, A; Merriam, S; Vanderberg, R	1
Bickerstaffe, A; Emery, JD; Hewabandu, N; McIntosh, JG; Minshall, J; Qama, A; Saya, S	1
De, A; Jawahar, N; Jubee, S; Reddy, ES	1
Heckman-Stoddard, BM; Miller, EA; Minasian, L; Pinsky, PF	1
Ahmed, OAA; Alhakamy, NA; Fahmy, UA	1
Fakolade, A; Fan, T	1
Baby, T; Bulbule, A; Gorain, M; Kundu, GC; Radharani, NNV; Roy, G; Shetti, D; Yadav, AS	1
Mohammadi, Z; Rahmani, S; Samadi, FY	1
Dorn, J; Drecoll, E; Frejno, M; Heinzlmeir, S; Helm, D; Hogrebe, A; Kleigrewe, K; Kuster, B; Kvasnicka, HM; Meng, C; Mergner, J; Oellerich, T; Ruprecht, B; Samaras, P; Scheich, S; Serve, H; Weichert, W; Wilhelm, M; Zecha, J	1
Shieh, Y; Tice, JA	1
DiNome, ML; Ganz, PA; Graham, D	1
Kohli, K; Mangla, B; Neupane, YR; Singh, A; Sonali, LJ; Soni, NK	1
Dietze, EC; Jones, VC; Jovanovic-Talisman, T; McCune, JS; Seewaldt, VL	1
Alves, KBF; Araujo-Neto, JT; Carneiro, ALB; Dardes, RCM; Haidar, MA; Souza, FA; Spadella, APC	1
Bowles, EJA; Ehrlich, K; Farrell, D; Gao, H; Graham, AL; Jayasekera, J; Knerr, S; Leppig, K; Li, T; Luta, G; Mandelblatt, JS; O'Neill, SC; Schwartz, MD; Wernli, KJ	1
Ahmed, OAA; Aldawsari, HM; Alhakamy, NA; Badr-Eldin, SM; Fahmy, UA; Neamatallah, T; Okbazghi, SZ	1
Gilman, EA; Hofstatter, EW; Mussallem, DM; Pruthi, S	1
Jain, A; Katare, OP; Kumar, R; Sharma, T; Singh, B	1
Pinkerton, JV	1
Aragaki, AK; Chlebowski, RT; Pan, K	1
Jordan, VC	24
Brovkovych, SD; Frasor, J; Kastrati, I; Siklos, MI; Thatcher, GRJ	1
Crew, KD	1
Bonanni, B; Caviglia, S; Costa, A; DeCensi, A; Fontana, V; Noonan, S; Pasa, A; Peccatori, F; Smith, SG	1
Boche, M; Kanade, R; Pokharkar, V	1
Kalam, A; Leekha, A; Talegaonkar, S; Verma, AK; Vohora, D	1
Evans, DG; Howell, A; Howell, SJ	2
Heckman-Stoddard, B; Miller, E; Minasian, L; Pinsky, PF	1
Curtis, HJ; Goldacre, B; Walker, AJ	1
Khazaei, M; Khazaei, MR; Mirzapur, P; Moradi, MT	1
Enteshari, S; Hashemi-Beni, B; Hassanzadeh, F; Minaiyan, M; Sadeghian-Rizi, S; Varshosaz, J	1
Brown, M; Buchwalter, G; Carlson, KE; Chandarlapaty, S; Dharmarajan, V; Fanning, SW; Fowler, CE; Greene, GL; Griffin, PR; Han, R; Hosfield, DJ; Houtman, R; Jeselsohn, R; Karimi, M; Katzenellenbogen, JA; Lainé, M; Martin, TA; Mayne, CG; Nettles, KW; Nowak, J; Nwachukwu, JC; Shen, Y; Tajkhorshid, E; Toy, W	1
Rajput, SJ; Shah, P	1
Conner, EA; Pinkerton, JV	1
D'Amelio, P; Isaia, GC	1
Burge, R; Chu, BC; Curkendall, S; Diakun, DR; Foster, SA; Krege, JH; Shi, N; Stock, J	1
Fu, R; Griffin, JC; Nelson, HD; Smith, ME	1
McCarthy, M	1
Molloy, ME; Perez White, B; Tonetti, DA; Zhang, Y; Zhao, H	1
Ingle, JN	1
Jones, NR; Lazarus, P; Manni, A; Sun, D	1
Ames, MM; Batzler, A; Carlson, EE; Costantino, JP; Flockhart, DA; Goetz, MP; Ingle, JN; Jenkins, GD; Kubo, M; Liu, M; Mushiroda, T; Nakamura, Y; Paik, S; Schaid, DJ; Vogel, VG; Wang, L; Weinshilboum, RM; Wickerham, DL; Wolmark, N	1
Bassi, F; Bonanni, B; Brenelli, F; Cazzaniga, M; DeCensi, A; Feroce, I; Gandini, S; Gjerde, J; Guerrieri-Gonzaga, A; Johansson, H; Lazzeroni, M; Lien, E; Luini, A; Macis, D; Pruneri, G; Sandri, M; Serrano, D; Varricchio, C	1
Wise, J	1
Ancona, E; Berretta, R; Bertocco, A; Capobianco, G; D'Antona, D; Di Gangi, S; Gizzo, S; Nardelli, GB; Noventa, M; Patrelli, TS; Saccardi, C; Vacilotto, A	1
Alford, SH; Fagerlin, A; Fuhrel-Forbis, A; Greene, SM; Korfage, IJ; McClure, JB; Smith, DM; Ubel, PA; Zikmund-Fisher, BJ	1
Moyer, VA	1
Atkinson, HH; Bandos, H; Costantino, JP; Espeland, MA; Geiger, AM; Klepin, HD; Lawrence, JA; Rapp, SR; Sink, KM	1
Pinkerton, JV; Thomas, S	1
Bisson, WH; Jang, HS; Koch, DC; Kolluri, SK; O'Donnell, EF	1
Chlebowski, RT	4
Carly, B; Guzy, L; Kang, X; Liebens, F; Lienart, V; Sajovitz, AM	1
Craig Jordan, V; Fan, P	1
Beck, RC; Beckenkamp, A; Buffon, A; Fontana, MC	1
Arsenyan, P; Domracheva, I; Gulbe, A; Kanepe-Lapsa, I; Paegle, E; Shestakova, I	1
DeRoo, LA; Nichols, HB; Sandler, DP; Scharf, DR	1
D'Antona, D; Di Gangi, S; Gizzo, S; Litta, P; Nardelli, GB; Noventa, M; Saccardi, C	1
Cho, DH; Choi, EK; Hwang, JJ; Jeong, SY; Kim, CS; Kim, DE; Kim, SB; Kim, Y; Koh, JY; Lee, JS; Suh, N	1
Carlson, EE; Couch, FJ; Goetz, MP; Ingle, JN; Kubo, M; Mushiroda, T; Nakamura, Y; Paik, S; Schaid, DJ; Vachon, CM; Wang, L; Weinshilboum, R; Wickerham, DL; Wolmark, N	1
Gail, MH	1
Bevers, TB	4
Chen, G; Gufford, BT; Lazarus, P; Oberlies, NH; Paine, MF; Vergara, AG	1
Daly, M; Holmberg, C; McCaskill-Stevens, W; Waters, EA; Whitehouse, K	1
Daly, M; Holmberg, C; McCaskill-Stevens, W; Whitehouse, K	1
Biglia, N; Bounous, VE; D'Alonzo, M; Pecchio, S; Robba, E; Sismondi, P	1
Cygankiewicz, AI; Jacenik, D; Krajewska, WM	1
Komm, BS; Pickar, JH	1
Bidinotto, LT; El-Bayoumy, K; Manni, A; Russo, J; Santucci-Pereira, J; Skibinski, CG; Thompson, HJ	1
Prossnitz, ER; Zekas, E	1
Fan, W; Jiang, D; Lei, J; Wang, S; Xu, L; Zhou, L	1
Briarava, M; Mocellin, S; Nitti, D; Pilati, P	1
Cuzick, J; Forster, A; Horne, R; Partridge, A; Sestak, I; Side, L; Smith, SG; Wardle, J; Wolf, MS	1
Larsen, L; Nimick, M; Rosengren, RJ; Taurin, S	1
Peek, GW; Tollefsbol, TO	1
Aliaga, C; Calcagnotto, A; Demers, LM; DuBrock, C; El-Bayoumy, K; Hamilton, C; Hartman, TJ; Liao, J; Manni, A; McGinley, J; Prokopczyk, B; Richie, JP; Sandhu, N; Schetter, SE; Signori, C; Thompson, HJ; Trushin, N	1
Ağardan, NB; Altıntaş, L; Değim, Z; Topal, T; Yılmaz, Ş	1
Dou, J; Li, F; Li, S; Liu, J; Wei, L	1
Callet, N; Fourme, E; Noguès, C; Reyal, F; Sénéchal, C; Stoppa-Lyonnet, D; This, P	1
Fagerlin, A; Hoerger, M; Scherer, LD	1
Elkhoely, AA; Kabel, AM	1
Flamini, MI; Neira, FJ; Sanchez, AM; Shortrede, JE; Uzair, ID	1
Demizu, Y; Fujisato, T; Inoue, H; Kato, M; Kurihara, M; Misawa, T; Naito, M; Shoda, T	1
Basile, I; Gallud, A; Garcia, M; Gary-Bobo, M; Maynadier, M	1
Cuzick, J; Horne, R; Meisel, SF; Side, L; Smith, SG; Wardle, J	1
Lemmo, W	1
Burns, RB; Libman, H; Schonberg, MA; Tung, NM	1
Olver, IN	1
Marsden, J	1
Aliaga, C; Calcagnotto, A; El-Bayoumy, K; Manni, A; Richie, JP; Schetter, SE; Trushin, N	1
Casa, AJ; Cui, X; Dearth, RK; Lee, AV; Litzenburger, BC	1
Chao, HT; Cheng, MH; Lee, WL; Wang, PH	2
Barrett-Connor, E; Cauley, JA; Collins, P; Geiger, MJ; Grady, D; Kornitzer, M; Mershon, J; Mosca, L; Song, J; Wenger, NK	1
Vogel, VG	5
Chow, CK; Eng-Wong, J; Galbo, CE; Orzano-Birgani, J; Prindiville, S; Venzon, D; Yao, J; Zujewski, JA	1
Ohta, H	1
Powles, TJ	5
Keating, GM; Moen, MD	1
Flamini, MI; Fu, XD; Garibaldi, S; Genazzani, AR; Giretti, MS; Goglia, L; Pisaneschi, S; Sanchez, AM; Simoncini, T; Tosi, V	1
Das, GM; Hsu, HC; John, S; Liu, W; Nayvelt, I; Thomas, T; Thomas, TJ; Yang, P	1
Chao, HT; Wang, PH	2
Alencar, AP; da Silva, BB; de Castro-Leão, AH; dos Santos, AR; Lopes-Costa, PV; Pires, CG	1
Howell, A	1
Kolesar, JM; Thomsen, A	1
Hoshi, SL; Kondo, M; Toi, M	2
Furtado-Veloso, AM; Lopes, IM; Lopes-Costa, PV; Santos, LG; Silva, BB	1
Brewster, DH; Clark, DI; Collins, J; Sharpe, KH	1
Cecchini, RS; Costantino, JP; Cronin, WM; Ford, LG; Vogel, VG; Wickerham, DL; Wolmark, N	1
Bauer, S; Browner, WS; Cummings, SR; Cuzick, J; Kerlikowske, K; Shepherd, J; Smith-Bindman, R; Tice, JA; Vachon, C; Vogel, V; Ziv, E	1
Mershon, JL; Mitchell, B; Qu, Y; Vogel, VG; Wong, M	1
Cutuli, B; Kerbrat, P; Lesur, A; Namer, M	1
Arun, B; Brown, P; Chlebowski, RT; Col, NF; Collyar, D; Cuzick, J; Garber, J; Hagerty, K; Hurley, P; Kramer, BS; Lippman, SM; Morrow, M; Pritchard, KI; Ropka, M; Runowicz, C; Visvanathan, K; Vogel, VG; Wade, JL	1
Jordan, VC; Peng, J; Sengupta, S	1
Barrett-Connor, E; Cox, DA; Grady, D; Mitlak, B; Mosca, L; Song, J	1
Bachleitner-Hofmann, T; Blaha, P; Dubsky, P; Fitzal, F; Gnant, M; Jakesz, R; Steger, G	1
Temin, S	1
Bevers, TB; Coker, L; Hogan, P; Legault, C; Maki, PM; Resnick, SM; Shumaker, SA	1
Decensi, A; Puntoni, M	1
Bodine, PV; Chang, KC; Komm, BS; Nagpal, S; Wang, Y	1
Ariazi, EA; Jordan, VC; Kim, H; Lewis-Wambi, JS; Patel, RR	1
Fu, R; Griffin, JC; Humphrey, L; Nelson, HD; Nygren, P; Smith, ME	1
Barad, DH; Bevers, TB; Coker, LH; Espeland, MA; Gaussoin, SA; Lane, DS; Limacher, M; Maki, PM; Rapp, SR; Resnick, SM; Shumaker, SA; Stefanick, ML	1
Becker, C	1
Inoue, D	1
Braverman, AS	1
Hooks, MA	1
Nattinger, AB	1
Kaufmann, Y; Klimberg, VS; Luo, S; Todorova, VK	1
Atkins, JN; Bevers, TB; Cecchini, RS; Costantino, JP; Cronin, WM; Fehrenbacher, L; Ford, LG; Ganz, PA; James, J; Jordan, VC; Margolese, RG; McCaskill-Stevens, W; Pajon, ER; Reis, SE; Robidoux, A; Runowicz, CD; Vogel, VG; Wade, JL; Wickerham, DL; Wolmark, N	1
Moore, CD; Reilly, CA; Yost, GS	1
da Silva, BB; dos Santos, AR; dos Santos, LG; Lopes-Costa, PV	1
Castle, PE	1
Brown, PH; Hortobagyi, GN	1
Ravdin, PM	1
Cuzick, J	5
Boudot, A; Flouriot, G; Habauzit, D; Kerdivel, G; Pakdel, F	1
Jarvis, RM; Rosengren, RJ; Stuart, EC	1
Borgström, F; Burge, RT; Ivergård, M; Kanis, J; Ström, O; Tosteson, AN	1
Foster, SA; Kar, R; Mershon, JL; Mitchell, B; Muram, D; Vedarajan, G; Whangbo, A	1
Kane, RL; Shamilyan, T; Tuttle, TM; Virnig, BA; Wang, SY	1
Clarfeld, RB; Costantino, JP; Grant, MD; McCaskill-Stevens, W; Vogel, VG; Wickerham, DL; Wolmark, N	1
Akamatsu, K; Kurose, H; Kusakabe, M; Li, ZL; Morimoto, J; Ohmichi, M; Otsuki, Y; Shibata, E; Shibata, MA	1
Schmidt, C	2
Archer, DF	1
Axelrod, D; Kleinberg, D; Singh, B; Smith, J	1
Jordan, VC; Ko, SS	1
Cheong, SJ; Jang, D; Jeong, HJ; Katzenellenbogen, JA; Kim, DW; Lim, ST; Sohn, MH	1
Clarke, BL; Khosla, S	1
Arun, B; Brown, PH; Castiglione, M; Cuzick, J; DeCensi, A; Dunn, B; Forbes, JF; Glaus, A; Howell, A; Vogel, V; von Minckwitz, G; Zwierzina, H	1
Alford, SH; Dillard, AJ; Fagerlin, A; Greene, S; Hayes, DF; McClure, JB; Nair, V; Pitsch, R; Smith, DM; Ubel, PA; Wiese, C; Zikmund-Fisher, BJ	1
Nelson, NJ	2
Anderson, GL; Costantino, JP; Freedman, AN; Gail, MH; Graubard, BI; McCaskill-Stevens, W; Vogel, VG; Yu, B	1
Amir, E; Goodwin, PJ	1
da Silva, BB; Lima, MA	1
Bergamaschi, A; Katzenellenbogen, BS	1
da Silva, BB; dos Santos, LG	1
Azambuja, E; Bozovic-Spasojevic, I; Cardoso, F; Dinh, P; McCaskill-Stevens, W	1
Cecchini, RS; Costantino, JP; Cronin, WM; Ford, LG; Runowicz, CD; Vogel, VG; Wickerham, DL; Wolmark, N	1
Ames, MM; Batzler, A; Carlson, EE; Costantino, JP; Flockhart, DA; Goetz, MP; Ingle, JN; Kubo, M; Mushiroda, T; Nakamura, Y; Paik, S; Safgren, S; Schaid, DJ; Vogel, VG; Weinshilboum, RM; Wickerham, DL; Wolmark, N	1
Creasman, WT	1
Costantino, JP; Goss, PE; Ingle, JN; Jenkins, GD; Kubo, M; McDonnell, SK; Schaid, DJ; Sinnwell, JP; Weinshilboum, RM; Wickerham, DL	1
Gabriel, EM; Jatoi, I	1
Cauley, JA; Cecchini, RS; Costantino, JP; Cronin, WM; Land, SR; Weissfeld, JL; Wickerham, DL; Wolmark, N	1
Imachi, H; Masugata, H; Miyai, Y; Murao, K; Nishiuchi, T; Yu, X	1
Achilefu, S; Akers, W; Gu, Y; Li, H; Ma, Y; Tang, B; Tian, J; Tu, Z	1
Freedman, AN; McNeel, TS; Stevens, WM; Waters, EA	1
Demers, LM; DuBrock, C; El-Bayoumy, K; Hamilton, C; Hartman, TJ; Liao, J; Manni, A; Prokopczyk, B; Richie, JP; Signori, C	1
Birkhäuser, M; Buchard, PA; De Geyter, C; Imthurn, B; Lamy, O; Lippuner, K; Litschgi, M; Luzuy, F; Schiessl, K; Stute, P	1
Eyster, KM; Hansen, KA	1
Hadji, P	1
Kolesar, JM; Simondsen, K; Zhang, Y	1
Ali, S; Barrett, AG; Buluwela, L; Coombes, RC; Hu, H; Kyle, F; Lai, CF; Ortlund, EA; Rey, J; Snyder, JP	1
Cuzick, J; Sestak, I	1
Bandos, H; Cauley, JA; Cecchini, RS; Costantino, JP; Cronin, WM; Weissfeld, JL; Wickerham, DL; Wolmark, N	1
Belli, AK; Buckley, JM; Coopey, SB; Gadd, MA; Garber, JE; Guidi, AJ; Hughes, KS; Kim, EM; Mazzola, E; Parmigiani, G; Polubriaginof, F; Roche, CA; Sharko, J; Smith, BL; Specht, MC	1
Avis, NE; Bandos, H; Coker, LH; Costantino, J; Danhauer, SC; Kidwell, K; Legault, C; Naughton, M; Naylor, C; Rapp, S; Shumaker, S; Terracciano, A; Vaughan, L	1
Cook, ED; Edwards, CL; Figueroa-Moseley, CD; Gibson, RV; McCaskill-Stevens, W; McElwain, DL; Paskett, ED; Roberson, NL; Wickerham, DL; Wilson, JW; Wolmark, N	1
Ingle, JN; Jenkins, GD; Schaid, DJ; Weinshilboum, RM	1
Banegas, MP; Barlow, WE; Fagerlin, A; Greene, SM; McClure, JB; Smith, DM; Ubel, PA; Zikmund-Fisher, BJ	1
Jordan, VC; Pappas, SG	2
Bradbury, J	2
Gnatuk, CL	1
Gluck, O; Maricic, M	3
Costantino, JP; Cronin, WM; Vogel, VG; Wickerham, DL; Wolmark, N	1
Chan, S	1
Burstein, HJ; Chlebowski, RT; Col, N; Collyar, DE; Cummings, SR; Eisen, A; Lipkus, I; Pfister, DG; Vogel, VG; Winer, EP	1
Nagykálnai, T	1
Brown, HA; Eisen, SF	1
Carley, W; Chen, J; Katti, S; Mader, MM; Marrero, D; Moehler, U; Muegge, I; Smith, RA; Stirtan, WG; Weaver, DR; Xiao, H	1
Cox, DA; Hurn, PD; Littleton-Kearney, MT; Ostrowski, NL; Rossberg, MI	1
Lopes, P; Trémollières, F	1
Hindle, WH	1
Wickerham, DL	1
Kelminski, A	1
Anderson, PW; Barrett-Connor, E; Baygani, SK; Collins, P; Grady, D; Kornitzer, M; Mosca, L; Moscarelli, E; Sashegyi, A; Wenger, NK	1
Chlebowski, RT; McTiernan, A	1
Menikoff, J	1
Rollins, G	1
Costantino, JP; Cronin, WM; Vogel, VG; Wickerham, DL	1
Ashley, S; Boyle, P; Cuzick, J; Edwards, R; Forbes, J; Powles, T; Veronesi, U	1
Hartmann, LC; Riggs, BL	1
Blackwood, A; Calzone, K; Domchek, SM; Eisen, A; Stopfer, J; Weber, BL	1
Runowicz, CD	1
Bianco, NR; Montano, MM; Perry, G; Smith, MA; Templeton, DJ	1
Kahán, Z; Thurzó, L	1
Berg, AO	1
Fabris, V; Helguero, LA; Lamb, CA; Lanari, C; Lucas, C; Molinolo, AA	1
Mortimer, JE; Urban, JH	1
Bentrem, DJ; Jordan, VC	3
Dijkstra, B; Hill, AD; McDermott, EW; O'Higgins, NJ; Prichard, RS	1
Kafka, A; Kreienberg, R	1
Höffken, K; Sayer, HG	1
Bergh, J	1
Du, B; Igarashi, H; Inoue, M; Kawagoe, J; Kimura, A; Kurachi, H; Kyo, S; Mabuchi, S; Mori-Abe, A; Ohmichi, M; Ohshima, C; Ohta, T; Saitoh, M; Takahashi, K; Takahashi, T	1
Ettinger, B; Grove, MR; Hammond, CS; Hebert, GM; Moncur, MM; Pressman, AR; Ray, GT; Tosteson, AN	1
Eckhardt, S	1
Goss, PE; Strassmer-Weippl, K	1
Hayes, DF	1
Chen, B; De Los Reyes, A; Gajdos, C; Jordan, VC; Lee, ES; Liu, H; Loweth, J; McKian, K; Osipo, C; Pearce, ST; Wing, L	1
Smith, RE	1
Bonanni, B; Cazzaniga, M; Decensi, A; Galli, A; Gonzaga, AG; Serrano, D	1
Lo, SS; Vogel, VG	1
Oh, AS; Reiter, R; Riegel, AT; Wellstein, A	1
Eng-Wong, J; Hursting, SD; Perkins, SN; Venzon, D; Zujewski, JA	1
Guyot, B; This, P	1
Kammerer, S	1
Beckmann, MW; Bender, HG; Dall, P; Djahansouzi, S; Hanstein, B	1
Costa, A; Decensi, A; Perego, E; Serrano, D	1
Ricart, JJ	1
Itabashi, A	2
Bryant, K; Costantino, J; Martino, S; McNabb, M; Mershon, J; Powles, T; Secrest, RJ	1
Frasor, J; Katzenellenbogen, BS	1
Balaguer, P; Bonnet, S; Cavaillès, V; Duong, V; Escande, A; Margueron, R; Vignon, F	1
Balasenthil, S; Mishra, SK; Nguyen, D; Vadlamudi, RK	1
Chee, YC	1
Barrett-Connor, E; Cauley, JA; Cox, DA; Geiger, MJ; Kulkarni, PM; Sashegyi, A	1
Bolton, JL; Li, W; Liu, H; Luckie, C; Thatcher, GR; van Breemen, RB; Yu, L; Zhang, F	1
Bryant, HU; Dowsett, SA; Mershon, J; Sporn, MB	1
Eng-Wong, J; Zujewski, JA	1
Sporn, MB	2
Delmas, PD; Kulkarni, PM; Plouffe, L; Silverman, SL; Stock, JL; Wong, M	1
Cauley, JA; Johnell, O; Kulkarni, PM; Stock, JL; Wong, M	1
Hussain, SA; Rea, DW; Stevens, A; Williams, S	1
Brown, P; Hilsenbeck, S; Kalidas, M	1
Barrett-Connor, E; Cauley, JA; Cummings, SR; Disch, D; Martino, S; Mershon, J; Powles, TJ; Secrest, RJ	1
Nozaki, M	1
Kurebayashi, J	1
Higuchi, T; Mizunuma, H	1
Shintani, M	1
Dosik, M; Kaufman, R	1
Borgström, F; Johnell, O; Jönsson, B; Kanis, JA; Oden, A; Sykes, D	2
Dunn, BK; Ford, LG; Wickerham, DL	1
Boisserie-Lacroix, M; Boutet, G; Trillaud, H	1
Hamaya, E; Kobayashi, H	1
Fabian, CJ; Kimler, BF	2
Surowiak, P; Zabel, M; Zasławski, R	1
Urano, T	2
Altan, M; Buyukcelik, A; Dogan, M; Doruk, H; Utkan, G; Yalcin, B; Yalcin, S	1
Aknin, C; Chalbos, D; Freiss, G; Galtier, F; Maudelonde, T; Puech, C; Vignon, F	1
Johansen, AM	1
Chen, B; Dardes, R; Dowsett, M; Gajdos, C; Johnston, SR; Jordan, VC; Kidwai, N	1
Cummings, SR; Diez-Perez, A; Eastell, R; Goemaere, S; Harris, ST; Kulkarni, PM; Qu, Y; Siddhanti, SR; Siris, ES; Song, J; Stock, JL; Wong, M; Zanchetta, JR	1
da Silva, BB; Gebrim, LH; Lopes, IM	1
Altschuler, A; Somkin, CP	1
Ariazi, EA; Glidewell-Kenney, C; Ishikawa, T; Jameson, JL; Lee, EJ; Pillai, S; Weiss, J	1
Teppa Garrán, AD; Terán Dávila, J	1
Ettinger, B; Fehrenbacher, L; Habel, LA; Pressman, A; Quesenberry, CP; Sidney, S; Suh-Burgmann, B	1
Franke, HR; Vermes, I; Werner, HM	1
Des Jarlais, G; Gregorich, SE; Haas, JS; Kaplan, CP; Kerlikowske, K; Pérez-Stable, EJ; Somkin, C	1
Barrett-Connor, E; Cox, DA; Dowsett, SA; Ensrud, K; Geiger, MJ; Genazzani, AR; McNabb, M	1
Leitão, A; Menezes, IR; Montanari, CA	1
Dodwell, D; Johnston, S; Wardley, A	1
Cuzick, J; Dixon, JM; Houssami, N	1
Baglietto, L; Bonanni, B; Cazzaniga, M; Decensi, A; Guerrieri-Gonzaga, A; Johansson, H; Luini, A; Mariette, F; Pelosi, G; Sandri, MT	1
Boscaro, M; Francucci, CM; Romagni, P	1
Cyrus-David, MS	1
Ariazi, E; Bertucci, A; Grigg, R; Jordan, VC; Lee, ES; Meeke, K; Morris, C; O'Regan, RM; Osipo, C; Sarker, MA	1
O'Regan, RM	2
Clarke, R; Dai, P; Lou, MA; Lu, JF; Nazarov, V; Wong, LJ	1
Gorman, C	1
Audran, M; Chappard, D; Hoppé, E; Legrand, E	1
Cella, D; Gradishar, WJ	1
Atkins, JN; Bevers, TB; Cecchini, RS; Costantino, JP; Cronin, WM; Fehrenbacher, L; Ford, LG; Ganz, PA; James, J; Jordan, VC; Lippman, SM; Margolese, RG; McCaskill-Stevens, W; Pajon, ER; Reis, SE; Robidoux, A; Runowicz, CD; Vogel, VG; Wade, JL; Wickerham, DL; Wolmark, N	1
Costantino, JP; Dakhil, S; Ganz, PA; Land, SR; Lee, M; Lockhart, JB; Pajon, ER; Ritter, MW; Vogel, VG; Wade, JL; Wickerham, DL; Wolmark, N	1
Vastag, B	1
Eng-Wong, J; Faupel-Badger, JM; Prindiville, SA; Venzon, D; Vonderhaar, BK; Zujewski, JA	1
Knox, AS; Lloyd, DG; Meegan, MJ; O'Sullivan, T; Smith, HM; Zisterer, DM	1
Barrett-Connor, E; Collins, P; Geiger, MJ; Grady, D; Kornitzer, M; McNabb, MA; Mosca, L; Wenger, NK	1
Stefanick, ML	1
Chow, C; Danforth, D; Eng-Wong, J; Gantz, S; Liewehr, D; Liu, ET; Reynolds, JC; Venzon, D; Zujewski, J	1
Cauley, JA; Cummings, SR; Disch, DP; Dowsett, SA; Lippman, ME; Martino, S; Mershon, JL	1
Matsumoto, T	1
Narod, SA	1
Pines, A	1
Fourchotte, V; Wickerham, DL	1
Draper, MW	1
Archer, DF; Mirkin, S; Wong, BC	1
Lippman, SM	1
Johnson, KA	1
Cauley, JA; Cummings, SR; Dowsett, SA; Mershon, JL; Song, J	1
Bean, GR; Kimler, BF; Seewaldt, VL	1
Szabo, E	1
Brown, PH; Uray, IP	1
Diez-Perez, A	1
Wenger, NK	1
Jordan, VC; Morrow, M	3
Goldstein, SR	5
Brce, J; Doyle, N; Ho, KK; Lee, HJ; Leong, GM; Leung, KC; Sjögren, K	1
Marzo Castillejo, M	1
Cummings, SR	1
Altobelli, G; Biglia, N; Cicatiello, L; Cimino, D; De Bortoli, M; Friard, O; Fuso, L; Ponzone, R; Ravo, M; Scafoglio, C; Sismondi, P; Weisz, A	1
Dunn, BK; Ford, LG	1
Johnston, JA; Klein, R; Meadows, ES; Ohsfeldt, RL; Rousculp, MD; Smolen, L	1
Jordan, VC; Sharma, CG; Swaby, RF	1
Chen, WY; Colditz, GA; Rosner, B	1
Cooperwood, JS; Khan, MO; Musa, MA	1
Armstrong, K; Micco, E; Tjia, J	1
Col, NF; Matloff, ET; Moyer, A; Shannon, KM	1
Mead, MN	1
Aumiller, J	1
Rubinstein, WS	1
Labrie, F	1
Avila, N; Eng-Wong, J; Forman, MR; Johnson, DV; Premkumar, A; Remaley, AT; Stratton, P; Venzon, DJ; Zujewski, J	1
Taguchi, T	1
Asaga, S; Jinno, H; Kitajima, M; Sakata, M	1
Wadman, M	1
Young, D	1
Sakemi, H	1
Bolton, JL; Dietz, BM; Dunlap, T; Kastrati, I; Lantvit, DD; Overk, CR; Qin, Z; Thatcher, GR; Yao, P; Yu, B	1
Schagen, SB; Schilder, CM	1
Asnis, A; Borgen, P; Dang, C; Dickler, MN; Duncan, BA; Heerdt, A; Hudis, C; Lake, D; Moasser, M; Norton, L; Panageas, K; Poggesi, I; Robson, M; Traina, TA	1
González Macías, J; Olmos Martínez, JM	1
Fabian, C	1
Anderson, GL; Bernstein, L; Bondy, M; Costantino, JP; Gail, MH; Malone, KE; Marchbanks, PA; McCaskill-Stevens, W; Newman, L; Norman, SA; Pee, D; Selvan, M; Simon, MS; Spirtas, R; Ursin, G	1
Takeuchi, Y	1
Mizunuma, H	1
Okano, H	1
Laxmi, YR; Liu, X; Okamoto, K; Okamoto, Y; Sekimoto, M; Shibutani, S; Suzuki, N	1
Ainsworth, P; Birenbaum-Carmeli, D; Couch, F; Domchek, S; Foulkes, WD; Friedman, E; Ghadirian, P; Gronwald, J; Kim-Sing, C; Klijn, J; Lubinski, J; Lynch, H; Manoukian, S; Metcalfe, KA; Moller, P; Narod, SA; Rosen, B; Sun, P; Tung, N; Wagner, T	1
Burshell, AL; Cauley, JA; Delmas, PD; Dowsett, SA; Mershon, JL; Secrest, RJ; Song, J	1
Reeder, JG; Vogel, VG	1
Castrellon, AB; Glück, S	1
Yin, CS	1
Gennari, L; Merlotti, D; Nuti, R; Paola, VD	1
Brentani, MM; Nagai, MA	1
Hansdóttir, H	1
Green, LR; Newboult, E; Valcaccia, B; Wakeling, AE	1
Bryant, HU; Cole, HW; Draper, MW; Fuchs-Young, R; Glasebrook, AL; Magee, DE; Rippy, MK; Short, LL; Termine, JD	1
Jiang, SY; Jordan, VC; Parker, CJ	1
Ziegler, J	1
Howlett, AC; Ruh, MF; Taylor, JA; Welshons, WV	1
Adrian, MD; Bryant, HU; Cho, S; Cole, HW; Finley, DR; Glasebrook, AL; Godfrey, AG; Grese, TA; Jones, CD; Lugar, CW; Magee, DE; Martin, MJ; Matsumoto, K; Pennington, LD; Phillips, DL; Rowley, ER; Short, LL; Winter, MA	1
Smigel, K	1
Bélanger, A; Caron, B; Cloutier, J; Dory, YL; Favre, A; Gauthier, S; Labrie, C; Labrie, F; Larouche, D; Leblanc, G; Mailhot, J; Martel, C; Mérand, Y; Ouellet, C; Schwerdtfeger, A; Simard, J	1
Catherino, WH; Jordan, VC; Levenson, AS	1
Gustafsson, J; Kuiper, GG; Kushner, PJ; Nilsson, S; Paech, K; Scanlan, TS; Webb, P	1
Bryant, HU; Cho, S; Dodge, JA; Frolik, CA; Glasebrook, AL; Lugar, CW; Martin, MJ; Osborne, JJ; Phillips, DL; Sato, M; Short, LL; Spangle, LA; Yang, NN	1
Adler, S; Sadovsky, Y	1
Jordan, VC; Kwaan, HC; Levenson, AS; Svoboda, KM	1
Jordan, VC; Levenson, AS	2
Baynes, KC; Compston, JE	1
Dove, A	1
Gibbs, WW	1
Davidson, NE; Hahm, HA; Nass, SJ	1
McNeil, C	1
Reynolds, T	1
Overmoyer, BA	1
Gradishar, WJ; Jordan, VC; Morrow, M; Pierce, LJ; Takei, H	1
Kardinal, CG; Veith, R	1
Bjarnason, NH; Black, D; Cauley, JA; Costa, A; Cummings, SR; Eckert, S; Glusman, JE; Grady, D; Jordan, VC; Krueger, KA; Lippman, ME; Morrow, M; Nickelsen, T; Norton, L; Powles, TJ	1
Col, NF; Eckman, MH; Goldberg, RJ; Orr, RK; Pauker, SG; Ross, EM; Wong, JB	1
Stephenson, J	1
Kuter, I	1
Hart, W; Netelenbos, JC	1
Mattimoe, D; Newton, W	1
Apgar, B	1
Christiansen, C	1
Feinberg, AW	1
Zurlinden, J	1
Gardner, N	1
Brown, PH; Lippman, SM	2
Evans, A; Healy, D; Vollenhoven, B	1
Lush, DT	1
Chlebowski, RT; Collyar, DE; Pfister, DG; Somerfield, MR	1
Christensen, DJ; Fowlkes, DM; McDonnell, DP; Nagel, SC; Norris, JD; Paige, LA; Wijayaratne, AL	1
Eppes, PG; Wilson, CT; Wozniak, TF	1
Arnaud, CD; Chiu, KM; Roe, EB	1
Burckhardt, P	1
Gaspard, UJ; Kalbus, MF; van den Brûle, FA	1
Cockcroft, N; Dahllund, J; Härkönen, P; Hemminki, K; Kangas, L; Koskinen, M; Laine, A; Peng, Z; Qu, Q; Väänänen, K; Zheng, H	1
Han, RK; Heisey, R; Pimlott, N	1
Minton, SE	1
Miller, JL	1
Jurida, N; Pávó, I; Szúcs, J	1
Cefalu, CA	1
Body, JJ; Sternon, J	1
Carolin, KA; Pass, HA	1
Aba, F; Beckmann, MW; Bender, HG; Jap, D; Kuschel, B; Lux, M	1
Boersma, CJ; Dijkema, R; Mosselman, S; Mulder, WR; Olijve, W; van den Wijngaard, A; van Zoelen, EJ	1
Cohen, FJ; Glusman, J; Gradishar, W; Lu, Y; Sledge, GW; Vogel, C	1
Funahashi, H	2
Chow, MS; Reddy, P	1
Mincey, BA; Moraghan, TJ; Perez, EA	1
Eriksen, EF	1
Muchmore, DB	1
Fisher, PW; Gowen, M; Nuttall, ME; Suva, LJ	1
Ambroggio, S; Biglia, N; Cozzarella, M; Ponzone, R; Roagna, R; Sgro, L; Sismondi, P	1
Yardley, DA	1
Birkhäuser, MH	1
Anchim, T; Dabrowska, M; Dziecioł, J; Swiatecka, J; Wołczyński, S	1
Terakawa, N	1
Osborne, MP; Rosenbaum Smith, SM	1
Hartmann, LC; Perez, EA; Rhodes, DJ	1
Eckert, S; Freedman, M; Lippman, ME; Lo, SC; O'Gorman, J; San Martin, J; Walls, EL; Zeng, J	1
Mamounas, EP	1
Fackenthal, JD; Olopade, MD; Olufunmilayo, I	1
Dalton, RR; Kallab, AM	1
Jordan, VC; O'Regan, RM	2
Ben-Rafael, Z; Kaplan, B; Nahum, R	1
Feigelson, HS; Henderson, BE	1
Fabian, CJ	1
Dardes, RC; Jordan, VC	1
Cauley, JA; Costa, A; Eckert, S; Farrerons, J; Jordan, VC; Karasik, A; Krueger, KA; Lippman, ME; Mellstrom, D; Morrow, M; Muchmore, DB; Ng, KW; Norton, L; Powles, TJ; Purdie, DW; Schmitt, H; Silfen, SL; Ste-Marie, LG; Stepan, JJ; Walls, EL	1
Moore, HC	1
Leris, C; Mokbel, K	1
Fuqua, SA; Russo, J; Shackney, SE; Stearns, ME	1
Plouffe, L	1
Altavilla, D; Arcoraci, V; Cancellieri, F; Corrado, F; Cucinotte, D; D'Anna, R; Frisina, N; Minutoli, L; Morabito, N; Saitta, A; Squadrito, F; Squadrito, G	1
Perrone, A; Tinelli, A; Tinelli, FG	1
Deb Los Reyes, A; Jordan, VC; Lee, ES; Liu, H; Zapf, JW	1
Eiken, PA; Kønig, KB; Schwarz, P	1
Tan-Chiu, E; Wickerham, DL	1
Cauley, JA; Cummings, SR; Eckert, S; Jamal, S; Krueger, KA; Lippman, ME; Sashegyi, A; Walls, EL	1
Swain, SM	1
Pałka, J; Surazyński, A; Swiatecka, J; Wołczynski, S	1
Feightner, J; Levine, M; Moutquin, JM; Walton, R	1
Neven, P; Vergote, I	1
Dhingra, K	1
Levine, M; Pritchard, KI; Walley, B	1
Mincey, BA	1
Pfeilschifter, J	1
Bundred, NJ; Cohen, FJ; Decensi, A; Dowsett, M; Hills, MJ; Lu, Y; Muchmore, DB; O'Brien, ME; Sainsbury, RC; Scott, T; Veronesi, P	1
Hartmann, L; Nelson, W; Stefanek, M	1
Anderson, PW; Barrett-Connor, E; Collins, P; Grady, D; Helterbrand, JD; Kornitzer, M; Mosca, L; Moscarelli, E; Paul, S; Wenger, NK; Wright, TJ	1
Gapstur, S; Jordan, VC; Morrow, M	1
Gradishar, WJ; O'Regan, RM	1
Kemner, JE; O'Connor, LJ; Ohsfeldt, RL; Solomon, TE	1
Lorraine, J	1
Bloss, JD; Rodabaugh, KJ	1
Tiitinen, A; Välimäki, MJ	1
Kellen, JA	1
Baglietto, L; Ballardini, B; Bonanni, B; Decensi, A; Guerrieri-Gonzaga, A; Johansson, H; Torrisi, R; Veronesi, G	1
Bentrem, DJ; Jordan, VC; Liu, H; Loweth, JA; McKian, KP; Park, WC; Reyes, Ade L; Schafer, JM; Zapf, JW	1
Albert, D; Armstrong, K; Chen, TM; Randall, TC; Schwartz, JS	1
Cauley, JA; Cummings, SR; Duong, T; Kenyon, E; Krueger, KA; Whitehead, M	1
Bentrem, DJ; Jordan, VC; O'Regan, RM	1
Cortet, B	1
Dickler, MN; Norton, L	1
Mosca, L	1
Barrett-Connor, E	1
Dunn, BK; Wolmark, N	1
Benson, JR	1
Jordan, VC; Park, WC	1
Diel, P; Michna, H; Olff, S; Schmidt, S	1
Fentiman, IS; Salih, AK	1
Gajdos, C; Jordan, VC	1
Kearney, CE; Purdie, DW	1
McKiernan, F; Wiley, C	1
Zujewski, J	1
Emons, G; Westphalen, S	1
Katzenellenbogen, BS; Katzenellenbogen, JA	1
Brown, M; Shang, Y	1
Twombly, R	1
Rhodes, DJ	1
Bentrem, DJ; Craig Jordan, V	1
Grady, D	1
Candas, B; Couillard, S; Gutman, M; Labrie, C; Labrie, F; Roy, J	1
Blau, R; Lower, EE; Rohatgi, N	1
Alba, E; Colla, F; Farina, C; Mazzoleni, A; Ragonesi, G	1
von Schoultz, E	1
Harris, R; Kinsinger, LS; Lohr, KN; Sox, HC; Woolf, SH	1
Bennett, JA; Bowser, SS; Bradley, L; Dickerman, HW; Gierthy, JF; Lincoln, DW; Roth, KE	1
Dauvois, S; Dumont, M; Hatton, AC; Labrie, C; Labrie, F; Mérand, Y; Poirier, D; Poulin, R; Simard, J; Zhao, HF	1
Couët, J; Dauvois, S; Dumont, M; Hatton, AC; Labrie, C; Labrie, F; Petitclerc, L; Poulin, R; Simard, J; Zhao, HF	1
Dufour, JM; Labrie, F; Levesque, C; Merand, Y; Poirier, D; Poulin, R	1
Dauvois, S; Haagensen, DE; Hatton, AC; Labrie, C; Labrie, F; Simard, J; Zhao, HF	1
Labrie, F; Simard, J	1
Baker, D; Labrie, F; Poulin, R	1
Balakrishnan, A; Edery, M; Imagawa, W; Nandi, S; Richards, J	1
Buzdar, AU; Holmes, F; Hortobagyi, G; Hug, V; Marcus, C	1
Banerjee, S; Finlay, TH; Katz, J; Levitz, M	1
Clark, GM; Hobbs, K; Osborne, CK	1

Reviews

235 review(s) available for raloxifene hydrochloride and Breast Cancer

Article	Year
Endocrine Therapy for Primary and Secondary Prevention After Diagnosis of High-Risk Breast Lesions or Preinvasive Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 06-10, Volume: 41, Issue:17 Topics: Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Female; Humans; Raloxifene Hydrochloride; Secondary Prevention; Tamoxifen	2023
Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA, 2019, 09-03, Volume: 322, Issue:9 Topics: Adult; Area Under Curve; Aromatase Inhibitors; Breast Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Humans; Mutation; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2019
Breast cancer chemoprevention: An update on current practice and opportunities for primary care physicians. Preventive medicine, 2019, Volume: 129 Topics: Breast Neoplasms; Chemoprevention; Female; Guidelines as Topic; Health Knowledge, Attitudes, Practice; Humans; Physicians, Primary Care; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2019
Medications for Primary Prevention of Breast Cancer. JAMA, 2020, 07-21, Volume: 324, Issue:3 Topics: Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Primary Prevention; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms; Venous Thromboembolism	2020
Metformin and Chemoprevention: Potential for Heart-Healthy Targeting of Biologically Aggressive Breast Cancer. Frontiers in public health, 2020, Volume: 8 Topics: Breast Neoplasms; Female; Humans; Metformin; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2020
Preventing Breast Cancer Through Identification and Pharmacologic Management of High-Risk Patients. Mayo Clinic proceedings, 2021, Volume: 96, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Curriculum; Decision Making, Shared; Education, Medical, Continuing; Estrogen Antagonists; Female; Health Personnel; Humans; Male; Middle Aged; Preventive Medicine; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; United States	2021
Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team. Breast cancer research and treatment, 2021, Volume: 190, Issue:1 Topics: Animals; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Raloxifene Hydrochloride; Retrospective Studies; Selective Estrogen Receptor Modulators; Students; Tamoxifen	2021
Personalized prevention in high risk individuals: Managing hormones and beyond. Breast (Edinburgh, Scotland), 2018, Volume: 39 Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Early Detection of Cancer; Female; Genes, BRCA1; Genes, BRCA2; Humans; Mammography; Middle Aged; Nitriles; Precision Medicine; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Tamoxifen; Triazoles	2018
Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators. Climacteric : the journal of the International Menopause Society, 2019, Volume: 22, Issue:2 Topics: Adult; Aged; Atrophy; Breast Neoplasms; Estrogens, Conjugated (USP); Female; Female Urogenital Diseases; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Vagina	2019
The use of raloxifene in osteoporosis treatment. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:7 Topics: Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2013
Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Annals of internal medicine, 2013, Apr-16, Volume: 158, Issue:8 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cataract; Endometrial Neoplasms; Female; Fractures, Bone; Humans; Medication Adherence; Patient Participation; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen; Thromboembolism; Treatment Outcome	2013
Pharmacogenomics of endocrine therapy in breast cancer. Journal of human genetics, 2013, Volume: 58, Issue:6 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Genome-Wide Association Study; Humans; Japan; Letrozole; Musculoskeletal Physiological Phenomena; Nitriles; Pharmacogenetics; Phenotype; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles	2013
Update on raloxifene: mechanism of action, clinical efficacy, adverse effects, and contraindications. Obstetrical & gynecological survey, 2013, Volume: 68, Issue:6 Topics: Blood Coagulation; Bone and Bones; Breast; Breast Neoplasms; Contraindications; Endometrium; Female; Humans; Hypercholesterolemia; Osteoporosis; Raloxifene Hydrochloride; Receptors, Estrogen; Risk Factors; Selective Estrogen Receptor Modulators; Thromboembolism	2013
Use of SERMs for treatment in postmenopausal women. The Journal of steroid biochemistry and molecular biology, 2014, Volume: 142 Topics: Breast Neoplasms; Clinical Trials as Topic; Dyspareunia; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Toremifene	2014
Current concepts in breast cancer chemoprevention. Polskie Archiwum Medycyny Wewnetrznej, 2014, Volume: 124, Issue:4 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Estrogen Antagonists; Estrogens; Female; Humans; Incidence; Nitriles; Postmenopause; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles	2014
Effect of preventive hormonal therapy on breast density: a systematic qualitative review. TheScientificWorldJournal, 2014, Volume: 2014 Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Humans; Raloxifene Hydrochloride; Tamoxifen	2014
Could in-vitro studies on Ishikawa cell lines explain the endometrial safety of raloxifene? Systematic literature review and starting points for future oncological research. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2015, Volume: 24, Issue:6 Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Endometrium; Female; Humans; In Vitro Techniques; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2015
Chemoprevention or mastectomy for women at high risk of developing breast cancer. Maturitas, 2015, Volume: 82, Issue:3 Topics: Age Factors; Anticarcinogenic Agents; Breast Neoplasms; Chemoprevention; Female; Humans; Mastectomy; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen	2015
[GPER receptor - the new player in estrogen signaling]. Postepy biochemii, 2015, Volume: 61, Issue:1 Topics: Animals; Autocrine Communication; Breast Neoplasms; Connective Tissue Growth Factor; Dual Specificity Phosphatase 1; Estradiol; Female; Fulvestrant; Gene Expression Regulation; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-fos; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, G-Protein-Coupled; Signal Transduction; Tamoxifen; Transcriptional Activation	2015
Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast. Post reproductive health, 2015, Volume: 21, Issue:3 Topics: Animals; Breast; Breast Neoplasms; Drug Therapy, Combination; Estradiol; Estrogen Antagonists; Estrogens; Estrogens, Conjugated (USP); Female; Fulvestrant; Humans; Indoles; Osteoporosis; Postmenopause; Protective Factors; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene	2015
Combination of Antiestrogens and Omega-3 Fatty Acids for Breast Cancer Prevention. BioMed research international, 2015, Volume: 2015 Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Estrogen Receptor Modulators; Fatty Acids, Omega-3; Female; Humans; Proteomics; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen	2015
Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials. Journal of the National Cancer Institute, 2016, Volume: 108, Issue:2 Topics: Adult; Aged; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Norpregnenes; Piperidines; Postmenopause; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes	2016
Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:4 Topics: Breast Neoplasms; Chemoprevention; Female; Humans; Raloxifene Hydrochloride; Tamoxifen	2016
The selective estrogen receptor modulators in breast cancer prevention. Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:5 Topics: Breast Neoplasms; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome	2016
[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?]. Bulletin du cancer, 2016, Volume: 103, Issue:3 Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Genetic Predisposition to Disease; Humans; Mastectomy; Mutation; Nitriles; Prophylactic Surgical Procedures; Raloxifene Hydrochloride; Tamoxifen; Triazoles	2016
Prevention of breast cancer. The Medical journal of Australia, 2016, Nov-21, Volume: 205, Issue:10 Topics: Alcohol Drinking; Australia; Breast Neoplasms; Female; Genes, BRCA1; Genetic Testing; Hormone Replacement Therapy; Humans; Life Style; Mammography; Mastectomy; Obesity; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Tobacco Use	2016
Breast cancer chemoprevention: A service in need of menopause specialist support. Post reproductive health, 2017, Volume: 23, Issue:1 Topics: Breast Neoplasms; Counseling; Female; Humans; Menopause; Patient Education as Topic; Physician's Role; Practice Guidelines as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; United Kingdom	2017
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Frontiers in bioscience : a journal and virtual library, 2008, May-01, Volume: 13 Topics: Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Male; Neoplasms; Prostatic Neoplasms; Raloxifene Hydrochloride; Receptor, IGF Type 1; Selective Estrogen Receptor Modulators; Signal Transduction; Treatment Outcome	2008
Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Maturitas, 2008, Jun-20, Volume: 60, Issue:2 Topics: Aged; Aged, 80 and over; Breast Neoplasms; Clinical Trials as Topic; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2008
Preventing breast cancer in high-risk women, 2008. Oncology (Williston Park, N.Y.), 2008, Volume: 22, Issue:6 Topics: Algorithms; Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Genetic Predisposition to Disease; Humans; Practice Guidelines as Topic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2008
[Role of estrogen and selective estrogen receptor modulators in anti-aging]. Clinical calcium, 2008, Volume: 18, Issue:7 Topics: Aging; Animals; Bone and Bones; Bone Density; Breast Neoplasms; Estrogen Replacement Therapy; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis; Perimenopause; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators	2008
Prevention of breast cancer using SERMs. Advances in experimental medicine and biology, 2008, Volume: 630 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2008
Raloxifene: a review of its use in the prevention of invasive breast cancer. Drugs, 2008, Volume: 68, Issue:14 Topics: Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Invasiveness; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2008
The endocrine prevention of breast cancer. Best practice & research. Clinical endocrinology & metabolism, 2008, Volume: 22, Issue:4 Topics: Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2008
Chemoprevention of breast cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Dec-01, Volume: 65, Issue:23 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Receptor Modulators; Female; Humans; Mass Screening; Practice Guidelines as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2008
The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert review of anticancer therapy, 2009, Volume: 9, Issue:1 Topics: Breast Neoplasms; Female; Humans; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2009
The use of tamoxifen and raloxifene for the prevention of breast cancer. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2009, Volume: 181 Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Raloxifene Hydrochloride; Tamoxifen	2009
Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. Journal of the National Cancer Institute, 2009, Mar-18, Volume: 101, Issue:6 Topics: Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast; Breast Neoplasms; Case-Control Studies; Confidence Intervals; Confounding Factors, Epidemiologic; Estrogen Receptor Modulators; Female; Gonadal Steroid Hormones; Humans; Life Style; Middle Aged; Models, Statistical; Odds Ratio; Postmenopause; Predictive Value of Tests; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Risk Factors; Risk Reduction Behavior; Tamoxifen	2009
Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene. Clinical interventions in aging, 2008, Volume: 3, Issue:4 Topics: Adult; Aged; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators	2008
[Breast cancer chemoprevention. Rational, trials results and future]. Bulletin du cancer, 2009, Volume: 96, Issue:5 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Family Health; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2009
Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anti-cancer agents in medicinal chemistry, 2009, Volume: 9, Issue:5 Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	2009
Breast cancer chemoprevention - a vision not yet realized. European journal of cancer care, 2009, Volume: 18, Issue:5 Topics: Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Triazoles	2009
The rationale and potential of cancer chemoprevention with special emphasis on breast cancer. European journal of cancer (Oxford, England : 1990), 2009, Volume: 45 Suppl 1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Raloxifene Hydrochloride; Retinoids; Tamoxifen	2009
Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Annals of internal medicine, 2009, Nov-17, Volume: 151, Issue:10 Topics: Breast Neoplasms; Endometrial Neoplasms; Estrogen Receptor Modulators; Female; Fractures, Bone; Humans; Norpregnenes; Raloxifene Hydrochloride; Stroke; Tamoxifen; Thromboembolism	2009
[Effects of SERMs on bone health. Raloxifene effects on breast cancer and cardiovascular events]. Clinical calcium, 2010, Volume: 20, Issue:3 Topics: Arteriosclerosis; Breast Neoplasms; Female; Humans; Osteoporosis, Postmenopausal; Pulmonary Embolism; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stroke; Venous Thrombosis	2010
Breast cancer: risk assessment and prevention. Southern medical journal, 2010, Volume: 103, Issue:4 Topics: Adult; Breast Neoplasms; Evidence-Based Medicine; Female; Humans; Mammography; Mastectomy; Middle Aged; Primary Prevention; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators	2010
In the clinic. Breast cancer screening and prevention. Annals of internal medicine, 2010, Apr-06, Volume: 152, Issue:7 Topics: Age Factors; Breast Neoplasms; Cost-Benefit Analysis; Estrogen Antagonists; Female; Humans; Mammography; Mass Screening; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Time Factors	2010
Ductal carcinoma in situ: risk factors and impact of screening. Journal of the National Cancer Institute. Monographs, 2010, Volume: 2010, Issue:41 Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Chemoprevention; Female; Hormone Replacement Therapy; Humans; Incidence; Mammography; Mass Screening; Middle Aged; Multicenter Studies as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen; Young Adult	2010
Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials. Journal of the National Cancer Institute. Monographs, 2010, Volume: 2010, Issue:41 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Chemoprevention; Clinical Trials as Topic; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hyperplasia; Incidence; Multicenter Studies as Topic; Pulmonary Embolism; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome	2010
Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention. Current drug targets, 2011, Volume: 12, Issue:13 Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Contraindications; Drug Therapy, Combination; Female; Humans; Italy; Mass Screening; Raloxifene Hydrochloride; Risk Assessment; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen	2011
Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:4 Topics: Bone Density Conservation Agents; Breast Neoplasms; Female; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators	2011
Modulators of androgen and estrogen receptor activity. Critical reviews in eukaryotic gene expression, 2010, Volume: 20, Issue:4 Topics: Androgen Receptor Antagonists; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Male; Osteoporosis; Prostatic Neoplasms; Raloxifene Hydrochloride; Receptors, Androgen; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	2010
Preventive therapy for breast cancer: a consensus statement. The Lancet. Oncology, 2011, Volume: 12, Issue:5 Topics: Anastrozole; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Consensus Development Conferences as Topic; Diphosphonates; Estrogen Receptor Modulators; Expert Testimony; Female; Fenretinide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Nitriles; Norpregnenes; Piperidines; Premenopause; Pyrrolidines; Raloxifene Hydrochloride; Retinoids; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Triazoles	2011
Chemoprevention for breast cancer. Cancer treatment reviews, 2012, Volume: 38, Issue:5 Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen	2012
Breast cancer chemoprevention. Expert review of anticancer therapy, 2012, Volume: 12, Issue:2 Topics: Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen	2012
Recommendations for raloxifene use in daily clinical practice in the Swiss setting. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2012, Volume: 21, Issue:12 Topics: Aged; Breast Neoplasms; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Switzerland	2012
The evolution of selective estrogen receptor modulators in osteoporosis therapy. Climacteric : the journal of the International Menopause Society, 2012, Volume: 15, Issue:6 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Endometrial Neoplasms; Female; Fractures, Bone; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Tetrahydronaphthalenes	2012
The controversy over estrogen replacement therapy: an update on clinical trials. Current women's health reports, 2002, Volume: 2, Issue:2 Topics: Aged; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Estrogen Replacement Therapy; Estrogens; Female; Humans; Middle Aged; Progestins; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators	2002
Raloxifene: recent information on skeletal and non-skeletal effects. Current opinion in rheumatology, 2002, Volume: 14, Issue:4 Topics: Bone and Bones; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures; Uterus	2002
A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer. Seminars in oncology, 2002, Volume: 29, Issue:3 Suppl 11 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes	2002
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Aug-01, Volume: 20, Issue:15 Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Enzyme Inhibitors; Estrogen Antagonists; Evidence-Based Medicine; Expert Testimony; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen	2002
[Selective estrogen receptor modulators (SERMs) in the practice]. Magyar onkologia, 2002, Volume: 46, Issue:2 Topics: Breast Neoplasms; Coronary Disease; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene	2002
Selective estrogen receptor modulators: tissue actions and potential for CNS protection. CNS drug reviews, 2002,Fall, Volume: 8, Issue:3 Topics: Animals; Breast Neoplasms; Cardiovascular System; Central Nervous System; Cognition; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Hormone Replacement Therapy; Humans; Hypothalamo-Hypophyseal System; Male; Neuroprotective Agents; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Receptors, Neurotransmitter; Structure-Activity Relationship; Tamoxifen; Thiophenes; Uterus	2002
[Specific estrogen receptor modulators (SERMs)]. Presse medicale (Paris, France : 1983), 2002, Sep-07, Volume: 31, Issue:28 Topics: Adult; Antineoplastic Agents, Hormonal; Bone and Bones; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Endometrium; Estradiol; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Lipid Metabolism; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Polyunsaturated Alkamides; Postmenopause; Prospective Studies; Quality of Life; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors	2002
National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:1 Pt 2 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Humans; Mastectomy; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen	2003
Chemoprevention of breast cancer: current and future prospects. Cancer metastasis reviews, 2002, Volume: 21, Issue:3-4 Topics: Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Forecasting; Humans; Raloxifene Hydrochloride; Tamoxifen	2002
Overview of the main outcomes in breast-cancer prevention trials. Lancet (London, England), 2003, Jan-25, Volume: 361, Issue:9354 Topics: Breast Neoplasms; Cause of Death; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Incidence; Middle Aged; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome	2003
Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. The New England journal of medicine, 2003, Feb-13, Volume: 348, Issue:7 Topics: Bone and Bones; Breast; Breast Neoplasms; Central Nervous System; Coronary Disease; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Urogenital System	2003
Application of breast cancer risk prediction models in clinical practice. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Feb-15, Volume: 21, Issue:4 Topics: Breast Neoplasms; Estrogen Antagonists; Female; Genes, BRCA1; Genes, BRCA2; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Models, Biological; Predictive Value of Tests; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen	2003
Anti-oestrogenic chemoprevention of breast cancer-the need to progress. European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:5 Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Pilot Projects; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2003
Chemoprevention of breast cancer: recommendations and rationale. American family physician, 2003, Mar-15, Volume: 67, Issue:6 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Antagonists; Evidence-Based Medicine; Female; Humans; Practice Guidelines as Topic; Quality of Life; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Tamoxifen; Venous Thrombosis	2003
[Breakthrough in breast cancer chemoprevention]. Orvosi hetilap, 2003, Mar-30, Volume: 144, Issue:13 Topics: Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Fenretinide; Genes, BRCA1; Genes, BRCA2; Humans; Insulin-Like Growth Factor I; Menopause; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Time Factors	2003
Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:5 Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Long-Term Care; Middle Aged; Neoplasm Staging; Postmenopause; Premenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Survival Rate; Tamoxifen; Treatment Outcome	2003
New approaches to the endocrine prevention and treatment of breast cancer. Cancer chemotherapy and pharmacology, 2003, Volume: 52 Suppl 1 Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome	2003
Antiestrogens: the past and the future. Zentralblatt fur Gynakologie, 2002, Volume: 124, Issue:12 Topics: Animals; Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Clinical Trials as Topic; Estrogen Receptor Modulators; Female; Humans; Raloxifene Hydrochloride; Tamoxifen; United States	2002
The prevention of breast cancer. The British journal of surgery, 2003, Volume: 90, Issue:7 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Double-Blind Method; Estrogen Antagonists; Female; Forecasting; Genes, BRCA1; Genes, BRCA2; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Retinoids; Tamoxifen	2003
[Perspectives for the hormonal therapy of breast cancer]. Magyar onkologia, 2003, Volume: 47, Issue:2 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Letrozole; Nitriles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Toremifene; Triazoles	2003
Prevention of breast cancer using SERMs and aromatase inhibitors. Journal of mammary gland biology and neoplasia, 2003, Volume: 8, Issue:1 Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2003
A review of selective estrogen receptor modulators and national surgical adjuvant breast and bowel project clinical trials. Seminars in oncology, 2003, Volume: 30, Issue:5 Suppl 16 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Risk; Sarcoma; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms	2003
Pharmacological prevention of breast cancer: quo vadis? Breast (Edinburgh, Scotland), 2003, Volume: 12, Issue:6 Topics: Anticarcinogenic Agents; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Fenretinide; Humans; Raloxifene Hydrochloride; Tamoxifen	2003
Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs). Best practice & research. Clinical endocrinology & metabolism, 2004, Volume: 18, Issue:1 Topics: Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Evidence-Based Medicine; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2004
[Raloxifene and breast: from the SERMs concept to its place in clinical practice]. Gynecologie, obstetrique & fertilite, 2004, Volume: 32, Issue:1 Topics: Aged; Animals; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2004
Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer. European journal of endocrinology, 2004, Volume: 150, Issue:3 Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; Mice; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tamoxifen	2004
Progress in chemoprevention of breast cancer. Critical reviews in oncology/hematology, 2004, Volume: 49, Issue:2 Topics: Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Female; Fenretinide; Hormone Replacement Therapy; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen	2004
[MORE study(raloxifene)]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Biomarkers; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Multicenter Studies as Topic; Osteocalcin; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome; Venous Thrombosis	2004
[Raloxifene hydrochloride]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Arteriosclerosis; Bone Density; Bone Resorption; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2004
The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials. The oncologist, 2004, Volume: 9, Issue:2 Topics: Adult; Aged; Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen	2004
Selective estrogen receptor modulation: concept and consequences in cancer. Cancer cell, 2004, Volume: 5, Issue:3 Topics: Apoptosis; Breast Neoplasms; Dimerization; Drug Resistance; Endometrial Neoplasms; Estrogen Antagonists; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Estrogens; Female; Hot Flashes; Humans; Osteoporosis; Protein Binding; Protein Conformation; Protein Interaction Mapping; Raloxifene Hydrochloride; Receptors, Estrogen; Signal Transduction; Tamoxifen	2004
Therapeutic targeting in the estrogen receptor hormonal pathway. Seminars in oncology, 2004, Volume: 31, Issue:1 Suppl 3 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression Regulation, Neoplastic; Humans; Ligands; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen	2004
Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action. Clinical therapeutics, 2004, Volume: 26, Issue:6 Topics: Aged; Aged, 80 and over; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators	2004
Raloxifene and its role in breast cancer prevention. Expert review of anticancer therapy, 2004, Volume: 4, Issue:4 Topics: Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Signal Transduction	2004
Arzoxifene: a promising new selective estrogen receptor modulator for clinical chemoprevention of breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Aug-15, Volume: 10, Issue:16 Topics: Anticarcinogenic Agents; Breast Neoplasms; Female; Humans; Molecular Structure; Neoplasm Staging; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Thiophenes	2004
Endocrine therapy for early breast cancer. Expert review of anticancer therapy, 2004, Volume: 4, Issue:5 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Estrogen Antagonists; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Postmenopause; Prognosis; Radiotherapy, Adjuvant; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen	2004
[Effects of raloxifene on other organs without bone: uterus]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Endometrium; Female; Humans; Myometrium; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Diseases	2004
[Additional effect of SERM: mammary gland]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol, LDL; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Meta-Analysis as Topic; Neoplasm Recurrence, Local; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism	2004
[Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Breast Neoplasms; Cardiovascular Diseases; Estrogen Replacement Therapy; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Venous Thrombosis	2004
[Which is the better choice, estrogen or SERMs in postmenopausal women?]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Breast Neoplasms; Estrogen Replacement Therapy; Female; Hip Fractures; Hot Flashes; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Uterine Hemorrhage	2004
Prevention of hormone-related cancers: breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-10, Volume: 23, Issue:2 Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase II as Topic; Female; Humans; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen	2005
[Menopausal hormonal therapies: impact on mammographic breast density]. Journal de radiologie, 2004, Volume: 85, Issue:10 Pt 1 Topics: Breast; Breast Neoplasms; Estrogen Receptor Modulators; Female; Hormone Replacement Therapy; Humans; Mammography; Mass Screening; Menopause; Norpregnenes; Raloxifene Hydrochloride	2004
[Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2005, Volume: 125, Issue:1 Topics: Animals; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Controlled Clinical Trials as Topic; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Stroke; Transcription Factors	2005
Selective estrogen-receptor modulators for primary prevention of breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Mar-10, Volume: 23, Issue:8 Topics: Aged; Breast Neoplasms; Female; Humans; Postmenopause; Premenopause; Primary Prevention; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	2005
[Selective estrogen receptor modulators]. Polskie Archiwum Medycyny Wewnetrznej, 2004, Volume: 112, Issue:5 Topics: Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome	2004
[Effects of estrogen and selective estrogen receptor modulators on osteoporosis]. Clinical calcium, 2005, Volume: 15, Issue:4 Topics: Breast Neoplasms; Coronary Disease; Estrogen Replacement Therapy; Estrogens; Evidence-Based Medicine; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators	2005
Breast cancer chemoprevention: a review of selective estrogen receptor modulators. Clinical journal of oncology nursing, 2005, Volume: 9, Issue:3 Topics: Breast Neoplasms; Female; Humans; Piperidines; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes	2005
Skeletal and nonskeletal effects of raloxifene. Current osteoporosis reports, 2003, Volume: 1, Issue:3 Topics: Aged; Breast Neoplasms; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fractures, Spontaneous; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Prognosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Severity of Illness Index; Spinal Fractures; Treatment Outcome	2003
[Selective estrogen receptors modulators (SERMs): biochemistry, pharmacology, and clinical use in gynecology]. Ginecologia y obstetricia de Mexico, 2005, Volume: 73, Issue:8 Topics: Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2005
Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. Breast (Edinburgh, Scotland), 2006, Volume: 15, Issue:5 Topics: Aromatase Inhibitors; Breast Neoplasms; Decision Trees; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Postmenopause; Raloxifene Hydrochloride; Tamoxifen	2006
The prevention, detection, and management of breast cancer. The Medical journal of Australia, 2006, Mar-06, Volume: 184, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Mammaplasty; Mammography; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Primary Prevention; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Sentinel Lymph Node Biopsy; Surgical Flaps; Tamoxifen; Time Factors; Trastuzumab; Ultrasonography, Mammary	2006
Raloxifene: bone and cardiovascular effects. Journal of endocrinological investigation, 2005, Volume: 28, Issue:10 Suppl Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Cardiovascular System; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators	2005
[Molecular mechanism tissue-specific actions of selective estrogen receptor modulators]. Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 2006, Volume: 43, Issue:2 Topics: Bone Density; Breast Neoplasms; Clinical Trials as Topic; Estrogens; Evidence-Based Medicine; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators	2006
[SERMs for treatment of osteoporosis: state-of-the-art and perspectives]. Gynecologie, obstetrique & fertilite, 2006, Volume: 34, Issue:5 Topics: Breast Neoplasms; Female; Fractures, Bone; France; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2006
The science of selective estrogen receptor modulators: concept to clinical practice. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Sep-01, Volume: 12, Issue:17 Topics: Breast Neoplasms; Female; Humans; Models, Biological; Neoplasm Invasiveness; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen	2006
[Selective estrogen receptor modulators (SERMs)]. Clinical calcium, 2006, Volume: 16, Issue:9 Topics: Breast Neoplasms; Female; Humans; Organ Specificity; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke	2006
Modifiers of risk of hereditary breast cancer. Oncogene, 2006, Sep-25, Volume: 25, Issue:43 Topics: Abortion, Therapeutic; Breast Feeding; Breast Neoplasms; Contraceptives, Oral; Female; Genes, BRCA1; Genes, BRCA2; Genetic Carrier Screening; Humans; Ovariectomy; Pregnancy; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2006
An update on breast cancer prevention trials. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2006, Volume: 16 Suppl 2 Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2006
An update on raloxifene. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2006, Volume: 16 Suppl 2 Topics: Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2006
Selecting targets for cancer prevention: where do we go from here? Nature reviews. Cancer, 2006, Volume: 6, Issue:11 Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Humans; Neoplasms; Raloxifene Hydrochloride; Tamoxifen	2006
Raloxifene and the prevention of breast cancer. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:16 Topics: Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic	2006
Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial. European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:17 Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2006
Prevention of breast cancer: current state of the science and future opportunities. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Evaluation, Preclinical; Drug Therapy, Combination; Estrogen Receptor Modulators; Estrogens; Female; Forecasting; Humans; Leuprolide; Mammary Neoplasms, Experimental; Mice; Middle Aged; Ovariectomy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Rats; Retinoids; Selective Estrogen Receptor Modulators; Tamoxifen	2006
[Menopausal hormone therapy and cardiovascular disease]. Revista espanola de cardiologia, 2006, Volume: 59, Issue:10 Topics: Age Factors; Aged; Breast Neoplasms; Cardiovascular Diseases; Cohort Studies; Coronary Angiography; Coronary Disease; Electrocardiography; Estrogen Replacement Therapy; Estrogens; Female; Follow-Up Studies; Heart Rate; Humans; Life Style; Mammography; Meta-Analysis as Topic; Middle Aged; Myocardial Infarction; Progestins; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Stroke; Time Factors	2006
Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nature reviews. Cancer, 2007, Volume: 7, Issue:1 Topics: Anticarcinogenic Agents; Breast Neoplasms; Chemoprevention; Endometrial Neoplasms; Female; Humans; Models, Biological; Models, Chemical; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	2007
The current status of breast cancer chemoprevention: a star is born. Journal of surgical oncology, 2007, Jan-01, Volume: 95, Issue:1 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk; Risk Assessment; Tamoxifen	2007
SERMs: meeting the promise of multifunctional medicines. Journal of the National Cancer Institute, 2007, Mar-07, Volume: 99, Issue:5 Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Canada; Evidence-Based Medicine; Female; Humans; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen; United States	2007
Primary prevention of breast cancer: new approaches. Maturitas, 2007, May-20, Volume: 57, Issue:1 Topics: Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Female; Humans; Life Style; Mammography; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2007
Hormonal interventions to prevent hormonal cancers: breast and prostate cancers. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2007, Volume: 16, Issue:3 Topics: Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Finasteride; Humans; Male; Primary Prevention; Prostatic Neoplasms; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2007
SERMs for the treatment and prevention of breast cancer. Reviews in endocrine & metabolic disorders, 2007, Volume: 8, Issue:3 Topics: Breast Neoplasms; Female; Humans; Postmenopause; Premenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2007
Moving forward with breast cancer prevention. Cancer, 2007, Jun-15, Volume: 109, Issue:12 Topics: Aged; Breast Neoplasms; Female; Humans; Middle Aged; Primary Prevention; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; United States	2007
Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs). Current medicinal chemistry, 2007, Volume: 14, Issue:11 Topics: Breast Neoplasms; Drug Design; Estrogen Receptor alpha; Female; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Stilbenes; Structure-Activity Relationship; Tamoxifen; Thiophenes; Toremifene	2007
Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics. Familial cancer, 2008, Volume: 7, Issue:1 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Drug Delivery Systems; Gene Expression Profiling; Genes, BRCA1; Genes, BRCA2; Genetic Carrier Screening; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Prognosis; Raloxifene Hydrochloride; Tamoxifen	2008
Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy. Nature clinical practice. Endocrinology & metabolism, 2007, Volume: 3, Issue:8 Topics: Aromatase Inhibitors; Breast Neoplasms; Dehydroepiandrosterone; Estrogen Antagonists; Female; Hormone Replacement Therapy; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms	2007
[Prevention of hereditary breast cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Jun-28, Volume: 65 Suppl 6 Topics: Apoptosis Regulatory Proteins; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Heterozygote; Humans; Magnetic Resonance Imaging; Mammography; Mastectomy, Simple; Mutation; Plastic Surgery Procedures; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2007
[Current perspective of chemoprevention in breast cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Jun-28, Volume: 65 Suppl 6 Topics: Apoptosis Regulatory Proteins; Aromatase Inhibitors; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Female; Humans; Meta-Analysis as Topic; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2007
Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature. Minerva ginecologica, 2007, Volume: 59, Issue:4 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cognition; Female; Gonadotropin-Releasing Hormone; Humans; Neuropsychological Tests; Nitriles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles	2007
The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women. Journal of the National Comprehensive Cancer Network : JNCCN, 2007, Volume: 5, Issue:8 Topics: Breast Neoplasms; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen	2007
[Osteoporosis in cancer survivors]. Medicina clinica, 2007, Nov-10, Volume: 129, Issue:17 Topics: Age Factors; Aged; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fractures, Bone; Humans; Hypogonadism; Male; Middle Aged; Neoplasms; Osteoporosis; Prostatic Neoplasms; Radiotherapy; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors	2007
Tamoxifen: catalyst for the change to targeted therapy. European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:1 Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Female; History, 20th Century; History, 21st Century; Humans; Osteoporosis; Raloxifene Hydrochloride; Rats; Selective Estrogen Receptor Modulators; Tamoxifen	2008
[Where do SERMs stand in the light of clinical application?]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Binding, Competitive; Breast Neoplasms; Drug Design; Female; Humans; Osteoporosis, Postmenopausal; Patient Compliance; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Selective Estrogen Receptor Modulators	2007
[CORE study]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Bone Density Conservation Agents; Breast Neoplasms; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk; Selective Estrogen Receptor Modulators; Time Factors	2007
[Evidence of raloxifene on postmenopausal osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Bone and Bones; Bone Density Conservation Agents; Breast Neoplasms; Evidence-Based Medicine; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Selective Estrogen Receptor Modulators; Spinal Fractures	2007
Breast cancer risk management. Clinical breast cancer, 2007, Volume: 7, Issue:11 Topics: Antineoplastic Agents; Breast Neoplasms; Cataract; Endometrial Neoplasms; Female; Humans; Primary Health Care; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism; United States; Women's Health	2007
Chemoprevention of breast cancer. Expert review of anticancer therapy, 2008, Volume: 8, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Carotenoids; Chemoprevention; Female; Gonadotropin-Releasing Hormone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Phytoestrogens; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2008
The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene. Taiwanese journal of obstetrics & gynecology, 2008, Volume: 47, Issue:1 Topics: Breast Neoplasms; Clinical Trials as Topic; Contraindications; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2008
Raloxifene in breast cancer prevention. Expert opinion on drug safety, 2008, Volume: 7, Issue:3 Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2008
Gene expression profiles in breast cancer to identify estrogen receptor target genes. Mini reviews in medicinal chemistry, 2008, Volume: 8, Issue:5 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Molecular Structure; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen	2008
Raloxifene for older women: a review of the literature. Clinical interventions in aging, 2008, Volume: 3, Issue:1 Topics: Bone and Bones; Breast Neoplasms; Cardiovascular System; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators	2008
Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. Breast cancer research and treatment, 1983, Volume: 3 Suppl Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Drug; Estrogen Antagonists; Female; Half-Life; Humans; Mammary Neoplasms, Experimental; Models, Biological; Piperidines; Pyrrolidines; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Receptors, Estrogen; Tamoxifen; Thiophenes	1983
Alternate antiestrogens and approaches to the prevention of breast cancer. Journal of cellular biochemistry. Supplement, 1995, Volume: 22 Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Drug Design; Estrogen Antagonists; Female; Humans; Liver Neoplasms, Experimental; Piperidines; Raloxifene Hydrochloride; Rats; Tamoxifen; Toremifene	1995
Selective modulation of estrogen receptor action. The Journal of clinical endocrinology and metabolism, 1998, Volume: 83, Issue:1 Topics: Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Humans; Menstrual Cycle; Ovulation; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen	1998
Status of antiestrogen breast cancer prevention trials. Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:3 Suppl 5 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method; Endometrial Neoplasms; Estrogen Antagonists; Female; Genes, BRCA1; Humans; Italy; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Toremifene; United Kingdom; United States	1998
Selective oestrogen receptor modulators: a new paradigm for HRT. Current opinion in obstetrics & gynecology, 1998, Volume: 10, Issue:3 Topics: Breast Neoplasms; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen	1998
Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. Journal of the National Cancer Institute, 1998, Jul-01, Volume: 90, Issue:13 Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Transforming Growth Factor alpha; Uterine Neoplasms	1998
The breast cancer prevention trial (P-1 study). The role of tamoxifen in preventing breast cancer. Cleveland Clinic journal of medicine, 1999, Volume: 66, Issue:1 Topics: Adolescent; Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Approval; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Middle Aged; Patient Selection; Piperidines; Prospective Studies; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen; United States; United States Food and Drug Administration	1999
Molecular biology of the estrogen receptor aids in the understanding of tamoxifen resistance and breast cancer prevention with raloxifene. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1998, Volume: 152 Topics: Animals; Breast Neoplasms; Crystallization; Drug Resistance, Neoplasm; Estrogen Antagonists; Female; Humans; Mutation; Piperidines; Raloxifene Hydrochloride; Stimulation, Chemical; Tamoxifen	1998
Current controversies in breast cancer management. Current problems in surgery, 1999, Volume: 36, Issue:3 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Estrogen Antagonists; Female; Humans; Lymphatic Metastasis; Mastectomy; Neoplasms, Hormone-Dependent; Patient Selection; Piperidines; Radiotherapy, Adjuvant; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk; Tamoxifen	1999
Prevention of breast cancer in high-risk women. The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society, 1999, Volume: 151, Issue:4 Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Incidence; Louisiana; Middle Aged; Piperidines; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen	1999
Estrogen receptor as a target for the prevention of breast cancer. The Journal of laboratory and clinical medicine, 1999, Volume: 133, Issue:5 Topics: Animals; Breast Neoplasms; Estrogen Antagonists; Humans; Meta-Analysis as Topic; Piperidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen	1999
Development of a new prevention maintenance therapy for postmenopausal women. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1999, Volume: 151 Topics: Adult; Aged; Animals; Breast Neoplasms; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Middle Aged; Piperidines; Postmenopause; Raloxifene Hydrochloride; Rats; Tamoxifen	1999
Tamoxifen, raloxifene, and the prevention of breast cancer. Endocrine reviews, 1999, Volume: 20, Issue:3 Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk Factors; Tamoxifen	1999
Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 6: Executive summary and consensus statement. Proceedings of a conference held at Boar's Head Inn, Charlottesville, Virginia, September 21-23, 1997. Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:6 Topics: Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Estrogen Antagonists; Estrogens; Estrogens, Non-Steroidal; Female; Humans; Isoflavones; Menopause; Osteoporosis; Phytoestrogens; Piperidines; Plant Preparations; Raloxifene Hydrochloride; Receptors, Estrogen; Survivors	1999
[Selective estrogen-receptor modulators (SERM's) in postmenopausal women]. Nederlands tijdschrift voor geneeskunde, 1999, Aug-28, Volume: 143, Issue:35 Topics: Aged; Breast Neoplasms; Cardiovascular Diseases; Female; Humans; Hypercholesterolemia; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	1999
Effect of SERMs on breast tissue. Journal of endocrinological investigation, 1999, Volume: 22, Issue:8 Topics: Animals; Breast; Breast Neoplasms; Estrogens; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	1999
Tamoxifen prevention of breast cancer: an instance of the fingerpost. Journal of the National Cancer Institute, 1999, Nov-03, Volume: 91, Issue:21 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Receptor Modulators; Europe; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; United States	1999
Modern antioestrogens and the coming revolution in women's health care. The Australian & New Zealand journal of obstetrics & gynaecology, 1999, Volume: 39, Issue:3 Topics: Bone and Bones; Breast Neoplasms; Clomiphene; Estradiol; Estrogen Receptor Modulators; Estrogens, Non-Steroidal; Female; Fulvestrant; Genital Diseases, Female; Humans; Isoflavones; Osteoporosis; Phytoestrogens; Plant Preparations; Plants; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Women's Health	1999
Preventing heart disease and cancer. What randomized, primary-prevention studies show. Postgraduate medicine, 1999, Oct-15, Volume: 106, Issue:5 Topics: Aged; Antineoplastic Agents; Aspirin; Breast Neoplasms; Coronary Disease; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Primary Prevention; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selenium; Tamoxifen; Vitamin E	1999
American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:6 Topics: Anticarcinogenic Agents; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Cataract; Endometrial Neoplasms; Estrogen Antagonists; Expert Testimony; Female; Humans; Incidence; Menopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Tamoxifen	1999
Selective estrogen receptor modulators and postmenopausal health. Advances in internal medicine, 2000, Volume: 45 Topics: Breast Neoplasms; Chemoprevention; Dementia; Female; Fractures, Bone; Heart Diseases; Humans; Lipoproteins; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Women's Health	2000
[Selective estrogen receptor modulators (SERM): new substances for hormone replacement therapy]. Schweizerische medizinische Wochenschrift, 1999, Dec-11, Volume: 129, Issue:49 Topics: Breast Neoplasms; Estrogen Replacement Therapy; Estrogens; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	1999
[Raloxifene: a selective modulator of estrogen receptors]. Journal de gynecologie, obstetrique et biologie de la reproduction, 1999, Volume: 28, Issue:8 Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators	1999
Chemoprevention of breast cancer in the older patient. Hematology/oncology clinics of North America, 2000, Volume: 14, Issue:1 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Retinoids; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2000
[Clinical experience with raloxifene]. Orvosi hetilap, 2000, Jan-30, Volume: 141, Issue:5 Topics: Breast Neoplasms; Cardiovascular Diseases; Endometrium; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2000
Selective oestrogen receptor modulation: molecular pharmacology for the millennium. European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:14 Topics: Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	1999
Prevention of breast cancer. Critical reviews in oncology/hematology, 2000, Volume: 33, Issue:3 Topics: Adult; Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Biological Products; Breast Neoplasms; Breast Neoplasms, Male; Carotenoids; Cathepsin D; Cell Adhesion Molecules; Cell Cycle; Clinical Trials, Phase III as Topic; Drug Screening Assays, Antitumor; Estrogens, Non-Steroidal; Female; Fenretinide; Genetic Predisposition to Disease; Hormone Antagonists; Humans; Isoflavones; Male; Mammary Neoplasms, Experimental; Mastectomy; Mice; Middle Aged; Neovascularization, Pathologic; Ovariectomy; Phytoestrogens; Plant Preparations; Raloxifene Hydrochloride; Rats; Retinoids; Risk Assessment; Risk Factors; Selenium; Tamoxifen; Terpenes	2000
[Breast cancer: assessment of individual risk and possibilities for prevention]. Zeitschrift fur arztliche Fortbildung und Qualitatssicherung, 2000, Volume: 94, Issue:3 Topics: Anticarcinogenic Agents; Breast Neoplasms; Female; Genetic Carrier Screening; Genetic Predisposition to Disease; Humans; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Tamoxifen	2000
Drugs for the gynecologist to prescribe in the prevention of breast cancer: current status and future trends. American journal of obstetrics and gynecology, 2000, Volume: 182, Issue:5 Topics: Breast Neoplasms; Drug Approval; Estrogen Antagonists; Female; Gynecology; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; United States; United States Food and Drug Administration	2000
Targeted antiestrogens for the prevention of breast cancer. Oncology research, 1999, Volume: 11, Issue:9 Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogen Receptor Modulators; Female; Forecasting; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen	1999
[Chemopreventive effect of tamoxifen on familial breast cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:6 Topics: Animals; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Neoplastic Syndromes, Hereditary; Raloxifene Hydrochloride; Rats; Seaweed; Tamoxifen; Tea	2000
Reducing the risk of breast cancer. The New England journal of medicine, 2000, Jul-20, Volume: 343, Issue:3 Topics: Anticarcinogenic Agents; Breast Neoplasms; Environment; Estrogen Antagonists; Female; Humans; Life Style; Mastectomy; Ovariectomy; Raloxifene Hydrochloride; Risk Factors; Tamoxifen	2000
Safety and efficacy of antiestrogens for prevention of breast cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2000, Jul-15, Volume: 57, Issue:14 Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Raloxifene Hydrochloride; Tamoxifen	2000
Prevention and treatment of osteoporosis in women with breast cancer. Mayo Clinic proceedings, 2000, Volume: 75, Issue:8 Topics: Aged; Alendronate; Bone Density; Breast Neoplasms; Calcitonin; Diphosphonates; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Ovariectomy; Ovary; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2000
Chemoprevention of breast cancer. Cancer treatment and research, 2000, Volume: 103 Topics: Adult; Aged; Animals; Anticarcinogenic Agents; Bone and Bones; Breast Diseases; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Clinical Trials as Topic; Endometrial Neoplasms; Estrogens; Female; Gonadal Steroid Hormones; Humans; Lipids; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Neoplastic Syndromes, Hereditary; Osteoporosis, Postmenopausal; Pilot Projects; Precancerous Conditions; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Reproductive History; Risk Factors; Safety; Selective Estrogen Receptor Modulators; Tamoxifen	2000
[Raloxifene]. Ugeskrift for laeger, 2000, Jul-31, Volume: 162, Issue:31 Topics: Breast Neoplasms; Endometrium; Estrogen Antagonists; Female; Humans; Menopause; Middle Aged; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Uterine Hemorrhage	2000
Chemoprevention of breast cancer. Breast cancer research and treatment, 2000, Volume: 62, Issue:1 Topics: Adult; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Mastectomy; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Tamoxifen	2000
[Breast cancer chemoprevention (tamoxifen, raloxifene, and others)]. Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58 Suppl Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Retinoids; Seaweed; Selective Estrogen Receptor Modulators; Tamoxifen; Tea	2000
Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects. The oncologist, 2000, Volume: 5, Issue:5 Topics: Bone and Bones; Breast; Breast Neoplasms; Cardiovascular System; Clinical Trials as Topic; Drug Evaluation, Preclinical; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Uterus	2000
In pursuit of the prevention of breast cancer. The American journal of the medical sciences, 2000, Volume: 320, Issue:4 Topics: Age Factors; Animals; Anticarcinogenic Agents; Breast Neoplasms; Cohort Studies; Confounding Factors, Epidemiologic; Contraceptives, Oral, Hormonal; Disease Models, Animal; Emigration and Immigration; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Female; Humans; Italy; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen; Twin Studies as Topic; United Kingdom	2000
[Indications for hormone replacement therapy]. Therapeutische Umschau. Revue therapeutique, 2000, Volume: 57, Issue:10 Topics: Aged; Alzheimer Disease; Anabolic Agents; Breast Neoplasms; Cardiovascular Diseases; Contraindications; Endometrial Neoplasms; Estrogen Replacement Therapy; Estrogens; Female; Humans; Middle Aged; Norpregnenes; Osteoporosis, Postmenopausal; Postmenopause; Progestins; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Thrombosis	2000
Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: a brief overview. Oncology, 2000, Volume: 59 Suppl 1 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	2000
Breast cancer chemoprevention. American journal of surgery, 2000, Volume: 180, Issue:4 Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen	2000
Breast cancer prevention trials. Current oncology reports, 2000, Volume: 2, Issue:6 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Double-Blind Method; Estrogen Antagonists; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Tamoxifen	2000
Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing. Journal of the National Cancer Institute, 2001, Jan-03, Volume: 93, Issue:1 Topics: Aged; Breast Neoplasms; Cholesterol; Coronary Disease; Drug Administration Schedule; Estrogen Replacement Therapy; Estrogens, Non-Steroidal; Female; Humans; Incidence; Medroxyprogesterone; Middle Aged; Osteoporosis, Postmenopausal; Progesterone Congeners; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen	2001
Progress in the prevention of breast cancer: concept to reality. The Journal of steroid biochemistry and molecular biology, 2000, Nov-30, Volume: 74, Issue:5 Topics: Bone Density; Breast Neoplasms; Coronary Disease; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	2000
Breast cancer chemoprevention. Hematology/oncology clinics of North America, 2000, Volume: 14, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Animals; Anticarcinogenic Agents; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Double-Blind Method; Endometrial Neoplasms; Estrogen Antagonists; Europe; Female; Humans; Hyperlipidemias; Hysterectomy; Mammary Neoplasms, Experimental; Menopause; Mice; Mice, Nude; Middle Aged; Neoplasms, Second Primary; Neoplastic Syndromes, Hereditary; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk Factors; Tamoxifen; United States	2000
Breast cancer genetics. Implications of clinical practice. Hematology/oncology clinics of North America, 2000, Volume: 14, Issue:3 Topics: Age of Onset; Anticarcinogenic Agents; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Case Management; Cyclin D1; DNA Mutational Analysis; Estrogen Antagonists; Female; Gene Frequency; Genes, BRCA1; Genes, erbB-2; Genetic Counseling; Genetic Testing; Humans; Male; Mammography; Mastectomy; Neoplasm Proteins; Neoplasms, Multiple Primary; Neoplastic Syndromes, Hereditary; Oncogenes; Ovarian Neoplasms; Ovariectomy; Phenotype; Raloxifene Hydrochloride; Retrospective Studies; Risk; Tamoxifen; Transcription Factors	2000
Chemoprevention of breast cancer. Southern medical journal, 2001, Volume: 94, Issue:1 Topics: Anticarcinogenic Agents; Breast Neoplasms; Chemoprevention; Contraindications; Endometrial Neoplasms; Estrogen Antagonists; Europe; Female; Humans; Incidence; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; United States; United States Food and Drug Administration	2001
Chemoprevention of breast cancer. Cancer treatment and research, 2001, Volume: 106 Topics: Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Female; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2001
[Prevention of breast cancer--what are the latest developments?]. Harefuah, 2001, Volume: 140, Issue:1 Topics: Anticarcinogenic Agents; Breast Neoplasms; Estrogen Replacement Therapy; Female; Humans; Raloxifene Hydrochloride; Tamoxifen	2001
Future possibilities in the prevention of breast cancer: breast cancer prevention trials. Breast cancer research : BCR, 2000, Volume: 2, Issue:4 Topics: Adult; Aged; Anticarcinogenic Agents; Bone Density; Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Estrogen Receptor Modulators; Female; Forecasting; Hormone Replacement Therapy; Humans; Incidence; Menopause; Meta-Analysis as Topic; Middle Aged; Neoplasm Proteins; Patient Compliance; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk; Risk Factors; Tamoxifen; Thromboembolism; Treatment Outcome	2000
Future possibilities in the prevention of breast cancer: role of genetic variation in breast cancer prevention. Breast cancer research : BCR, 2000, Volume: 2, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Aromatase; Breast Neoplasms; Case-Control Studies; Estradiol Dehydrogenases; Estrogen Receptor alpha; Estrogens; Ethnicity; Female; Forecasting; Genetic Predisposition to Disease; Genetic Testing; Humans; Middle Aged; Models, Genetic; Ovary; Polymorphism, Genetic; Raloxifene Hydrochloride; Receptors, Estrogen; Reproductive History; Risk Factors; Selective Estrogen Receptor Modulators; Steroid 17-alpha-Hydroxylase; Tamoxifen	2000
Breast cancer chemoprevention: beyond tamoxifen. Breast cancer research : BCR, 2001, Volume: 3, Issue:2 Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Retinoids; Selective Estrogen Receptor Modulators; Tamoxifen	2001
Novel agents to modulate oestrogen action. British medical bulletin, 2000, Volume: 56, Issue:3 Topics: Breast Neoplasms; Coronary Disease; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	2000
The prevention of breast cancer: an overview. Current medical research and opinion, 2001, Volume: 16, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Breast Neoplasms; Cyclooxygenase Inhibitors; Estrogen Receptor Modulators; Evidence-Based Medicine; Female; Humans; Life Style; Mastectomy; Primary Prevention; Raloxifene Hydrochloride; Risk Factors; Tamoxifen	2001
Selective estrogen receptor modulators. An aid in unraveling the links between estrogen and breast cancer. Postgraduate medicine, 2001, Volume: Spec No Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulation; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	2001
Cardiovascular effects of raloxifene hydrochloride. Cardiovascular drug reviews, 2001,Spring, Volume: 19, Issue:1 Topics: Animals; Bone and Bones; Brain; Breast Neoplasms; Cardiovascular System; Endothelium, Vascular; Female; Genitalia, Female; Humans; Lipids; Osteoporosis, Postmenopausal; Pituitary Gland; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators	2001
[An alternative to postmenopausal Hormone Replacement Therapy? Selective Estrogens Receptors Modulators (SERMs)]. Minerva ginecologica, 2001, Volume: 53, Issue:2 Topics: Adult; Aged; Animals; Bone and Bones; Brain; Breast; Breast Neoplasms; Cardiovascular System; Endometrial Neoplasms; Female; Haplorhini; Hormone Replacement Therapy; Humans; Menopause; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus; Vagina	2001
[SERM--selective estrogen receptor modulators]. Ugeskrift for laeger, 2001, Apr-09, Volume: 163, Issue:15 Topics: Aged; Bone Marrow; Breast; Breast Neoplasms; Cardiovascular Diseases; Endometrium; Estrogen Antagonists; Female; Humans; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen	2001
Breast cancer chemoprevention: current status and future directions. Seminars in oncology, 2001, Volume: 28, Issue:3 Topics: Anticarcinogenic Agents; Breast Neoplasms; Female; Humans; Incidence; Italy; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; United Kingdom; United States	2001
Tamoxifen to raloxifene and beyond. Seminars in oncology, 2001, Volume: 28, Issue:3 Topics: Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2001
Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2001, Jun-12, Volume: 164, Issue:12 Topics: Adult; Breast Neoplasms; Canada; Female; Humans; Middle Aged; Practice Guidelines as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen	2001
Tamoxifen, screening and new oestrogen receptor modulators. Best practice & research. Clinical obstetrics & gynaecology, 2001, Volume: 15, Issue:3 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Dose-Response Relationship, Drug; Endometrial Neoplasms; Endosonography; Female; Humans; Hysteroscopy; Mass Screening; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Sensitivity and Specificity; Tamoxifen	2001
Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer. Cancer investigation, 2001, Volume: 19, Issue:6 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Design; Estrogen Receptor Modulators; Female; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen	2001
[Hormone replacement and selective estrogen receptor modulators (SERMS) in the prevention and treatment of postmenopausal osteoporosis]. Der Orthopade, 2001, Volume: 30, Issue:7 Topics: Administration, Oral; Age Factors; Aged; Bone Density; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Progestins; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Time Factors; Uterine Neoplasms	2001
Risk-reduction mastectomy: clinical issues and research needs. Journal of the National Cancer Institute, 2001, Sep-05, Volume: 93, Issue:17 Topics: Anticarcinogenic Agents; Attitude to Health; Breast Neoplasms; Decision Making; Estrogen Receptor Modulators; Female; Genes, BRCA1; Genes, Tumor Suppressor; Heterozygote; Humans; Incidence; Mammography; Mastectomy; Mutation; Ovariectomy; Population Surveillance; Raloxifene Hydrochloride; Risk; Tamoxifen	2001
Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. Journal of the National Cancer Institute, 2001, Oct-03, Volume: 93, Issue:19 Topics: Adult; Aged; Bone and Bones; Breast; Breast Neoplasms; Cardiovascular System; Cinnamates; Clinical Trials as Topic; Coronary Disease; Endometrial Neoplasms; Estrogen Replacement Therapy; Female; Heart; Hot Flashes; Humans; Middle Aged; Models, Biological; Organ Specificity; Osteoporosis; Postmenopause; Premenopause; Prospective Studies; Protein Structure, Tertiary; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk; Risk Assessment; Selective Estrogen Receptor Modulators; Stilbenes; Tamoxifen; Thrombophilia; Transcription, Genetic	2001
Breast cancer prevention. Clinical obstetrics and gynecology, 2001, Volume: 44, Issue:3 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Life Style; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2001
Raloxifene. Current drug targets, 2001, Volume: 2, Issue:4 Topics: Breast Neoplasms; Clinical Trials as Topic; Drugs, Investigational; Endometrium; Female; Humans; Lipoproteins; Osteoporosis; Ovulation; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators	2001
Breast cancer chemoprevention: current clinical practice and future direction. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2001, Volume: 55, Issue:9-10 Topics: Anticarcinogenic Agents; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Tamoxifen	2001
A brief review of the International Breast Cancer Intervention Study (IBIS), the other current breast cancer prevention trials, and proposals for future trials. Annals of the New York Academy of Sciences, 2001, Volume: 949 Topics: Adult; Age Distribution; Aged; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2001
Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial. Annals of the New York Academy of Sciences, 2001, Volume: 949 Topics: Adenocarcinoma; Breast Neoplasms; Cardiovascular Diseases; Estrogen Replacement Therapy; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2001
The effect of SERMs on the endometrium. Annals of the New York Academy of Sciences, 2001, Volume: 949 Topics: Breast Neoplasms; Endometrial Neoplasms; Endometrium; Female; Humans; Neoplasm Invasiveness; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2001
Raloxifene: risks and benefits. Annals of the New York Academy of Sciences, 2001, Volume: 949 Topics: Breast Neoplasms; Endometrial Neoplasms; Endometrium; Female; Hot Flashes; Humans; Morbidity; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Thromboembolism	2001
Role of antiestrogens and aromatase inhibitors in breast cancer treatment. Current opinion in obstetrics & gynecology, 2002, Volume: 14, Issue:1 Topics: Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2002
Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention. Trends in molecular medicine, 2002, Volume: 8, Issue:2 Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	2002
Breast cancer risk reduction: strategies for women at increased risk. Annual review of medicine, 2002, Volume: 53 Topics: Breast Neoplasms; Female; Humans; Mastectomy; Ovariectomy; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2002
Breast cancer prevention: present and future. Cancer treatment reviews, 2001, Volume: 27, Issue:5 Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Genetic Predisposition to Disease; Humans; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Risk Factors; Tamoxifen	2001
Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade. Clinical breast cancer, 2002, Volume: 2, Issue:4 Topics: Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cinnamates; Drug Design; Forecasting; Humans; Molecular Biology; Piperidines; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stilbenes; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Toremifene; Treatment Outcome	2002
Selective estrogen receptor modulators. Climacteric : the journal of the International Menopause Society, 1998, Volume: 1, Issue:2 Topics: Aged; Animals; Breast Neoplasms; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	1998
Treatment of estrogen deficiency symptoms in women surviving breast cancer. Climacteric : the journal of the International Menopause Society, 1998, Volume: 1, Issue:2 Topics: Breast Neoplasms; Estrogen Replacement Therapy; Female; Heart Diseases; Humans; Menopause; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Survivors	1998
Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention. Environmental and molecular mutagenesis, 2002, Volume: 39, Issue:2-3 Topics: Antineoplastic Agents; Breast Neoplasms; Female; Fenretinide; Humans; Incidence; Insulin-Like Growth Factor I; Multicenter Studies as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen	2002
Chemoprevention of breast cancer: implications for postmenopausal women. Drugs & aging, 2002, Volume: 19, Issue:1 Topics: Anticarcinogenic Agents; Breast Neoplasms; Chemoprevention; Estrogens; Female; Gene Expression Regulation, Neoplastic; Hormone Replacement Therapy; Humans; Postmenopause; Precancerous Conditions; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2002
Identifying and counseling women at increased risk for breast cancer. Mayo Clinic proceedings, 2002, Volume: 77, Issue:4 Topics: Adult; Breast Neoplasms; Clinical Trials as Topic; Counseling; Female; Humans; Life Style; Middle Aged; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen	2002
Tamoxifen, raloxifene and the prevention of breast cancer. Minerva endocrinologica, 2002, Volume: 27, Issue:2 Topics: Adult; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Coronary Disease; Drug Design; Endometrial Neoplasms; Estrogens; Female; Humans; Incidence; Mammary Neoplasms, Experimental; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Osteoporosis; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen	2002
Review of raloxifene and its clinical applications in osteoporosis. Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:6 Topics: Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Uterine Diseases	2002
[Antiestrogen therapy in the treatment of breast neoplasms]. Minerva ginecologica, 2002, Volume: 54, Issue:3 Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Forecasting; Humans; Indoles; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Triazoles	2002
Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Annals of internal medicine, 2002, Jul-02, Volume: 137, Issue:1 Topics: Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Evidence-Based Medicine; Female; Humans; Primary Prevention; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2002

Trials

54 trial(s) available for raloxifene hydrochloride and Breast Cancer

Article	Year
Effects of Raloxifene Combined with Low-dose Conjugated Estrogen on the Endometrium in Menopausal Women at High Risk for Breast Cancer. Clinics (Sao Paulo, Brazil), 2021, Volume: 76 Topics: Breast Neoplasms; Double-Blind Method; Endometrium; Estrogens, Conjugated (USP); Female; Humans; Menopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2021
Effect of Personalized Breast Cancer Risk Tool on Chemoprevention and Breast Imaging: ENGAGED-2 Trial. JNCI cancer spectrum, 2021, Volume: 5, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Density; Breast Neoplasms; Communication; Female; Humans; Internet-Based Intervention; Magnetic Resonance Imaging; Mammography; Middle Aged; Odds Ratio; Patient Reported Outcome Measures; Psychological Distress; Raloxifene Hydrochloride; Risk; Self Report; Tamoxifen; Washington	2021
A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer. Breast cancer research : BCR, 2013, Jun-20, Volume: 15, Issue:3 Topics: Adolescent; Adult; Biomarkers, Tumor; Breast Neoplasms; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Middle Aged; Placebos; Premenopause; Raloxifene Hydrochloride; Tamoxifen	2013
Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention. Breast cancer research : BCR, 2013, Volume: 15, Issue:5 Topics: Adult; Aged; Breast Neoplasms; Chemoprevention; Decision Making; Decision Support Techniques; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Humans; Informed Consent; Internet; Middle Aged; Premedication; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2013
Cognitive factors associated with adherence to oral antiestrogen therapy: results from the cognition in the study of tamoxifen and raloxifene (Co-STAR) study. Cancer prevention research (Philadelphia, Pa.), 2014, Volume: 7, Issue:1 Topics: Aged; Anticarcinogenic Agents; Breast Neoplasms; Cognition; Cognition Disorders; Female; Humans; Logistic Models; Medication Adherence; Middle Aged; Neuropsychological Tests; Postmenopause; Raloxifene Hydrochloride; Risk; Tamoxifen	2014
Influence of Obesity on Breast Density Reduction by Omega-3 Fatty Acids: Evidence from a Randomized Clinical Trial. Cancer prevention research (Philadelphia, Pa.), 2016, Volume: 9, Issue:4 Topics: Adult; Aged; Body Mass Index; Breast; Breast Density; Breast Neoplasms; Docosahexaenoic Acids; Drug Combinations; Drug Therapy, Combination; Eicosapentaenoic Acid; Estrogen Antagonists; Female; Follow-Up Studies; Humans; Mammography; Middle Aged; Obesity; Raloxifene Hydrochloride; Tamoxifen	2016
Stearoyl-CoA desaturase-1, a novel target of omega-3 fatty acids for reducing breast cancer risk in obese postmenopausal women. European journal of clinical nutrition, 2017, Volume: 71, Issue:6 Topics: Adult; Aged; Biomarkers; Body Mass Index; Breast Density; Breast Neoplasms; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Drug Combinations; Eicosapentaenoic Acid; Estrogen Receptor Modulators; Fatty Acids; Fatty Acids, Monounsaturated; Fatty Acids, Omega-3; Female; Follow-Up Studies; Humans; Middle Aged; Obesity; Oleic Acid; Palmitic Acid; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Stearoyl-CoA Desaturase	2017
Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. Journal of the National Cancer Institute, 2008, Jun-18, Volume: 100, Issue:12 Topics: Aged; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Incidence; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Odds Ratio; Osteoporosis, Postmenopausal; Proportional Hazards Models; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Spine	2008
Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2008, Volume: 17, Issue:7 Topics: Breast Neoplasms; Disease Progression; Female; Follow-Up Studies; Humans; Incidence; Magnetic Resonance Imaging; Mammography; Premenopause; Prognosis; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Time Factors	2008
[Expression of Bax protein in normal tissue of premenopausal women treated with raloxifene]. Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia, 2008, Volume: 30, Issue:4 Topics: Adult; bcl-2-Associated X Protein; Breast; Breast Neoplasms; Double-Blind Method; Female; Fibroadenoma; Humans; Premenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Young Adult	2008
Incidence of invasive breast cancer in postmenopausal women after discontinuation of long-term raloxifene administration. Clinical breast cancer, 2009, Volume: 9, Issue:1 Topics: Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Double-Blind Method; Female; Humans; Incidence; Prognosis; Raloxifene Hydrochloride; Survival Rate; Treatment Outcome	2009
Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-01, Volume: 27, Issue:31 Topics: Aged; Breast Neoplasms; Cognition; Female; Humans; Middle Aged; Neuropsychological Tests; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2009
Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition. Journal of women's health (2002), 2010, Volume: 19, Issue:3 Topics: Aged; Breast Neoplasms; Cognition; Estrogens, Conjugated (USP); Female; Humans; Middle Aged; Neuropsychological Tests; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2010
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cataract; Double-Blind Method; Drug Utilization; Endometrial Neoplasms; Estrogens; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Incidence; Middle Aged; Myocardial Ischemia; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism; Uterus	2010
Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid. Breast cancer research and treatment, 2011, Volume: 127, Issue:3 Topics: Adult; Aged; Anticarcinogenic Agents; Breast Neoplasms; Decision Making; Female; Health Knowledge, Attitudes, Practice; Humans; Middle Aged; Patient Education as Topic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2011
Expression of Ki-67 and Bcl-2 biomarkers in normal breast tissue from women of reproductive age treated with raloxifene. Archives of gynecology and obstetrics, 2012, Volume: 285, Issue:1 Topics: Adolescent; Adult; Biomarkers, Tumor; Biopsy; Breast; Breast Neoplasms; Female; Fibroadenoma; Humans; Ki-67 Antigen; Proto-Oncogene Proteins c-bcl-2; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Young Adult	2012
Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Nov-01, Volume: 17, Issue:21 Topics: Aged; Breast Neoplasms; Case-Control Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Female; Humans; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Tamoxifen	2011
Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies. Genetic epidemiology, 2012, Volume: 36, Issue:1 Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Data Mining; Female; Genome-Wide Association Study; Genome, Human; Humans; Linkage Disequilibrium; Models, Genetic; Nitriles; Polymorphism, Single Nucleotide; Raloxifene Hydrochloride; Software; Tamoxifen; Triazoles	2012
Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial. European journal of clinical nutrition, 2012, Volume: 66, Issue:8 Topics: Adult; Aged; Biomarkers; Breast Neoplasms; C-Reactive Protein; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Drug Combinations; Eicosapentaenoic Acid; Endpoint Determination; Estrogen Antagonists; Fatty Acids, Omega-3; Feasibility Studies; Feeding Behavior; Female; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Linear Models; Lipid Peroxidation; Middle Aged; Motor Activity; Oxidative Stress; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Signal Transduction	2012
National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities. Clinical trials (London, England), 2013, Volume: 10, Issue:2 Topics: Antineoplastic Agents; Black or African American; Breast Neoplasms; Chemoprevention; Community-Based Participatory Research; Double-Blind Method; Female; Hispanic or Latino; Humans; Patient Education as Topic; Patient Selection; Racial Groups; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Tamoxifen; White People	2013
Results from a randomized trial of a web-based, tailored decision aid for women at high risk for breast cancer. Patient education and counseling, 2013, Volume: 91, Issue:3 Topics: Aged; Breast Neoplasms; Conflict, Psychological; Decision Support Techniques; Female; Humans; Internet; Michigan; Middle Aged; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Treatment Outcome	2013
The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clinical breast cancer, 2002, Volume: 3, Issue:2 Topics: Adult; Aged; Anticarcinogenic Agents; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Invasiveness; Patient Participation; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2002
The Study of Tamoxifen and Raloxifene (STAR trial) for the prevention of breast cancer. Hawaii medical journal, 2002, Volume: 61, Issue:9 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Eligibility Determination; Female; Hawaii; Humans; Patient Participation; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen	2002
Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. The American journal of cardiology, 2002, Dec-01, Volume: 90, Issue:11 Topics: Aged; Breast Neoplasms; Coronary Disease; Double-Blind Method; Estrogen Antagonists; Female; Humans; Myocardial Infarction; Patient Selection; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Treatment Outcome	2002
Overview of the main outcomes in breast-cancer prevention trials. Lancet (London, England), 2003, Jan-25, Volume: 361, Issue:9354 Topics: Breast Neoplasms; Cause of Death; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Incidence; Middle Aged; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome	2003
Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2003, Volume: 12, Issue:12 Topics: Administration, Oral; Adult; Age Factors; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Leptin; Middle Aged; Pilot Projects; Premenopause; Probability; Raloxifene Hydrochloride; Risk Assessment; Sensitivity and Specificity; Statistics, Nonparametric	2003
Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:8 Topics: Aged; Breast Neoplasms; Coronary Disease; Double-Blind Method; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Pulmonary Embolism; Raloxifene Hydrochloride; Risk Assessment; Stroke; Treatment Outcome	2004
Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy. The Journal of family practice, 2004, Volume: 53, Issue:10 Topics: Adult; Aged; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Cerebrovascular Disorders; Estrogen Replacement Therapy; Female; Humans; Logistic Models; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures	2004
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. Journal of the National Cancer Institute, 2004, Dec-01, Volume: 96, Issue:23 Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Drug Administration Schedule; Estrogen Receptor Modulators; Female; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Patient Selection; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; United States	2004
Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2005, Volume: 16, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Treatment Outcome; United Kingdom	2005
Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2005, Volume: 20, Issue:9 Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Double-Blind Method; Female; Femoral Neck Fractures; Femur Neck; Fracture Healing; Fractures, Bone; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Placebos; Poisson Distribution; Postmenopause; Proportional Hazards Models; Raloxifene Hydrochloride; Risk; Time Factors; Treatment Outcome	2005
Effects of raloxifene on normal breast tissue from premenopausal women. Breast cancer research and treatment, 2006, Volume: 95, Issue:2 Topics: Adult; Breast; Breast Neoplasms; Cell Division; Double-Blind Method; Epithelium; Female; Fibroadenoma; Humans; Ki-67 Antigen; Middle Aged; Premenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2006
Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. The American journal of cardiology, 2006, Feb-15, Volume: 97, Issue:4 Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Cerebrovascular Disorders; Coronary Disease; Female; Follow-Up Studies; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	2006
Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer. Breast cancer research and treatment, 2006, Volume: 98, Issue:2 Topics: Aged; Breast Neoplasms; Collagen Type I; Dehydroepiandrosterone Sulfate; Double-Blind Method; Female; Gonadal Steroid Hormones; Humans; Middle Aged; Peptides; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Sex Hormone-Binding Globulin	2006
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 2006, Jun-21, Volume: 295, Issue:23 Topics: Adult; Aged; Breast Neoplasms; Cataract; Cause of Death; Double-Blind Method; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Myocardial Ischemia; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Thrombosis; Uterine Neoplasms	2006
Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 2006, Jun-21, Volume: 295, Issue:23 Topics: Adult; Aged; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Postmenopause; Quality of Life; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2006
Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2006, Volume: 15, Issue:6 Topics: Adult; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Estradiol; Female; Humans; Middle Aged; Neoplasm Invasiveness; Pilot Projects; Premenopause; Prolactin; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Sex Hormone-Binding Globulin	2006
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. The New England journal of medicine, 2006, Jul-13, Volume: 355, Issue:2 Topics: Aged; Breast Neoplasms; Coronary Disease; Double-Blind Method; Female; Humans; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Thromboembolism	2006
Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:10 Topics: Adult; Bone Density; Breast Neoplasms; Female; Fibrinogen; Humans; Lipids; Middle Aged; Premenopause; Quality of Life; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2006
Risk factors for breast cancer in older women: the relative contribution of bone mineral density and other established risk factors. Breast cancer research and treatment, 2007, Volume: 102, Issue:2 Topics: Aged; Bone Density; Breast Neoplasms; Estradiol; Estrogen Replacement Therapy; Female; Follow-Up Studies; Humans; Incidence; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome; United States	2007
Gynecologic and hormonal effects of raloxifene in premenopausal women. Fertility and sterility, 2007, Volume: 88, Issue:6 Topics: Adult; Breast Neoplasms; Calcium Carbonate; Carcinoma; Dehydroepiandrosterone Sulfate; Drug Administration Schedule; Drug Therapy, Combination; Female; Genitalia, Female; Gonadal Steroid Hormones; Humans; Menstrual Cycle; Middle Aged; Polyps; Premenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Ultrasonography; Uterine Diseases	2007
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast cancer research and treatment, 2008, Volume: 111, Issue:2 Topics: Aged; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Therapy, Combination; Estradiol; Estrone; Female; Humans; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2008
Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis. Current medical research and opinion, 2008, Volume: 24, Issue:3 Topics: Aged; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Femur; Follow-Up Studies; Humans; Incidence; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Risk Factors; Selective Estrogen Receptor Modulators; United States	2008
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA, 1999, Jun-16, Volume: 281, Issue:23 Topics: Aged; Breast Neoplasms; Double-Blind Method; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Follow-Up Studies; Humans; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Thromboembolism	1999
Drugs can reduce the incidence of breast cancer: now what? Delaware medical journal, 1999, Volume: 71, Issue:9 Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Middle Aged; Osteoporosis; Postmenopause; Premenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms	1999
Does raloxifene reduce postmenopausal women's risk of breast cancer? Canadian family physician Medecin de famille canadien, 2000, Volume: 46 Topics: Adult; Aged; Breast Neoplasms; Double-Blind Method; Estrogen Antagonists; Family Practice; Female; Humans; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Assessment	2000
Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. Journal of the National Cancer Institute, 2001, Jan-03, Volume: 93, Issue:1 Topics: Breast; Breast Neoplasms; Double-Blind Method; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Image Interpretation, Computer-Assisted; Mammography; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2001
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast cancer research and treatment, 2001, Volume: 65, Issue:2 Topics: Aged; Aged, 80 and over; Australia; Breast Neoplasms; Double-Blind Method; Estrogen Antagonists; Europe; Female; Follow-Up Studies; Humans; Incidence; Mammography; Middle Aged; New Zealand; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Ultrasonography, Mammary; United States	2001
Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jun-15, Volume: 19, Issue:12 Topics: Aged; Aged, 80 and over; Breast Neoplasms; Double-Blind Method; Estrogens; Female; Humans; Incidence; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome	2001
Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2001, Volume: 10, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Breast Neoplasms; Double-Blind Method; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Italy; Ki-67 Antigen; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tumor Cells, Cultured	2001
Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer. British journal of cancer, 2001, Dec-14, Volume: 85, Issue:12 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Depression, Chemical; Dose-Response Relationship, Drug; Female; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Mastectomy; Middle Aged; Neoplasm Proteins; Postmenopause; Premedication; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2001
Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA, 2002, Jan-09, Volume: 287, Issue:2 Topics: Aged; Breast Neoplasms; Estradiol; Female; Hot Flashes; Humans; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Venous Thrombosis	2002
Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial. Annals of the New York Academy of Sciences, 2001, Volume: 949 Topics: Adenocarcinoma; Breast Neoplasms; Cardiovascular Diseases; Estrogen Replacement Therapy; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2001
The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). Annals of the New York Academy of Sciences, 2001, Volume: 949 Topics: Breast Neoplasms; Carcinoma in Situ; Drug Resistance; Estrogen Receptor Modulators; Female; Humans; Raloxifene Hydrochloride; Tamoxifen; United States	2001

Other Studies

326 other study(ies) available for raloxifene hydrochloride and Breast Cancer

Article	Year
Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator. Journal of medicinal chemistry, 1997, May-09, Volume: 40, Issue:10 Topics: Animals; Breast Neoplasms; Cell Division; Estrogen Antagonists; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Structure; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tumor Cells, Cultured	1997
Molecular and Metabolomic Investigation of Celecoxib Antiproliferative Activity in Mono-and Combination Therapy against Breast Cancer Cell Models. Anti-cancer agents in medicinal chemistry, 2022, Volume: 22, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Breast Neoplasms; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Humans; Metabolomics; Raloxifene Hydrochloride	2022
Searching for an ideal SERM: Mining tamoxifen structure-activity relationships. Bioorganic & medicinal chemistry letters, 2021, 11-15, Volume: 52 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Drug; Estrogen Receptor alpha; Female; Humans; Molecular Structure; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen	2021
Combination therapy of calcitriol inhibits the proliferation of breast cancer cells: new concept of nonclassical function of calcitriol. Hormone molecular biology and clinical investigation, 2021, Nov-15, Volume: 43, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Calcitriol; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Raloxifene Hydrochloride	2021
Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment. European journal of medicinal chemistry, 2022, Feb-05, Volume: 229 Topics: Anastrozole; Antineoplastic Agents; Apoptosis; Biological Products; Breast Neoplasms; Cell Proliferation; Down-Regulation; Estrogen Receptor alpha; Humans; Letrozole; MCF-7 Cells; Molecular Docking Simulation; Protein Binding; Proteolysis; Raloxifene Hydrochloride; Reactive Oxygen Species; Sesterterpenes; Signal Transduction; Structure-Activity Relationship; Tamoxifen	2022
Mitophagy Induction and Aryl Hydrocarbon Receptor-Mediated Redox Signaling Contribute to the Suppression of Breast Cancer Cell Growth by Taloxifene Antioxidants & redox signaling, 2022, Volume: 37, Issue:13-15 Topics: Breast Neoplasms; Female; Humans; Inflammasomes; Mitophagy; NLR Family, Pyrin Domain-Containing 3 Protein; Oxidation-Reduction; Raloxifene Hydrochloride; Reactive Oxygen Species; Receptors, Aryl Hydrocarbon	2022
Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen. Breast cancer research and treatment, 2022, Volume: 193, Issue:2 Topics: Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Female; Humans; Male; Raloxifene Hydrochloride; Tamoxifen	2022
Design and evaluation of hyaluronic acid-coated PLGA nanoparticles of raloxifene hydrochloride for treatment of breast cancer. Drug development and industrial pharmacy, 2021, Volume: 47, Issue:12 Topics: Breast Neoplasms; Drug Carriers; Female; Humans; Hyaluronic Acid; Lactic Acid; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Raloxifene Hydrochloride	2021
Folic acid anchored urchin-like raloxifene nanoparticles for receptor targeting in breast cancer: Synthesis, optimisation and in vitro biological evaluation. International journal of pharmaceutics, 2022, Jul-25, Volume: 623 Topics: Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Folic Acid; Humans; Nanoparticles; Particle Size; Raloxifene Hydrochloride; Serum Albumin, Bovine	2022
Association of raloxifene and tamoxifen therapy with cognitive performance, odds of mild cognitive impairment, and brain MRI markers of neurodegeneration. Cancer medicine, 2023, Volume: 12, Issue:3 Topics: Aged; Brain; Breast Neoplasms; Cognition; Cognitive Dysfunction; Cross-Sectional Studies; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	2023
Formulation, optimization and characterization of raloxifene hydrochloride loaded PLGA nanoparticles by using Taguchi design for breast cancer application. Chemical biology & drug design, 2023, Volume: 102, Issue:3 Topics: Breast Neoplasms; Drug Carriers; Female; Humans; Lactic Acid; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Raloxifene Hydrochloride	2023
Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. Breast cancer research and treatment, 2023, Volume: 201, Issue:2 Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Genes, BRCA1; Humans; Mutation; Raloxifene Hydrochloride; Risk Factors; Tamoxifen	2023
Preparation of fluorescent sensor based on Zn metal-organic framework for detection and determination of raloxifene as an anticancer drug. Environmental research, 2024, Jan-01, Volume: 240, Issue:Pt 2 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Female; Fluorescent Dyes; Humans; Metal-Organic Frameworks; Raloxifene Hydrochloride; Water; Zinc	2024
Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer. Cancer prevention research (Philadelphia, Pa.), 2019, Volume: 12, Issue:11 Topics: Adult; Aged; Breast Neoplasms; Estrogen Antagonists; Female; Genetic Predisposition to Disease; Humans; Middle Aged; Prognosis; Prospective Studies; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen	2019
Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA, 2019, 09-03, Volume: 322, Issue:9 Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Humans; Middle Aged; Mutation; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2019
Breast Cancer Chemoprevention: A Practical Guide for the Primary Care Provider. Journal of women's health (2002), 2020, Volume: 29, Issue:1 Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Decision Making, Shared; Female; Humans; Middle Aged; Physician-Patient Relations; Primary Health Care; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen	2020
Benefits and harms of selective oestrogen receptor modulators (SERMs) to reduce breast cancer risk: a cross-sectional study of methods to communicate risk in primary care. The British journal of general practice : the journal of the Royal College of General Practitioners, 2019, Volume: 69, Issue:689 Topics: Australia; Breast Neoplasms; Cross-Sectional Studies; Decision Making; Female; General Practice; Health Communication; Humans; Logistic Models; Patient Education as Topic; Primary Health Care; Raloxifene Hydrochloride; Risk; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen	2019
Folic acid-conjugated raloxifene hydrochloride carbon nanotube for targeting breast cancer cells. Drug development research, 2020, Volume: 81, Issue:3 Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Delivery Systems; Drug Liberation; Estrogen Antagonists; Female; Folic Acid; Humans; Inhibitory Concentration 50; Nanotubes, Carbon; Particle Size; Raloxifene Hydrochloride; Temperature	2020
Breast Cancer Characteristics and Survival among Users versus Nonusers of Raloxifene. Cancer prevention research (Philadelphia, Pa.), 2020, Volume: 13, Issue:1 Topics: Aged; Aged, 80 and over; Breast; Breast Neoplasms; Drug Prescriptions; Female; Follow-Up Studies; Humans; Mammography; Medicare Part D; Neoplasm Grading; Prognosis; Raloxifene Hydrochloride; SEER Program; Selective Estrogen Receptor Modulators; Survival Analysis; Survival Rate; United States	2020
Vitamin E TPGS based transferosomes augmented TAT as a promising delivery system for improved transdermal delivery of raloxifene. PloS one, 2019, Volume: 14, Issue:12 Topics: Administration, Cutaneous; Animals; Anticarcinogenic Agents; Breast Neoplasms; Drug Carriers; Female; Humans; MCF-7 Cells; Raloxifene Hydrochloride; Rats, Wistar; Selective Estrogen Receptor Modulators; Skin Absorption; tat Gene Products, Human Immunodeficiency Virus; Vitamin E	2019
Medication Use to Reduce Risk of Breast Cancer. American family physician, 2020, 03-15, Volume: 101, Issue:6 Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Medication Adherence; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators	2020
RGD functionalized chitosan nanoparticle mediated targeted delivery of raloxifene selectively suppresses angiogenesis and tumor growth in breast cancer. Nanoscale, 2020, May-21, Volume: 12, Issue:19 Topics: Breast Neoplasms; Cell Line, Tumor; Chitosan; Drug Delivery Systems; Humans; Nanoparticles; Oligopeptides; Raloxifene Hydrochloride; Tumor Microenvironment	2020
Chitosan-Raloxifene nanoparticle containing doxorubicin as a new double-effect targeting vehicle for breast cancer therapy. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2020, Volume: 28, Issue:2 Topics: Breast Neoplasms; Cell Proliferation; Cell Survival; Chitosan; Doxorubicin; Drug Compounding; Drug Delivery Systems; Drug Liberation; Female; Humans; MCF-7 Cells; Nanoparticles; Raloxifene Hydrochloride; Receptors, Estrogen	2020
Proteome activity landscapes of tumor cell lines determine drug responses. Nature communications, 2020, 07-20, Volume: 11, Issue:1 Topics: Adenylate Kinase; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Computational Biology; Computer Simulation; Cytarabine; Drug Development; Genomics; Humans; Leukemia, Myeloid, Acute; Neoplasms; Proteome; Proteomics; Raloxifene Hydrochloride; Receptors, Progesterone; Signal Transduction	2020
Breast Cancer Risk-Reducing Medications. JAMA, 2020, 07-21, Volume: 324, Issue:3 Topics: Adult; Age Factors; Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2020
Nanostructured lipid carrier potentiated oral delivery of raloxifene for breast cancer treatment. Nanotechnology, 2020, Nov-20, Volume: 31, Issue:47 Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Drug Carriers; Ethylene Glycols; Fatty Acids; Female; Humans; MCF-7 Cells; Nanostructures; Raloxifene Hydrochloride; Rats, Wistar; Selective Estrogen Receptor Modulators	2020
Optimized semisolid self-nanoemulsifying system based on glyceryl behenate: A potential nanoplatform for enhancing antitumor activity of raloxifene hydrochloride in MCF-7 human breast cancer cells. International journal of pharmaceutics, 2021, May-01, Volume: 600 Topics: Animals; Apoptosis; Breast Neoplasms; Fatty Acids; Female; Humans; MCF-7 Cells; Raloxifene Hydrochloride; Rats; Rats, Wistar	2021
Raloxifene-loaded SLNs with enhanced biopharmaceutical potential: QbD-steered development, in vitro evaluation, in vivo pharmacokinetics, and IVIVC. Drug delivery and translational research, 2022, Volume: 12, Issue:5 Topics: Animals; Biological Availability; Biological Products; Breast Neoplasms; Caco-2 Cells; Drug Carriers; Female; Humans; Nanoparticles; Particle Size; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Surface-Active Agents	2022
Selective Estrogen Receptor Modulators in Gynecology Practice. Clinical obstetrics and gynecology, 2021, 12-01, Volume: 64, Issue:4 Topics: Breast Neoplasms; Estrogens, Conjugated (USP); Female; Gynecology; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2021
Breast Cancer Prevention: Time for Change. JCO oncology practice, 2021, Volume: 17, Issue:12 Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Tamoxifen	2021
A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor κB Pathways with Hybrid Drugs for Breast Cancer Therapy. Hormones & cancer, 2017, Volume: 8, Issue:3 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Fumarates; Humans; MCF-7 Cells; Molecular Targeted Therapy; NF-kappa B; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen	2017
What Factors Influence Decision-Making about Breast Cancer Chemoprevention among High-Risk Women? Cancer prevention research (Philadelphia, Pa.), 2017, Volume: 10, Issue:11 Topics: Breast Neoplasms; Chemoprevention; Decision Making; Female; Humans; Raloxifene Hydrochloride; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen	2017
A Survey among Breast Cancer Specialists on the Low Uptake of Therapeutic Prevention with Tamoxifen or Raloxifene. Cancer prevention research (Philadelphia, Pa.), 2018, Volume: 11, Issue:1 Topics: Adult; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Practice Patterns, Physicians'; Prognosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Specialization; Surveys and Questionnaires; Tamoxifen	2018
Self-Assembling Raloxifene Loaded Mixed Micelles: Formulation Optimization, In Vitro Cytotoxicity and In Vivo Pharmacokinetics. AAPS PharmSciTech, 2018, Volume: 19, Issue:3 Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Cytotoxins; Drug Liberation; Female; Humans; Hydrophobic and Hydrophilic Interactions; MCF-7 Cells; Micelles; Poloxamer; Polyethylene Glycols; Raloxifene Hydrochloride; Rats; Rats, Wistar; Solubility	2018
Combined Raloxifene and Letrozole for Breast Cancer Patients. Archives of medical research, 2017, Volume: 48, Issue:6 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Letrozole; Nitriles; Raloxifene Hydrochloride	2017
Use of raloxifene and tamoxifen by breast cancer risk level in a Medicare-eligible cohort. American journal of obstetrics and gynecology, 2018, Volume: 218, Issue:6 Topics: Aged; Breast Neoplasms; Carcinoma; Chemoprevention; Cohort Studies; Estrogen Antagonists; Female; Humans; Medicare; Medicare Part D; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen; United States	2018
Impact of NICE guidance on tamoxifen prescribing in England 2011-2017: an interrupted time series analysis. British journal of cancer, 2018, Volume: 118, Issue:9 Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; England; Female; Guideline Adherence; Humans; Interrupted Time Series Analysis; Practice Guidelines as Topic; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Tamoxifen	2018
Apoptosis induction in human breast cancer cell lines by synergic effect of raloxifene and resveratrol through increasing proapoptotic genes. Life sciences, 2018, Jul-15, Volume: 205 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Caspases; Cell Line, Tumor; Cell Survival; Drug Synergism; Female; Humans; MCF-7 Cells; Nitric Oxide; Raloxifene Hydrochloride; Resveratrol; Selective Estrogen Receptor Modulators; Stilbenes	2018
Synthesis and Anti-cancer agents in medicinal chemistry, 2018, Volume: 18, Issue:14 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Esters; Ethers; Female; Humans; Magnetic Resonance Spectroscopy; Maleates; Mice, Inbred BALB C; Micelles; Nylons; Particle Size; Polystyrenes; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, G-Protein-Coupled; Resins, Synthetic; Selective Estrogen Receptor Modulators; Spectroscopy, Fourier Transform Infrared	2018
The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. eLife, 2018, 11-29, Volume: 7 Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Indoles; Ligands; MCF-7 Cells; Mutant Proteins; Mutation; Piperazines; Protein Binding; Protein Domains; Protein Structure, Secondary; Pyridines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen	2018
Investigation of in vitro permeability and in vivo pharmacokinetic behavior of bare and functionalized MCM-41 and MCM-48 mesoporous silica nanoparticles: a burst and controlled drug release system for raloxifene. Drug development and industrial pharmacy, 2019, Volume: 45, Issue:4 Topics: Administration, Oral; Animals; Biological Availability; Breast Neoplasms; Caco-2 Cells; Chemical Engineering; Delayed-Action Preparations; Drug Carriers; Drug Liberation; Drug Screening Assays, Antitumor; Estrogen Antagonists; Female; Humans; Intestinal Mucosa; Mice; Nanoparticles; Osteoporosis; Permeability; Raloxifene Hydrochloride; Silicon Dioxide	2019
Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. BMC women's health, 2013, Mar-23, Volume: 13 Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Cohort Studies; Comorbidity; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Raloxifene Hydrochloride; Retrospective Studies; United States; Women's Health	2013
Breast cancer drugs should be offered to healthy but high risk women, US panel concludes. BMJ (Clinical research ed.), 2013, Apr-18, Volume: 346 Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Middle Aged; Postmenopause; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk; Tamoxifen; United States	2013
Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer. Molecular cancer, 2013, May-01, Volume: 12 Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Caveolin 1; Cell Nucleus; Cell Proliferation; Cytoplasm; Disease Models, Animal; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Gene Expression; Humans; Mice; Protein Binding; Protein Kinase C-alpha; Protein Transport; Raloxifene Hydrochloride; Tamoxifen; Xenograft Model Antitumor Assays	2013
Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo. Cancer prevention research (Philadelphia, Pa.), 2013, Volume: 6, Issue:7 Topics: Breast Neoplasms; Cells, Cultured; Estrogen Antagonists; Female; Gene Expression Regulation, Neoplastic; Genotype; Glucuronides; Glucuronosyltransferase; Humans; Jejunum; Microsomes, Liver; Polymorphism, Genetic; Raloxifene Hydrochloride; Tandem Mass Spectrometry	2013
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer discovery, 2013, Volume: 3, Issue:7 Topics: BRCA1 Protein; Breast Neoplasms; Cathepsins; DNA-Binding Proteins; Estrogen Receptor Modulators; Female; Genome-Wide Association Study; Humans; Polymorphism, Single Nucleotide; Precision Medicine; Proteins; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	2013
NICE recommends preventive drugs for breast cancer. BMJ (Clinical research ed.), 2013, Jun-25, Volume: 346 Topics: Academies and Institutes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2013
Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement. Annals of internal medicine, 2013, Nov-19, Volume: 159, Issue:10 Topics: Adult; Aged; Biomedical Research; Breast Neoplasms; Decision Making; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2013
Summaries for patients. Using medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force. Annals of internal medicine, 2013, Nov-19, Volume: 159, Issue:10 Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2013
Experts add second drug to breast cancer prevention regimen. Harvard women's health watch, 2013, Volume: 21, Issue:2 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Tamoxifen; United States; Women's Health	2013
The aryl hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen receptor-negative hepatoma and breast cancer cells. Cell death & disease, 2014, Jan-30, Volume: 5 Topics: Animals; Apoptosis; Breast Neoplasms; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Humans; Liver Neoplasms; Mice; Protein Binding; Raloxifene Hydrochloride; Receptors, Aryl Hydrocarbon; Receptors, Estrogen	2014
Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations. Steroids, 2014, Volume: 90 Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Estrogens; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2014
Controlled release of raloxifene by nanoencapsulation: effect on in vitro antiproliferative activity of human breast cancer cells. International journal of nanomedicine, 2014, Volume: 9 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Delayed-Action Preparations; Diffusion; Humans; MCF-7 Cells; Nanocapsules; Particle Size; Polymethacrylic Acids; Raloxifene Hydrochloride; Treatment Outcome	2014
Lowering your breast cancer risk. A daily pill can hold the key to prevention for some women. The Johns Hopkins medical letter health after 50, 2014, Volume: 25, Issue:15 Topics: Adult; Breast Neoplasms; Female; Genetic Predisposition to Disease; Humans; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen	2014
Selenium analogues of raloxifene as promising antiproliferative agents in treatment of breast cancer. European journal of medicinal chemistry, 2014, Nov-24, Volume: 87 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred BALB C; NIH 3T3 Cells; Raloxifene Hydrochloride; Selenium; Spectrometry, Mass, Electrospray Ionization	2014
Risk-benefit profiles of women using tamoxifen for chemoprevention. Journal of the National Cancer Institute, 2015, Volume: 107, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Cohort Studies; Drug Administration Schedule; Estrogen Antagonists; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Middle Aged; Odds Ratio; Primary Prevention; Puerto Rico; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; United States	2015
Raloxifene induces autophagy-dependent cell death in breast cancer cells via the activation of AMP-activated protein kinase. Molecules and cells, 2015, Volume: 38, Issue:2 Topics: Adenine; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Breast Neoplasms; Caspases; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Membrane Proteins; Microtubule-Associated Proteins; Raloxifene Hydrochloride; Signal Transduction	2015
A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2. Breast cancer research and treatment, 2015, Volume: 149, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Female; Genetic Predisposition to Disease; Genotype; Humans; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Prognosis; Raloxifene Hydrochloride; Receptors, Estrogen; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2015
Twenty-five years of breast cancer risk models and their applications. Journal of the National Cancer Institute, 2015, Volume: 107, Issue:5 Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Hormonal; Breast Density; Breast Neoplasms; Cause of Death; Counseling; Early Detection of Cancer; Female; Humans; Incidence; Mammary Glands, Human; Mammography; Mass Screening; Mastectomy; Middle Aged; Models, Statistical; Public Health; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; SEER Program; Selective Estrogen Receptor Modulators; Tamoxifen; United States; Unnecessary Procedures; White People	2015
Breast cancer risk reduction therapy: the low-hanging fruit. Journal of the National Comprehensive Cancer Network : JNCCN, 2015, Volume: 13, Issue:4 Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma in Situ; Female; Humans; Hyperplasia; Nitriles; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles	2015
Milk Thistle Constituents Inhibit Raloxifene Intestinal Glucuronidation: A Potential Clinically Relevant Natural Product-Drug Interaction. Drug metabolism and disposition: the biological fate of chemicals, 2015, Volume: 43, Issue:9 Topics: Breast Neoplasms; Drug Interactions; Female; Glucuronides; Humans; Intestinal Mucosa; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Silybum marianum	2015
My Lived Experiences Are More Important Than Your Probabilities: The Role of Individualized Risk Estimates for Decision Making about Participation in the Study of Tamoxifen and Raloxifene (STAR). Medical decision making : an international journal of the Society for Medical Decision Making, 2015, Volume: 35, Issue:8 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Decision Making; Estrogen Antagonists; Female; Health Knowledge, Attitudes, Practice; Humans; Interviews as Topic; Middle Aged; National Cancer Institute (U.S.); Probability; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen; United States	2015
Gaining control over breast cancer risk: Transforming vulnerability, uncertainty, and the future through clinical trial participation - a qualitative study. Sociology of health & illness, 2015, Volume: 37, Issue:8 Topics: Adult; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Interviews as Topic; Middle Aged; Narration; Qualitative Research; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Sociology, Medical; Tamoxifen; Uncertainty	2015
Estrogen-mediated inactivation of FOXO3a by the G protein-coupled estrogen receptor GPER. BMC cancer, 2015, Oct-15, Volume: 15 Topics: Breast Neoplasms; Cell Proliferation; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, G-Protein-Coupled; RNA, Small Interfering; Tamoxifen	2015
Reversal effects of Raloxifene on paclitaxel resistance in 2 MDR breast cancer cells. Cancer biology & therapy, 2015, Volume: 16, Issue:12 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Density Conservation Agents; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin B1; Drug Resistance, Neoplasm; Female; Humans; Mitosis; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Raloxifene Hydrochloride	2015
A novel curcumin derivative increases the cytotoxicity of raloxifene in estrogen receptor-negative breast cancer cell lines. International journal of oncology, 2016, Volume: 48, Issue:1 Topics: Apoptosis; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cell Movement; Curcumin; Drug Synergism; Female; Human Umbilical Vein Endothelial Cells; Humans; Neoplasm Invasiveness; Raloxifene Hydrochloride; Receptors, Estrogen; Signal Transduction	2016
Combinatorial PX-866 and Raloxifene Decrease Rb Phosphorylation, Cyclin E2 Transcription, and Proliferation of MCF-7 Breast Cancer Cells. Journal of cellular biochemistry, 2016, Volume: 117, Issue:7 Topics: Breast Neoplasms; Cell Proliferation; Cyclins; E2F1 Transcription Factor; Female; Gonanes; Humans; MCF-7 Cells; Raloxifene Hydrochloride; Retinoblastoma Protein; Transcription, Genetic	2016
The Effectiveness of Raloxifene-Loaded Liposomes and Cochleates in Breast Cancer Therapy. AAPS PharmSciTech, 2016, Volume: 17, Issue:4 Topics: Animals; Antineoplastic Agents; beta-Cyclodextrins; Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Chemistry, Pharmaceutical; Female; Humans; Liposomes; Matrix Metalloproteinase 2; MCF-7 Cells; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Taurocholic Acid	2016
Affective forecasting and medication decision making in breast-cancer prevention. Health psychology : official journal of the Division of Health Psychology, American Psychological Association, 2016, Volume: 35, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Chemoprevention; Decision Making; Decision Support Techniques; Female; Follow-Up Studies; Forecasting; Humans; Intention; Medication Adherence; Middle Aged; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen	2016
Ameliorative potential of fluoxetine/raloxifene combination on experimentally induced breast cancer. Tissue & cell, 2016, Volume: 48, Issue:2 Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catalase; Fluoxetine; Humans; Interleukin-6; Malondialdehyde; Raloxifene Hydrochloride; Rats; Superoxide Dismutase; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha	2016
Paxillin, a novel controller in the signaling of estrogen to FAK/N-WASP/Arp2/3 complex in breast cancer cells. Molecular and cellular endocrinology, 2016, 07-15, Volume: 430 Topics: Actin Cytoskeleton; Actin-Related Protein 2-3 Complex; Breast Neoplasms; cdc42 GTP-Binding Protein; Cell Adhesion; Cell Line, Tumor; Cell Movement; Estrogen Receptor alpha; Estrogens; Female; Focal Adhesion Protein-Tyrosine Kinases; GTP-Binding Protein alpha Subunits, Gi-Go; GTP-Binding Protein beta Subunits; Humans; Neoplasm Invasiveness; Paxillin; Phosphorylation; Protein Transport; Raloxifene Hydrochloride; Signal Transduction; src-Family Kinases; Wiskott-Aldrich Syndrome Protein, Neuronal	2016
Synthesis and evaluation of raloxifene derivatives as a selective estrogen receptor down-regulator. Bioorganic & medicinal chemistry, 2016, 07-01, Volume: 24, Issue:13 Topics: Breast Neoplasms; Down-Regulation; Female; Humans; Inhibitory Concentration 50; MCF-7 Cells; Protein Binding; Raloxifene Hydrochloride; Receptors, Estrogen	2016
A Raloxifene Withdrawal Response: Translational Research, Definitions, and Clinical Applications. Integrative cancer therapies, 2016, Volume: 15, Issue:3 Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Raloxifene Hydrochloride; Substance Withdrawal Syndrome; Translational Research, Biomedical	2016
Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer. Oncology reports, 2016, Volume: 36, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Leupeptins; MCF-7 Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Tamoxifen	2016
Clinician-Reported Barriers to Implementing Breast Cancer Chemoprevention in the UK: A Qualitative Investigation. Public health genomics, 2016, Volume: 19, Issue:4 Topics: Adult; Antineoplastic Agents, Hormonal; Attitude of Health Personnel; Breast Neoplasms; Chemoprevention; Clinical Competence; Female; Humans; Male; Middle Aged; Physicians, Family; Qualitative Research; Raloxifene Hydrochloride; Tamoxifen; United Kingdom	2016
Anti-Estrogen Withdrawal Effect With Raloxifene? A Case Report. Integrative cancer therapies, 2016, Volume: 15, Issue:3 Topics: Aged; Breast Neoplasms; Capecitabine; Estrogen Antagonists; Estrogens; Female; Humans; Neoplasm Recurrence, Local; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2016
Should We Offer Medication to Reduce Breast Cancer Risk?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Annals of internal medicine, 2016, 08-02, Volume: 165, Issue:3 Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Decision-Making; Female; Humans; Middle Aged; Practice Guidelines as Topic; Primary Health Care; Raloxifene Hydrochloride; Risk Assessment; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen	2016
The rise of raloxifene and the fall of invasive breast cancer. Journal of the National Cancer Institute, 2008, Jun-18, Volume: 100, Issue:12 Topics: Aged; Animals; Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Evidence-Based Medicine; Female; Humans; Incidence; Middle Aged; Neoplasm Invasiveness; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2008
Toward optimal health: advances in breast cancer detection and management. Interview by Jodi R. Godfrey. Journal of women's health (2002), 2008, Volume: 17, Issue:7 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Mammography; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; United States	2008
Effects of raloxifene on breast cancer cell migration and invasion through the actin cytoskeleton. Journal of cellular and molecular medicine, 2009, Volume: 13, Issue:8B Topics: Actins; Breast Neoplasms; Cell Line, Tumor; Cytoskeleton; Female; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Raloxifene Hydrochloride	2009
Regulation of estrogenic effects by beclin 1 in breast cancer cells. Cancer research, 2008, Oct-01, Volume: 68, Issue:19 Topics: Apoptosis Regulatory Proteins; Beclin-1; Breast Neoplasms; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Raloxifene Hydrochloride; Signal Transduction; Tissue Distribution; Tumor Cells, Cultured	2008
To switch or not to switch: should the study of tamoxifen and raloxifene (STAR) trial alter our decision? Taiwanese journal of obstetrics & gynecology, 2008, Volume: 47, Issue:3 Topics: Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Decision Making; Disease-Free Survival; Female; Humans; Incidence; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome	2008
Effects of raloxifene on Ki-67 and CD34 antigen expression in breast cancer. Gynecologic and obstetric investigation, 2009, Volume: 67, Issue:2 Topics: Adult; Aged; Antigens, CD34; Biomarkers; Biopsy, Needle; Breast Neoplasms; Cohort Studies; Female; Follow-Up Studies; Humans; Immunohistochemistry; Ki-67 Antigen; Mastectomy, Segmental; Microvessels; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neovascularization, Pathologic; Observer Variation; Preoperative Care; Probability; Raloxifene Hydrochloride; Receptors, Estrogen; Reference Values; Risk Assessment; Sensitivity and Specificity; Survival Rate; Treatment Outcome	2009
Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan. British journal of cancer, 2009, Jan-27, Volume: 100, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Lobular; Cost-Benefit Analysis; Female; Humans; Japan; Markov Chains; Middle Aged; Neoplasm Invasiveness; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Tamoxifen	2009
Declining breast cancer incidence and decreased HRT use. Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662 Topics: Age Distribution; Aged; Breast Neoplasms; Estrogen Replacement Therapy; Female; Humans; Incidence; Mass Screening; Middle Aged; Raloxifene Hydrochloride; Scotland; Selective Estrogen Receptor Modulators	2009
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jul-01, Volume: 27, Issue:19 Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2009
Raloxifene and risk for stroke based on the framingham stroke risk score. The American journal of medicine, 2009, Volume: 122, Issue:8 Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Spinal Fractures; Stroke	2009
Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan. Japanese journal of clinical oncology, 2009, Volume: 39, Issue:11 Topics: Adult; Aged; Anticarcinogenic Agents; Breast Neoplasms; Chemoprevention; Cost-Benefit Analysis; Drug Costs; Estrogen Receptor Modulators; Evidence-Based Medicine; Female; Humans; Japan; Middle Aged; Primary Prevention; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Tamoxifen	2009
American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Gynecologic oncology, 2009, Volume: 115, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fenretinide; Humans; Raloxifene Hydrochloride; Tamoxifen	2009
Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. The Journal of steroid biochemistry and molecular biology, 2010, Volume: 118, Issue:1-2 Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogens, Conjugated (USP); Female; Gene Expression; Gene Expression Profiling; Humans; Indoles; Oligonucleotide Array Sequence Analysis; Pyrrolidines; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; Selective Estrogen Receptor Modulators; Signal Transduction; Tetrahydronaphthalenes; Up-Regulation	2010
New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. Breast (Edinburgh, Scotland), 2009, Volume: 18 Suppl 3 Topics: Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Drug Delivery Systems; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, G-Protein-Coupled; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen	2009
Another selective estrogen-receptor modulator for osteoporosis. The New England journal of medicine, 2010, Feb-25, Volume: 362, Issue:8 Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism	2010
The role of the primary care physician in the prevention, diagnosis and treatment of breast cancer: contemporary knowledge and controversies. Southern medical journal, 2010, Volume: 103, Issue:4 Topics: Breast Neoplasms; Evidence-Based Medicine; Female; Humans; Mastectomy; Patient Participation; Physician's Role; Physicians, Family; Primary Prevention; Radiography; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators	2010
Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:2 Topics: Acetylcysteine; Amino Acid Transport System ASC; Antioxidants; Apoptosis; Biological Transport; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Fragmentation; Dose-Response Relationship, Drug; Estradiol; Female; Gene Expression; Glutamine; Glutathione; Humans; Minor Histocompatibility Antigens; Oxidative Stress; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen	2011
CYP3A4-Mediated oxygenation versus dehydrogenation of raloxifene. Biochemistry, 2010, Jun-01, Volume: 49, Issue:21 Topics: Apoproteins; Breast Neoplasms; Chemoprevention; Cytochrome P-450 CYP3A; DNA Damage; Female; Humans; Raloxifene Hydrochloride; Tamoxifen	2010
Evaluation of Ki-67 and Bcl-2 antigen expression in breast carcinomas of women treated with raloxifene. Cell proliferation, 2010, Volume: 43, Issue:2 Topics: Aged; Biopsy; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Nucleus; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators	2010
Do selective estrogen receptor modulators treat cervical precancer and cancer? Time to pool data from relevant trials. International journal of cancer, 2011, Feb-15, Volume: 128, Issue:4 Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Uterine Neoplasms	2011
Two good choices to prevent breast cancer: great taste, less filling. Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:6 Topics: Adenocarcinoma; Breast Neoplasms; Drug Utilization; Endometrial Neoplasms; Estrogens; Female; Follow-Up Studies; Humans; Incidence; Meta-Analysis as Topic; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus	2010
The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention. Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:6 Topics: Adenocarcinoma; Breast Neoplasms; Decision Support Techniques; Drug Utilization; Estrogens; Female; Humans; Incidence; Internet; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Patient Education as Topic; Physicians, Family; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen	2010
Long-term follow-up in cancer prevention trials (It ain't over 'til it's over). Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:6 Topics: Adenocarcinoma; Breast Neoplasms; Double-Blind Method; Drug Utilization; Endometrial Neoplasms; Estrogens; Female; Follow-Up Studies; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Humans; Incidence; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Papillomavirus Vaccines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Reduction Behavior; Sample Size; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Cervical Neoplasms	2010
Development and validation of a test for environmental estrogens: Checking xeno-estrogen activity by CXCL12 secretion in BREAST CANCER CELL LINES (CXCL-test). Environmental toxicology, 2010, Volume: 25, Issue:5 Topics: Benzhydryl Compounds; Breast Neoplasms; Cell Line, Tumor; Chemokine CXCL12; Dose-Response Relationship, Drug; Environmental Monitoring; Environmental Pollutants; Estradiol; Estrogen Receptor Modulators; Estrogens; Ethinyl Estradiol; Female; Genistein; Humans; Phenols; Raloxifene Hydrochloride; Tamoxifen; Time Factors	2010
In vitro mechanism of action for the cytotoxicity elicited by the combination of epigallocatechin gallate and raloxifene in MDA-MB-231 cells. Oncology reports, 2010, Volume: 24, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catechin; Cell Line, Tumor; ErbB Receptors; Estrogen Receptor alpha; Female; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Raloxifene Hydrochloride; Receptor, ErbB-2; Ribosomal Protein S6 Kinases; Selective Estrogen Receptor Modulators; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Transcription Factor RelA	2010
Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer. Bone, 2010, Volume: 47, Issue:5 Topics: Aged; Algorithms; Breast Neoplasms; Cost-Benefit Analysis; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride	2010
Patient characteristics and utilization of breast cancer screening or diagnostic procedures prior to initiation of raloxifene, bisphosphonates and calcitonin. Current medical research and opinion, 2010, Volume: 26, Issue:11 Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Calcitonin; Databases, Factual; Diagnostic Techniques and Procedures; Diphosphonates; Female; Humans; Mass Screening; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Retrospective Studies	2010
Raloxifene inhibits tumor growth and lymph node metastasis in a xenograft model of metastatic mammary cancer. BMC cancer, 2010, Oct-19, Volume: 10 Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Estrogen Receptor alpha; Female; Humans; Lymphatic Metastasis; Male; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Sex Factors	2010
Tipping the balance for the primary prevention of breast cancer. Journal of the National Cancer Institute, 2010, Nov-17, Volume: 102, Issue:22 Topics: Adult; Age Factors; Aged; Anticarcinogenic Agents; Biomarkers, Tumor; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Confounding Factors, Epidemiologic; Estradiol; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Risk Assessment; Sample Size; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Treatment Outcome	2010
Third-generation SERMs may face uphill battle. Journal of the National Cancer Institute, 2010, Nov-17, Volume: 102, Issue:22 Topics: Anticarcinogenic Agents; Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Drug Industry; Estradiol; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal; Patents as Topic; Primary Prevention; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; United States; United States Food and Drug Administration	2010
The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women. Menopause (New York, N.Y.), 2011, Volume: 18, Issue:1 Topics: Breast Neoplasms; Estrogen Antagonists; Estrogens; Female; Female Urogenital Diseases; Humans; Indoles; Osteoporosis, Postmenopausal; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes	2011
Prevention of breast cancer: the case for studying inhibition of IGF-1 actions. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22 Suppl 1 Topics: Animals; Breast Neoplasms; Female; Humans; Insulin-Like Growth Factor I; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Somatostatin; Tamoxifen	2011
Reduction of stimulated sodium iodide symporter expression by estrogen receptor ligands in breast cancer cells. Nuclear medicine and biology, 2011, Volume: 38, Issue:2 Topics: Animals; Biological Transport; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Interactions; Estradiol; Female; Gene Expression Regulation, Neoplastic; Humans; Iodine Radioisotopes; Ligands; Mice; Mice, Inbred BALB C; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Symporters; Tamoxifen; Tretinoin; Xenograft Model Antitumor Assays	2011
Breast cancer prevention in high-risk women: searching for new options. Journal of the National Cancer Institute, 2011, May-04, Volume: 103, Issue:9 Topics: Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Genes, BRCA1; Genes, BRCA2; Heterozygote; Humans; Mastectomy; Mutation; Ovariectomy; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2011
Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-10, Volume: 29, Issue:17 Topics: Aged; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Estrogen Antagonists; Female; Hispanic or Latino; Humans; Middle Aged; Raloxifene Hydrochloride; Tamoxifen	2011
Breast cancer chemoprevention gets personal. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-10, Volume: 29, Issue:17 Topics: Breast Neoplasms; Chemoprevention; Female; Humans; Raloxifene Hydrochloride; Tamoxifen	2011
Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance. Oncogene, 2012, Jan-05, Volume: 31, Issue:1 Topics: 14-3-3 Proteins; Apoptosis; Breast Neoplasms; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; MicroRNAs; Raloxifene Hydrochloride; Receptor, ErbB-2; Selective Estrogen Receptor Modulators; Tamoxifen	2012
The effect of raloxifene on telomerase expression in breast carcinoma samples from postmenopausal women. European journal of obstetrics, gynecology, and reproductive biology, 2011, Volume: 159, Issue:1 Topics: Aged; Antineoplastic Agents; Biopsy; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Down-Regulation; Female; Humans; Immunohistochemistry; Mammary Glands, Human; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Telomerase	2011
Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). American journal of obstetrics and gynecology, 2011, Volume: 205, Issue:6 Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Hyperplasia; Estrogen Antagonists; Female; Follow-Up Studies; Hot Flashes; Humans; Incidence; Leiomyoma; Middle Aged; Ovarian Cysts; Polyps; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Uterine Neoplasms; Vaginal Discharge	2011
The breast cancer chemoprevention debate. Journal of the National Cancer Institute, 2011, Nov-16, Volume: 103, Issue:22 Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Female; Humans; Models, Statistical; Nitriles; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles	2011
What is the significance of gynecologic symptoms in the participants in the NSABP study? American journal of obstetrics and gynecology, 2011, Volume: 205, Issue:6 Topics: Breast Neoplasms; Female; Humans; Leiomyoma; Raloxifene Hydrochloride; Tamoxifen; Uterine Neoplasms	2011
Four decades of discovery in breast cancer research and treatment--an interview with V. Craig Jordan. Interview by Marc Poirot. The International journal of developmental biology, 2011, Volume: 55, Issue:7-9 Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; England; Female; History, 20th Century; History, 21st Century; Humans; Mice; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Translational Research, Biomedical	2011
Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials. Cancer prevention research (Philadelphia, Pa.), 2012, Volume: 5, Issue:4 Topics: Adult; Aged; Body Mass Index; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Invasiveness; Obesity; Postmenopause; Premenopause; Proportional Hazards Models; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk; Tamoxifen	2012
Raloxifene inhibits menin-dependent estrogen receptor activation in breast cancer cells. Journal of endocrinological investigation, 2011, Volume: 34, Issue:11 Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Estrogen Receptor alpha; Female; Humans; Proto-Oncogene Proteins; Raloxifene Hydrochloride	2011
The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor β expression. Molecular and cellular biochemistry, 2012, Volume: 366, Issue:1-2 Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Cyclin B; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Inhibitory Concentration 50; Raloxifene Hydrochloride; Receptors, Progesterone; Trefoil Factor-1; Tumor Suppressor Proteins	2012
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast cancer research and treatment, 2012, Volume: 134, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Chemoprevention; Drug Utilization; Female; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Tamoxifen; United States	2012
What happened to WHI: menopausal hormonal therapy in 2012. Clinical obstetrics and gynecology, 2012, Volume: 55, Issue:3 Topics: Atrophy; Breast Neoplasms; Endometrial Neoplasms; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Estrogens; Female; Hot Flashes; Humans; Menopause; Middle Aged; Norpregnenes; Patient Selection; Raloxifene Hydrochloride; Vagina	2012
Exemestane for primary prevention of breast cancer in postmenopausal women. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2012, Aug-15, Volume: 69, Issue:16 Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Estrogen Antagonists; Female; Genetic Predisposition to Disease; Humans; Middle Aged; Postmenopause; Primary Prevention; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen	2012
Discovery of a new class of liver receptor homolog-1 (LRH-1) antagonists: virtual screening, synthesis and biological evaluation. ChemMedChem, 2012, Volume: 7, Issue:11 Topics: Animals; Breast Neoplasms; Chlorocebus aethiops; COS Cells; Drug Design; Female; Humans; Ligands; Models, Molecular; Protein Conformation; Raloxifene Hydrochloride; Receptors, Cytoplasmic and Nuclear	2012
Preventive therapy for breast cancer. Current oncology reports, 2012, Volume: 14, Issue:6 Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Meta-Analysis as Topic; Middle Aged; Piperidines; Preventive Medicine; Pyrrolidines; Raloxifene Hydrochloride; Receptor, ErbB-2; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes	2012
Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR). Cancer prevention research (Philadelphia, Pa.), 2012, Volume: 5, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carcinoma; Cell Count; Combined Modality Therapy; Female; Humans; Mammography; Middle Aged; Neoplasm Invasiveness; Postmenopause; Predictive Value of Tests; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen	2012
The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast cancer research and treatment, 2012, Volume: 136, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anticarcinogenic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemoprevention; Female; Humans; Hyperplasia; Mammary Glands, Human; Middle Aged; Precancerous Conditions; Raloxifene Hydrochloride; Tamoxifen	2012
Positive and negative affect, depression, and cognitive processes in the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Trial. Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition, 2013, Volume: 20, Issue:5 Topics: Adult; Affect; Aged; Antineoplastic Agents; Breast Neoplasms; Cognition; Depression; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen	2013
Breast cancer facts. The Journal of the Oklahoma State Medical Association, 2012, Volume: 105, Issue:10 Topics: Age Distribution; Breast Neoplasms; Breast Neoplasms, Male; Early Detection of Cancer; Estrogen Replacement Therapy; Exercise; Female; Humans; Male; Overweight; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Survival Rate; Tamoxifen; United States	2012
Two-phase designs to follow-up genome-wide association signals with DNA resequencing studies. Genetic epidemiology, 2013, Volume: 37, Issue:3 Topics: Breast Neoplasms; Case-Control Studies; Computer Simulation; Female; Genome-Wide Association Study; Humans; Linkage Disequilibrium; Models, Genetic; Polymorphism, Single Nucleotide; Raloxifene Hydrochloride; Sequence Analysis, DNA; Tamoxifen	2013
Raloxifene for the treatment and prevention of breast cancer? Expert review of anticancer therapy, 2001, Volume: 1, Issue:3 Topics: Breast Neoplasms; Cardiovascular Diseases; Female; Humans; Lipids; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Uterus	2001
USPSTF releases guidelines on breast-cancer chemoprevention. Lancet (London, England), 2002, Jul-06, Volume: 360, Issue:9326 Topics: Anticarcinogenic Agents; Breast Neoplasms; Female; Humans; Practice Guidelines as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen; United States	2002
Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells. Molecular pharmacology, 2002, Volume: 62, Issue:4 Topics: Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Catalysis; Enzyme Activation; Epithelial Cells; Estrogen Antagonists; Humans; Phospholipase D; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured	2002
Solid-phase synthesis and investigation of benzofurans as selective estrogen receptor modulators. Bioorganic & medicinal chemistry letters, 2002, Oct-21, Volume: 12, Issue:20 Topics: Benzofurans; Breast Neoplasms; Cell Line; Drug Design; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; Models, Molecular; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators	2002
Breast cancer prevention and surveillance. Clinical obstetrics and gynecology, 2002, Volume: 45, Issue:3 Topics: Breast Neoplasms; Female; Humans; Incidence; Life Style; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2002
ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists: Number 39, October 2002. Selective estrogen receptor modulators. Obstetrics and gynecology, 2002, Volume: 100, Issue:4 Topics: Bone Resorption; Breast Neoplasms; Cardiovascular Diseases; Endometrium; Female; Genitalia, Female; Hot Flashes; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism	2002
Task force cautious about chemoprevention. Official guidelines are out about taking tamoxifen and raloxifene to prevent breast cancer. These drugs can help, but they aren't for everyone. Harvard women's health watch, 2002, Volume: 10, Issue:2 Topics: Advisory Committees; Age Factors; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Female; Humans; Practice Guidelines as Topic; Primary Prevention; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; United States	2002
Tamoxifen versus raloxifene in the prevention of breast cancer. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38 Suppl 6 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome	2002
ACOG practice bulletin. Selective estrogen receptor modulators. Number 39, October 2002 (replaces Committee Opinion Number 224, October 1999). International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2002, Volume: 79, Issue:3 Topics: Adult; Bone and Bones; Bone Density; Breast Neoplasms; Cardiovascular System; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms	2002
Biological significance of interventions that change breast density. Journal of the National Cancer Institute, 2003, Jan-01, Volume: 95, Issue:1 Topics: Anticarcinogenic Agents; Breast; Breast Neoplasms; Estrogen Replacement Therapy; Estrogens; Female; Humans; Mammography; Middle Aged; Progestins; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2003
The hidden alternative: getting investigational treatments off-study. Lancet (London, England), 2003, Jan-04, Volume: 361, Issue:9351 Topics: Biomedical Research; Breast Neoplasms; Female; Humans; Informed Consent; Patient Rights; Physician-Patient Relations; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen; United States	2003
Tamoxifen and raloxifene may benefit women at high risk for breast cancer. Report on medical guidelines & outcomes research, 2002, Jul-26, Volume: 13, Issue:14 Topics: Anticarcinogenic Agents; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Female; Humans; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; United States	2002
Experts hopeful about designer estrogens. For some women, selective estrogen receptor modulators (SERMs) help prevent breast cancer. Health news (Waltham, Mass.), 2003, Volume: 9, Issue:4 Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2003
Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage. Molecular endocrinology (Baltimore, Md.), 2003, Volume: 17, Issue:7 Topics: 8-Hydroxy-2'-Deoxyguanosine; Breast Neoplasms; DNA Damage; DNA Repair; DNA-Binding Proteins; Enzyme Activation; Epithelial Cells; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Guanine; Humans; NAD(P)H Dehydrogenase (Quinone); Oxidative Stress; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Xeroderma Pigmentosum Group A Protein	2003
Chemoprevention of breast cancer: recommendations and rationale. The American journal of nursing, 2003, Volume: 103, Issue:5 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism	2003
Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma. Breast cancer research and treatment, 2003, Volume: 79, Issue:1 Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Division; Chorionic Gonadotropin, beta Subunit, Human; Estradiol; Estrogen Receptor Modulators; Female; Medroxyprogesterone Acetate; Melitten; Mice; Mice, Inbred BALB C; Raloxifene Hydrochloride; Receptors, Progesterone; Tamoxifen; Tumor Cells, Cultured	2003
[SERM for early osteoporosis therapy. Risk for first spinal fracture reduced to half]. MMW Fortschritte der Medizin, 2003, May-29, Volume: 145, Issue:22 Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Humans; Incidence; Osteoporosis, Postmenopausal; Placebos; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Time Factors	2003
[From alcohol abstinence to total surgery. Preventive strategies in breast carcinoma]. MMW Fortschritte der Medizin, 2003, Jun-12, Volume: 145, Issue:24 Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Dietary Fats; Estradiol; Estrogen Antagonists; Ethanol; Follow-Up Studies; Humans; Incidence; Insulin-Like Growth Factor I; Mastectomy; Middle Aged; Obesity; Osteoporosis; Ovariectomy; Placebos; Postmenopause; Primary Prevention; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Sports; Tamoxifen; Time Factors	2003
[Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient]. MMW Fortschritte der Medizin, 2003, Jun-12, Volume: 145, Issue:24 Topics: Adult; Age Factors; Aged; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Immunotherapy; Letrozole; Meta-Analysis as Topic; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Premenopause; Prognosis; Quality of Health Care; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Toremifene; Trastuzumab; Triazoles	2003
Breast-cancer prevention: is the risk-benefit ratio in favour of tamoxifen? Lancet (London, England), 2003, Jul-19, Volume: 362, Issue:9379 Topics: Adult; Aged; Anticarcinogenic Agents; Breast Neoplasms; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Tamoxifen; Treatment Outcome	2003
Raloxifene inhibits estrogen-induced up-regulation of telomerase activity in a human breast cancer cell line. The Journal of biological chemistry, 2003, Oct-31, Volume: 278, Issue:44 Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Nucleus; Chromones; DNA-Binding Proteins; Enzyme Inhibitors; Estrogen Antagonists; Estrogens; Genes, Reporter; Humans; Luciferases; Microscopy, Fluorescence; Models, Biological; Morpholines; NF-kappa B; Phosphatidylinositol 3-Kinases; Phosphorylation; Plasmids; Promoter Regions, Genetic; Protein Binding; Protein Processing, Post-Translational; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; Telomerase; Time Factors; Up-Regulation	2003
Early discontinuation of treatment for osteoporosis. The American journal of medicine, 2003, Aug-15, Volume: 115, Issue:3 Topics: Alendronate; Bone Diseases, Metabolic; Breast Neoplasms; California; Cohort Studies; Estrogen Replacement Therapy; Female; Health Care Surveys; Health Knowledge, Attitudes, Practice; Heart Diseases; Humans; Interviews as Topic; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Treatment Refusal	2003
Playing the old piano: another tune for endocrine therapy? Journal of the National Cancer Institute, 2003, Nov-05, Volume: 95, Issue:21 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Clinical Trials as Topic; Diethylstilbestrol; Disease Progression; Drug Administration Schedule; Estrogen Receptor Modulators; Female; Humans; Male; Neoplasms, Hormone-Dependent; Ovariectomy; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Treatment Outcome	2003
Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. Journal of the National Cancer Institute, 2003, Nov-05, Volume: 95, Issue:21 Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Female; Humans; Mice; Mice, Nude; NF-kappa B; Ovariectomy; Polymerase Chain Reaction; Raloxifene Hydrochloride; RNA, Messenger; RNA, Neoplasm; Selective Estrogen Receptor Modulators	2003
Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity. Oncogene, 2004, Jan-15, Volume: 23, Issue:2 Topics: Breast Neoplasms; Cell Line, Tumor; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Gene Expression Regulation, Neoplastic; Genistein; Humans; Ligands; Nuclear Receptor Coactivator 3; Ovarian Neoplasms; Protein Isoforms; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription Factors	2004
[New prevention strategies against breast cancer and cervical carcinoma. What can you advice to your patients]. MMW Fortschritte der Medizin, 2003, Dec-11, Volume: 145, Issue:50 Topics: Adolescent; Adult; Age Factors; Anastrozole; Anticarcinogenic Agents; Breast Neoplasms; Celecoxib; Child; Double-Blind Method; Estrogen Antagonists; Female; Germany; Hormone Replacement Therapy; Humans; Hysterectomy; Life Style; Mammography; Menarche; Menopause; Middle Aged; Nitriles; Ovariectomy; Pregnancy; Pyrazoles; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Sulfonamides; Tamoxifen; Triazoles; Uterine Cervical Neoplasms	2003
[Chemoprevention of breast cancer. Clinical trials in pharmacological prevention]. Medicina, 2004, Volume: 64, Issue:1 Topics: Anticarcinogenic Agents; Aromatase; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2004
Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens. Journal of molecular endocrinology, 2004, Volume: 32, Issue:2 Topics: Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, Reporter; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Pyrrolidines; Raloxifene Hydrochloride; Response Elements; Tamoxifen; Thiophenes; Transcription, Genetic; Tumor Cells, Cultured	2004
Cloning and functional characterization of PELP1/MNAR promoter. Gene, 2004, Apr-14, Volume: 330 Topics: Base Sequence; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cloning, Molecular; Co-Repressor Proteins; Codon, Initiator; DNA; Endometrial Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression; HeLa Cells; Humans; Luciferases; Molecular Sequence Data; Osteosarcoma; Promoter Regions, Genetic; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; RNA, Messenger; Sequence Analysis, DNA; Tamoxifen; Trans-Activators; Transcription Factors	2004
Refining clinical practice: transforming science research into the art of medicine. Annals of the Academy of Medicine, Singapore, 2004, Volume: 33, Issue:3 Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Antagonists; Estrogens; Female; Genes, BRCA1; Humans; Raloxifene Hydrochloride; Tamoxifen	2004
Oxidation of raloxifene to quinoids: potential toxic pathways via a diquinone methide and o-quinones. Chemical research in toxicology, 2004, Volume: 17, Issue:7 Topics: Animals; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Glutathione; Humans; Indolequinones; Microsomes, Liver; Oxidation-Reduction; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators	2004
Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis. Journal of the American Geriatrics Society, 2004, Volume: 52, Issue:9 Topics: Age Distribution; Aged; Bone Density; Breast Neoplasms; Calcium; Cardiovascular Diseases; Female; Global Health; Hip Fractures; Humans; Incidence; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Patient Selection; Population Surveillance; Prevalence; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Vitamin D	2004
Defining the role of raloxifene for the prevention of breast cancer. Journal of the National Cancer Institute, 2004, Dec-01, Volume: 96, Issue:23 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Confounding Factors, Epidemiologic; Estrogen Receptor Modulators; Female; Humans; Incidence; Multicenter Studies as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Selective Estrogen Receptor Modulators; United States	2004
Raloxifene rebound regression. Cancer investigation, 2004, Volume: 22, Issue:5 Topics: Antineoplastic Agents; Bone Diseases, Metabolic; Breast Neoplasms; Carcinoma, Ductal; Cyclophosphamide; Doxorubicin; Estrogen Antagonists; Female; Fluorouracil; Humans; Lung Neoplasms; Middle Aged; Raloxifene Hydrochloride; Remission Induction; Selective Estrogen Receptor Modulators; Tamoxifen	2004
Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. PharmacoEconomics, 2004, Volume: 22, Issue:17 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Female; Humans; Middle Aged; Models, Economic; Osteoporosis; Quality-Adjusted Life Years; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures; Sweden; Treatment Outcome	2004
CORE breast-cancer prevention trial. The Lancet. Oncology, 2005, Volume: 6, Issue:1 Topics: Breast Neoplasms; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators	2005
Re: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. Journal of the National Cancer Institute, 2005, Apr-06, Volume: 97, Issue:7 Topics: Breast Neoplasms; Confounding Factors, Epidemiologic; Cyclooxygenase 2; Double-Blind Method; Drug Synergism; Enzyme Inhibitors; Female; Humans; Incidence; Membrane Proteins; Osteoporosis, Postmenopausal; Prostaglandin-Endoperoxide Synthases; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Thromboembolism; Treatment Outcome; United States	2005
Anti-growth factor activities of benzothiophenes in human breast cancer cells. The Journal of steroid biochemistry and molecular biology, 2005, Volume: 94, Issue:5 Topics: Breast Neoplasms; Cell Proliferation; Estrogen Antagonists; Humans; Insulin-Like Growth Factor I; Phosphorylation; Protein Serine-Threonine Kinases; Protein Tyrosine Phosphatase, Non-Receptor Type 13; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Thiophenes; Transcription Factor AP-1; Transcription, Genetic	2005
Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex. International journal of oncology, 2005, Volume: 27, Issue:2 Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA, Complementary; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression Regulation, Neoplastic; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation, Missense; Ovariectomy; Raloxifene Hydrochloride; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Selective Estrogen Receptor Modulators; Sequence Analysis, DNA; Tamoxifen; Transfection; Xenograft Model Antitumor Assays	2005
Women's decision making about whether or not to use breast cancer chemoprevention. Women & health, 2005, Volume: 41, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Attitude to Health; Breast Neoplasms; California; Chemoprevention; Decision Making; Female; Humans; Middle Aged; Patient Education as Topic; Raloxifene Hydrochloride; Risk Assessment; Surveys and Questionnaires; Tamoxifen; Women's Health	2005
ERE-independent ERalpha target genes differentially expressed in human breast tumors. Molecular and cellular endocrinology, 2005, Dec-21, Volume: 245, Issue:1-2 Topics: Breast Neoplasms; DNA, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Mammary Glands, Human; Mutation; Oligonucleotide Array Sequence Analysis; Protein Binding; Raloxifene Hydrochloride; Receptor Cross-Talk; Response Elements; Signal Transduction; Tamoxifen; Transcription Factors	2005
Use of raloxifene among women with a history of breast cancer. Breast cancer research and treatment, 2006, Volume: 96, Issue:2 Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Bone Density; Breast Neoplasms; California; Drug Utilization Review; Female; Health Maintenance Organizations; Humans; Middle Aged; Neoplasm Staging; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Registries; Selective Estrogen Receptor Modulators	2006
Apoptosis and proliferation in breast cancer cells, cultured in vitro: effects of SERMs. Climacteric : the journal of the International Menopause Society, 2005, Volume: 8, Issue:3 Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Contraceptive Agents, Female; Dydrogesterone; Estradiol; Estrogen Replacement Therapy; Humans; Medroxyprogesterone Acetate; Norethindrone; Norethindrone Acetate; Norpregnenes; Progesterone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured	2005
Breast cancer risk reduction options: awareness, discussion, and use among women from four ethnic groups. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2006, Volume: 15, Issue:1 Topics: Adult; Aged; Attitude to Health; Breast Neoplasms; Ethnicity; Genetic Testing; Humans; Interviews as Topic; Logistic Models; Middle Aged; Multivariate Analysis; Raloxifene Hydrochloride; Risk Reduction Behavior; Selective Estrogen Receptor Modulators; Tamoxifen; White People; Women	2006
Three-dimensional models of non-steroidal ligands: a comparative molecular field analysis. Steroids, 2006, Volume: 71, Issue:6 Topics: Binding Sites; Binding, Competitive; Breast Neoplasms; Cell Line, Tumor; Computer Simulation; Estrogens; Female; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Ligands; Models, Molecular; Molecular Conformation; Molecular Structure; Quantitative Structure-Activity Relationship; Raloxifene Hydrochloride; Receptors, Estrogen; Reproducibility of Results; Selective Estrogen Receptor Modulators; Tamoxifen	2006
The future of women of minority race/ethnicity in breast cancer chemoprevention therapy. Ethnicity & disease, 2006,Winter, Volume: 16, Issue:1 Topics: Adult; Antineoplastic Agents, Hormonal; Black or African American; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Raloxifene Hydrochloride; Tamoxifen; United States	2006
Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Apr-01, Volume: 12, Issue:7 Pt 1 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Quinazolines; Raloxifene Hydrochloride; RNA, Messenger; Structure-Activity Relationship; Transplantation, Heterologous; Trastuzumab; Xenograft Model Antitumor Assays	2006
Chemoprevention of breast cancer. Lancet (London, England), 2006, Apr-29, Volume: 367, Issue:9520 Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2006
AIB1 gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines. BMC cancer, 2006, May-02, Volume: 6 Topics: Acetyltransferases; Alleles; Breast Neoplasms; Cell Line, Tumor; Cloning, Molecular; Drug Resistance, Neoplasm; Estradiol; Fulvestrant; Histone Acetyltransferases; Humans; Nuclear Receptor Coactivator 3; Oncogene Proteins; Peptides; Polymerase Chain Reaction; Pyrrolidines; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; Selective Estrogen Receptor Modulators; Sequence Analysis, DNA; Tamoxifen; Thiophenes; Trans-Activators	2006
Raloxifene (Evista) for breast cancer prevention in postmenopausal women. The Medical letter on drugs and therapeutics, 2006, May-08, Volume: 48, Issue:1234 Topics: Breast Neoplasms; Female; Humans; Incidence; Neoplasm Invasiveness; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen	2006
A better option? Time, 2006, May-01, Volume: 167, Issue:18 Topics: Breast Neoplasms; Choice Behavior; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen; Treatment Outcome; Uncertainty	2006
A STARring role for raloxifene? The Lancet. Oncology, 2006, Volume: 7, Issue:6 Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Information Dissemination; Mass Media; Peer Review, Research; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2006
Selective estrogen receptor modulators and prevention of invasive breast cancer. JAMA, 2006, Jun-21, Volume: 295, Issue:23 Topics: Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2006
Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs. Journal of the National Cancer Institute, 2006, Jun-07, Volume: 98, Issue:11 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cataract; Contraindications; Controlled Clinical Trials as Topic; Drug Approval; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Thromboembolism; Treatment Outcome; United States; United States Food and Drug Administration; Uterine Neoplasms	2006
Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes: synthesis, structure-activity relationships and molecular modeling study for flexible estrogen receptor antagonists. Medicinal chemistry (Shariqah (United Arab Emirates)), 2006, Volume: 2, Issue:2 Topics: Antineoplastic Agents; Binding Sites; Breast Neoplasms; Cell Proliferation; Cells, Cultured; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; Inhibitory Concentration 50; Ligands; Models, Molecular; Raloxifene Hydrochloride; Receptors, Estrogen; Structure-Activity Relationship; Styrenes; Tamoxifen	2006
Risk-benefit profiles of raloxifene for women. The New England journal of medicine, 2006, Jul-13, Volume: 355, Issue:2 Topics: Aged; Breast Neoplasms; Coronary Disease; Female; Humans; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Spinal Fractures	2006
The changing perspective on breast cancer and chemotherapy. Three new developments are better able to predict breast cancer recurrence and chemotherapy effectiveness. Health news (Waltham, Mass.), 2006, Volume: 12, Issue:8 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Raloxifene Hydrochloride; Risk Factors; Tamoxifen	2006
Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Sep-01, Volume: 12, Issue:17 Topics: Aged; Breast Neoplasms; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Osteoporosis, Postmenopausal; Placebos; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome	2006
Raloxifene works as well as tamoxifen in preventing invasive breast cancer. Mayo Clinic women's healthsource, 2006, Volume: 10, Issue:10 Topics: Anticarcinogenic Agents; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2006
A STAR is born. Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:9 Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Raloxifene Hydrochloride; Tamoxifen	2006
STAR trial reports. European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:12 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Estrogen Antagonists; Female; Humans; Multicenter Studies as Topic; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen	2006
Lessons from RUTH. Climacteric : the journal of the International Menopause Society, 2006, Volume: 9, Issue:5 Topics: Breast Neoplasms; Coronary Artery Disease; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Thromboembolism	2006
Effects of 17beta-estradiol, progesterone, synthetic progestins, tibolone, and raloxifene on vascular endothelial growth factor and Thrombospondin-1 messenger RNA in breast cancer cells. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2006, Volume: 16 Suppl 2 Topics: Breast Neoplasms; Estradiol; Female; Gene Expression Regulation, Neoplastic; Hormones; Humans; Norpregnenes; Progesterone; Progesterone Congeners; Raloxifene Hydrochloride; RNA, Messenger; Thrombospondin 1; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A	2006
The dilemma and promise of cancer chemoprevention. Nature clinical practice. Oncology, 2006, Volume: 3, Issue:10 Topics: Breast Neoplasms; Chemoprevention; Estrogen Antagonists; Humans; Neoplasms; Raloxifene Hydrochloride; Risk Factors	2006
Editorial: The SERM of my dreams. The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:10 Topics: Bone Density; Breast Neoplasms; Coronary Disease; Female; Humans; Osteoporosis; Premenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2006
Long-term raloxifene in a woman at high risk for breast cancer. The New England journal of medicine, 2006, Oct-12, Volume: 355, Issue:15 Topics: Adult; Breast Neoplasms; Estrogens; Female; Humans; Magnetic Resonance Imaging; Mammography; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2006
Prevention of breast cancer using selective oestrogen receptor modulators (SERMs). Breast cancer research : BCR, 2006, Volume: 8, Issue:5 Topics: Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen	2006
Beyond raloxifene for the prevention of osteoporosis and breast cancer. British journal of pharmacology, 2007, Volume: 150, Issue:1 Topics: Breast Neoplasms; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2007
Selective estrogen receptor modulators (SERMS). Arquivos brasileiros de endocrinologia e metabologia, 2006, Volume: 50, Issue:4 Topics: Biomarkers; Bone Density; Bone Remodeling; Breast Neoplasms; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene	2006
Raloxifene vs tamoxifen. JAMA, 2007, Jan-17, Volume: 297, Issue:3 Topics: Bone Density Conservation Agents; Breast Neoplasms; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2007
Regulation of growth hormone signaling by selective estrogen receptor modulators occurs through suppression of protein tyrosine phosphatases. Endocrinology, 2007, Volume: 148, Issue:5 Topics: Breast Neoplasms; Cell Line, Tumor; Dactinomycin; Estrogen Antagonists; Estrogens; Human Growth Hormone; Humans; Intracellular Signaling Peptides and Proteins; Janus Kinase 2; Kidney; Protein Synthesis Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Protein Tyrosine Phosphatases; Raloxifene Hydrochloride; Receptors, Estrogen; Signal Transduction; STAT5 Transcription Factor; Suppressor of Cytokine Signaling Proteins; Tamoxifen	2007
Bone builder vs. breast cancer. The Johns Hopkins medical letter health after 50, 2007, Volume: 18, Issue:11 Topics: Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2007
[Prevention of breast cancer 2007. New evidence?]. Atencion primaria, 2007, Volume: 39, Issue:3 Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Estrogen Antagonists; Female; Humans; Mammography; Mass Screening; Middle Aged; Primary Prevention; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Tamoxifen	2007
Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes. Maturitas, 2007, May-20, Volume: 57, Issue:1 Topics: Breast Neoplasms; Carcinoma; Down-Regulation; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured; Up-Regulation	2007
Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC women's health, 2007, Apr-17, Volume: 7 Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Cost-Benefit Analysis; Female; Fractures, Bone; Humans; Middle Aged; Models, Econometric; Quality-Adjusted Life Years; Raloxifene Hydrochloride; Risk; Thromboembolism	2007
Osteoporosis drug effective in preventing breast cancer. Mayo Clinic health letter (English ed.), 2007, Volume: 25, Issue:4 Topics: Anticarcinogenic Agents; Bone Density Conservation Agents; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride	2007
Interest in breast cancer chemoprevention among older women. Breast cancer research and treatment, 2008, Volume: 108, Issue:3 Topics: Aged; Breast Neoplasms; Chemoprevention; Comorbidity; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice; Humans; Middle Aged; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Surveys and Questionnaires; Tamoxifen	2008
Should menopausal women at increased risk for breast cancer use tamoxifen, raloxifene, or hormone therapy?: a framework for personalized risk assessment and counseling. Journal of cancer education : the official journal of the American Association for Cancer Education, 2007,Spring, Volume: 22, Issue:1 Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Decision Making; Endometrial Neoplasms; Estrogen Antagonists; Female; Genetic Counseling; Genetic Predisposition to Disease; Health Knowledge, Attitudes, Practice; Health Status; Humans; Menopause; Middle Aged; Models, Biological; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Tamoxifen	2007
Estrogens shield breast cancer cells. Environmental health perspectives, 2007, Volume: 115, Issue:6 Topics: Breast Neoplasms; Estrogens; Female; Gene Expression Regulation, Neoplastic; Granzymes; Humans; Immunologic Surveillance; Killer Cells, Natural; Raloxifene Hydrochloride; Receptors, Estrogen; Serpins; Tamoxifen	2007
NCI and the STELLAR trial. Lancet (London, England), 2007, Jun-30, Volume: 369, Issue:9580 Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Letrozole; National Institutes of Health (U.S.); Nitriles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Triazoles; United States	2007
[Drug prevention and proper nutrition. Prevention of breast cancer as in coronary heart disease?]. MMW Fortschritte der Medizin, 2007, Feb-15, Volume: 149, Issue:7 Topics: Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Clinical Trials as Topic; Combined Modality Therapy; Coronary Disease; Diet, Fat-Restricted; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Male; Neoplasm Recurrence, Local; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2007
A reconsideration of tamoxifen use for breast cancer. Taiwanese journal of obstetrics & gynecology, 2007, Volume: 46, Issue:2 Topics: Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen	2007
Hope for axed cancer-prevention trial. Nature, 2007, Aug-23, Volume: 448, Issue:7156 Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Letrozole; National Institutes of Health (U.S.); Nitriles; Preventive Medicine; Raloxifene Hydrochloride; Triazoles; United States	2007
Raloxifene examined for breast cancer prevention. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, Sep-01, Volume: 64, Issue:17 Topics: Anticarcinogenic Agents; Bone Density Conservation Agents; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2007
Follow-up of patients with early breast cancer. The New England journal of medicine, 2007, Sep-06, Volume: 357, Issue:10 Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Uterus	2007
Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms. Molecular cancer therapeutics, 2007, Volume: 6, Issue:9 Topics: Animals; Antioxidants; Breast Neoplasms; Carcinoma, Hepatocellular; Chemoprevention; Female; Humans; Liver; Liver Neoplasms; Luciferases; Mice; NAD(P)H Dehydrogenase (Quinone); Oxidation-Reduction; Peroxides; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Thiophenes; Tumor Cells, Cultured	2007
Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2007, Volume: 16, Issue:11 Topics: Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Tamoxifen	2007
Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices--counterpoint. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2007, Volume: 16, Issue:11 Topics: Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Tamoxifen	2007
Projecting individualized absolute invasive breast cancer risk in African American women. Journal of the National Cancer Institute, 2007, Dec-05, Volume: 99, Issue:23 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Biopsy; Black or African American; Breast Neoplasms; Carcinoma, Ductal, Breast; Confounding Factors, Epidemiologic; Estrogen Receptor Modulators; Female; Forecasting; Humans; Incidence; Logistic Models; Mammography; Mass Screening; Middle Aged; Odds Ratio; Raloxifene Hydrochloride; Risk Assessment; SEER Program; Tamoxifen; United States; Women's Health	2007
Increased antitumor potential of the raloxifene prodrug, raloxifene diphosphate. International journal of cancer, 2008, May-01, Volume: 122, Issue:9 Topics: 9,10-Dimethyl-1,2-benzanthracene; Administration, Oral; Animals; Antineoplastic Agents, Hormonal; Biological Availability; Breast Neoplasms; Carcinogens; Cell Line, Tumor; Cell Proliferation; Estrogen Receptor Modulators; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Organophosphates; Phosphorylation; Prodrugs; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Transplantation, Heterologous	2008
International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. International journal of cancer, 2008, May-01, Volume: 122, Issue:9 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Chi-Square Distribution; Estrogen Receptor Modulators; Europe; Female; Genes, BRCA1; Genes, BRCA2; Genetic Variation; Heterozygote; Humans; Mass Screening; Mastectomy; Middle Aged; Mutation; Ovariectomy; Population Surveillance; Primary Prevention; Raloxifene Hydrochloride; Research Design; Surveys and Questionnaires; Tamoxifen	2008
Chemoprevention of breast cancer. Breast cancer (Tokyo, Japan), 2008, Volume: 15, Issue:1 Topics: Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Tamoxifen	2008
Tamoxifen: to use or not to use. Taiwanese journal of obstetrics & gynecology, 2008, Volume: 47, Issue:1 Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasm Recurrence, Local; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2008
Non-steroidal antioestrogens--receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. Journal of steroid biochemistry, 1984, Volume: 20, Issue:1 Topics: Animals; Breast Neoplasms; Cell Line; Estrogen Antagonists; Female; Humans; Mammary Neoplasms, Experimental; Piperidines; Pyrrolidines; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tamoxifen; Thiophenes; Uterus	1984
Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Annals of the New York Academy of Sciences, 1995, Jun-12, Volume: 761 Topics: Animals; Bone Density; Breast Neoplasms; Cell Division; Cholesterol; Ethinyl Estradiol; Female; Humans; Middle Aged; Organ Size; Organ Specificity; Piperidines; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured; Uterus	1995
A model to describe how a point mutation of the estrogen receptor alters the structure-function relationship of antiestrogens. Breast cancer research and treatment, 1993, Volume: 26, Issue:2 Topics: Breast Neoplasms; Cell Division; Estradiol; Estrogen Antagonists; Female; Humans; Models, Biological; Piperidines; Point Mutation; Raloxifene Hydrochloride; Receptors, Estrogen; Transfection; Tumor Cells, Cultured	1993
Raloxifene, retinoids, and lavender: "me too" tamoxifen alternatives under study. Journal of the National Cancer Institute, 1996, Aug-21, Volume: 88, Issue:16 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Drugs, Investigational; Estrogen Antagonists; Female; Humans; Lavandula; Male; Neoplasms; Oils, Volatile; Ovarian Neoplasms; Piperidines; Plant Oils; Plants, Medicinal; Prostatic Neoplasms; Raloxifene Hydrochloride; Retinoids; Tamoxifen; Toremifene	1996
Failure of cannabinoid compounds to stimulate estrogen receptors. Biochemical pharmacology, 1997, Jan-10, Volume: 53, Issue:1 Topics: Breast Neoplasms; Cannabinoids; Cell Division; Dronabinol; Estrogens; Humans; Phenanthridines; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Transcriptional Activation; Tumor Cells, Cultured	1997
Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. Journal of medicinal chemistry, 1997, Jan-17, Volume: 40, Issue:2 Topics: Adenocarcinoma; Animals; Binding Sites; Bone and Bones; Breast Neoplasms; Cell Division; Cholesterol; Estrogen Antagonists; Female; Humans; Male; Organ Size; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Structure-Activity Relationship; Uterus	1997
Next generation of SERMs being seen in clinic. Journal of the National Cancer Institute, 1997, Jul-02, Volume: 89, Issue:13 Topics: Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Clinical Trials, Phase III as Topic; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Osteoporosis; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen	1997
(S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen. Journal of medicinal chemistry, 1997, Jul-04, Volume: 40, Issue:14 Topics: Administration, Oral; Animals; Benzopyrans; Binding, Competitive; Breast Neoplasms; Cytosol; Diethylstilbestrol; Estradiol; Estrogen Antagonists; Female; Humans; Mice; Molecular Structure; Ovariectomy; Piperidines; Propionates; Raloxifene Hydrochloride; Receptors, Estrogen; Stereoisomerism; Structure-Activity Relationship; Uterus	1997
Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. The Journal of steroid biochemistry and molecular biology, 1997, Volume: 60, Issue:5-6 Topics: Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mutation; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; RNA, Neoplasm; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured	1997
Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science (New York, N.Y.), 1997, Sep-05, Volume: 277, Issue:5331 Topics: Animals; Breast Neoplasms; Cell Line; Diethylstilbestrol; Enhancer Elements, Genetic; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; HeLa Cells; Humans; Ligands; Piperidines; Polyunsaturated Alkamides; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Tamoxifen; Transcription Factor AP-1; Transcriptional Activation; Transfection; Tumor Cells, Cultured; Uterus	1997
Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity. The Journal of steroid biochemistry and molecular biology, 1997, Volume: 61, Issue:1-2 Topics: Adenocarcinoma; Animals; Bone Resorption; Breast Neoplasms; Cell Division; Cells, Cultured; Estradiol; Estrogen Antagonists; Female; Glucuronates; Humans; Interleukin-6; Organ Specificity; Osteoclasts; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tissue Distribution; Transforming Growth Factor beta; Tumor Cells, Cultured	1997
Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells. Cancer letters, 1998, Mar-13, Volume: 125, Issue:1-2 Topics: Breast Neoplasms; Estrogen Antagonists; Female; Gene Expression Regulation, Neoplastic; Humans; Piperidines; Plasminogen Activator Inhibitor 1; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Tumor Cells, Cultured; Urokinase-Type Plasminogen Activator	1998
The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer research, 1998, May-01, Volume: 58, Issue:9 Topics: Aspartic Acid; Blotting, Northern; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Humans; Mutagenesis, Site-Directed; Piperidines; Point Mutation; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured	1998
Anti-estrogens come of age: a pioneer looks back. Journal of the National Cancer Institute, 1998, May-06, Volume: 90, Issue:9 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Coronary Disease; Estrogen Antagonists; Female; Humans; Menopause; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Uterine Neoplasms	1998
Tamoxifen, raloxifene findings unlikely to encourage genetic screening for breast cancer. Nature medicine, 1998, Volume: 4, Issue:6 Topics: BRCA2 Protein; Breast Neoplasms; Estrogen Antagonists; Estrogens; Female; Genes, BRCA1; Genetic Testing; Humans; Neoplasm Proteins; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Transcription Factors	1998
The prevention pill. Scientific American, 1998, Volume: 278, Issue:6 Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Piperidines; Raloxifene Hydrochloride; Tamoxifen	1998
Clear thinking on tamoxifen. The Johns Hopkins medical letter health after 50, 1998, Volume: 10, Issue:5 Topics: Anticarcinogenic Agents; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Piperidines; Raloxifene Hydrochloride; Tamoxifen	1998
Breast cancer biology blossoms in the clinic. Nature medicine, 1998, Volume: 4, Issue:7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Piperidines; Raloxifene Hydrochloride; Receptor, ErbB-2; Tamoxifen; Trastuzumab	1998
Until there's more information, caution advised in using tamoxifen or raloxifene for breast cancer prevention. Mayo Clinic health letter (English ed.), 1998, Volume: 16, Issue:7 Topics: Anticarcinogenic Agents; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Piperidines; Raloxifene Hydrochloride; Tamoxifen	1998
In search of the perfect SERM: beyond tamoxifen and raloxifene. Journal of the National Cancer Institute, 1998, Jul-01, Volume: 90, Issue:13 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Neoplasms, Hormone-Dependent; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen	1998
New hope for prevention, treatment of breast cancer. Harvard health letter, 1998, Volume: 23, Issue:10 Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Piperidines; Raloxifene Hydrochloride; Tamoxifen	1998
Designer estrogens. Scientific American, 1998, Volume: 279, Issue:4 Topics: Breast Neoplasms; Coronary Disease; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Humans; Molecular Structure; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Structure-Activity Relationship; Tamoxifen	1998
Tamoxifen debate hinges on whose risk is high enough. Journal of the National Cancer Institute, 1998, Oct-07, Volume: 90, Issue:19 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Decision Making; Estrogen Antagonists; Female; Humans; Physician's Role; Piperidines; Raloxifene Hydrochloride; Risk; Tamoxifen	1998
Tamoxifen for prevention of breast cancer. The Medical letter on drugs and therapeutics, 1999, Jan-01, Volume: 41, Issue:1043 Topics: Adult; Breast Neoplasms; Cerebrovascular Disorders; Drug Costs; Endometrial Neoplasms; Estrogen Antagonists; Estrogens; Female; Fractures, Bone; Humans; Middle Aged; Myocardial Infarction; Osteoporosis, Postmenopausal; Piperidines; Placebos; Pulmonary Embolism; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Tamoxifen; Thrombophlebitis	1999
Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 5: Selective estrogen receptor modulators and hormone replacement therapy. Proceedings of a conference. Charlottesville, Virginia, USA. September 21-23, 1997. Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:5 Topics: Antineoplastic Agents; Bone Density; Breast Neoplasms; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Female; Humans; Menopause; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Survivors; Tamoxifen	1999
Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. Archives of internal medicine, 1999, Jul-12, Volume: 159, Issue:13 Topics: Alendronate; Bone Density; Breast Neoplasms; Coronary Disease; Decision Support Techniques; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Hip Fractures; Humans; Life Expectancy; Lipids; Markov Chains; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Risk; Risk Factors; Sensitivity and Specificity	1999
Experts debate drugs for healthy women with breast cancer risk. JAMA, 1999, Jul-14, Volume: 282, Issue:2 Topics: Adult; Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Middle Aged; Piperidines; Raloxifene Hydrochloride; Risk Assessment; Tamoxifen	1999
Raloxifene as a multifunctional medicine? Current trials will show whether it is effective in both osteoporosis and breast cancer. BMJ (Clinical research ed.), 1999, Aug-07, Volume: 319, Issue:7206 Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Osteoporosis; Piperidines; Raloxifene Hydrochloride	1999
Breast cancer highlights. The oncologist, 1999, Volume: 4, Issue:4 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Antagonists; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphatic Metastasis; Neoplasm Staging; Piperidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen	1999
Designer estrogens: breast cancer benefit, remaining questions. Health news (Waltham, Mass.), 1999, Jul-25, Volume: 5, Issue:9 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Estrogen Antagonists; Female; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen	1999
Does raloxifene reduce breast cancer risk? The Journal of family practice, 1999, Volume: 48, Issue:9 Topics: Aged; Breast Neoplasms; Double-Blind Method; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Incidence; Piperidines; Postmenopause; Raloxifene Hydrochloride; Risk Factors	1999
Is raloxifene the answer to the HRT story? American family physician, 1999, Sep-15, Volume: 60, Issue:4 Topics: Bone and Bones; Breast Neoplasms; Cardiovascular System; Estrogen Replacement Therapy; Estrogens; Family Practice; Female; Humans; Patient Education as Topic; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; United States	1999
Preventing "unpreventable" cancers. Harvard women's health watch, 1999, Volume: 7, Issue:3 Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Mastectomy; Ovarian Neoplasms; Raloxifene Hydrochloride; Risk Factors; Tamoxifen	1999
Sex steroid analogs. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 1999, Volume: 9 Suppl 2 Topics: Animals; Bone Resorption; Breast Neoplasms; Estrogen Antagonists; Female; Gonadal Steroid Hormones; Hormones; Humans; Norpregnenes; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Risk; Tamoxifen	1999
Reaping the benefits of designer estrogens. The Johns Hopkins medical letter health after 50, 1999, Volume: 11, Issue:9 Topics: Breast Neoplasms; Female; Hormone Replacement Therapy; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	1999
Fewer fractures with raloxifene. Health news (Waltham, Mass.), 1999, Oct-01, Volume: 5, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	1999
Breast cancer hopes. Nursing spectrum (D.C./Baltimore metro ed.), 1998, Jun-01, Volume: 8, Issue:11 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Mammography; Raloxifene Hydrochloride; Tamoxifen	1998
Women gain ground with BreastCare. Program ensures screening, treatment for poor. The Journal of the Arkansas Medical Society, 1999, Volume: 96, Issue:5 Topics: Adult; Arkansas; Breast Neoplasms; Clinical Trials as Topic; Costs and Cost Analysis; Double-Blind Method; Estrogen Antagonists; Female; Humans; Mammography; Mass Screening; Medical Indigency; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	1999
Comparative analyses of mechanistic differences among antiestrogens. Endocrinology, 1999, Volume: 140, Issue:12 Topics: Blood Proteins; Breast Neoplasms; Cell Division; Cinnamates; Drug Stability; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Gene Expression; Humans; Protein Binding; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen; Stilbenes; Tamoxifen; Transcription, Genetic; Tumor Cells, Cultured	1999
Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology, 2000, Volume: 141, Issue:2 Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Bone and Bones; Breast Neoplasms; Cholesterol; Estrogen Antagonists; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Organ Size; Osteoporosis; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Reference Values; Tamoxifen; Toremifene; Transplantation, Heterologous; Tumor Cells, Cultured; Uterus	2000
Report examines strategies for reducing breast cancer risk. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1999, Jul-01, Volume: 56, Issue:13 Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk	1999
Raloxifene therapy in the reduction of fractures. American family physician, 2000, Mar-01, Volume: 61, Issue:5 Topics: Aged; Blood Coagulation Factors; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Estrogen Receptor Modulators; Female; Fractures, Bone; Humans; Incidence; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome	2000
[Raloxifene (Celvista, Evista)]. Revue medicale de Bruxelles, 2000, Volume: 21, Issue:1 Topics: Arteriosclerosis; Bone and Bones; Breast Neoplasms; Controlled Clinical Trials as Topic; Endometrium; Female; Fractures, Bone; Heart Diseases; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Prospective Studies; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Thromboembolism; Uterine Hemorrhage	2000
Antiestrogens specifically up-regulate bone morphogenetic protein-4 promoter activity in human osteoblastic cells. Molecular endocrinology (Baltimore, Md.), 2000, Volume: 14, Issue:5 Topics: Adenocarcinoma; Base Sequence; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Bone Neoplasms; Breast Neoplasms; Cells, Cultured; Dimerization; Drug Design; Endometrial Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Female; Gene Expression Regulation; Humans; Molecular Sequence Data; Neoplasms, Hormone-Dependent; Organ Specificity; Osteoblasts; Osteogenesis; Osteoporosis; Osteosarcoma; Postmenopause; Promoter Regions, Genetic; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; Stimulation, Chemical; Transfection; Tumor Cells, Cultured	2000
Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer, 2000, May-01, Volume: 88, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Confidence Intervals; Disease Progression; Estrogen Antagonists; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Postmenopause; Quality of Life; Raloxifene Hydrochloride; Receptors, Estrogen; Remission Induction; Safety; Selective Estrogen Receptor Modulators; Survival Rate; Tamoxifen	2000
A brief review of the current breast cancer prevention trials and proposals for future trials. European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:10 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Female; Hot Flashes; Humans; Menstruation Disturbances; Meta-Analysis as Topic; Middle Aged; Raloxifene Hydrochloride; Risk Factors; Tamoxifen	2000
Drugs for prevention and treatment of postmenopausal osteoporosis. The Medical letter on drugs and therapeutics, 2000, Oct-16, Volume: 42, Issue:1090 Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Resorption; Breast Neoplasms; Calcitonin; Calcium; Calcium Channel Blockers; Clinical Trials as Topic; Densitometry; Dose-Response Relationship, Drug; Estrogens; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Vitamin D	2000
Update on raloxifene to prevent endometrial-breast cancer. European journal of cancer (Oxford, England : 1990), 2000, Volume: 36 Suppl 4 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2000
The selective oestrogen receptor modulators idoxifene and raloxifene have fundamentally different cell-specific oestrogen-response element (ERE)-dependent/independent mechanisms in vitro. European journal of cancer (Oxford, England : 1990), 2000, Volume: 36 Suppl 4 Topics: Breast Neoplasms; Cell Division; Estrogen Antagonists; Estrogens; Female; Humans; Raloxifene Hydrochloride; Repressor Proteins; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured	2000
How to manage the menopause following therapy for breast cancer. is raloxifene a safe alternative? European journal of cancer (Oxford, England : 1990), 2000, Volume: 36 Suppl 4 Topics: Blood Coagulation Disorders; Bone Diseases; Breast Neoplasms; Female; Humans; Lipids; Menopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Uterine Diseases	2000
[Biochemical mechanism of raloxifen and tamoxifen action for the prevention of breast cancer. Studies in vitro]. Ginekologia polska, 2000, Volume: 71, Issue:9 Topics: Adenocarcinoma; Apoptosis; Breast Neoplasms; Cell Division; Estrogen Antagonists; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Cells, Cultured	2000
[SERM-therapy in postmenopause. Protection of bone and breast]. MMW Fortschritte der Medizin, 2001, Jan-25, Volume: 143, Issue:4 Topics: Breast Neoplasms; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Treatment Outcome	2001
Managing menopause after breast cancer: balancing risks and benefits. Cleveland Clinic journal of medicine, 2001, Volume: 68, Issue:3 Topics: Adult; Alendronate; Antidepressive Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Calcitonin; Climacteric; Cohort Studies; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Follow-Up Studies; Heart Diseases; Humans; Menopause; Menopause, Premature; Neoplasm Recurrence, Local; Osteoporosis; Pregnancy; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors	2001
Raloxifene for breast cancer prevention. JAMA, 2001, Apr-25, Volume: 285, Issue:16 Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2001
Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. Cancer research, 2001, May-01, Volume: 61, Issue:9 Topics: Allosteric Regulation; Breast Neoplasms; Estrogen Receptor alpha; Gene Expression Regulation, Neoplastic; Humans; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured	2001
Tamoxifen and contralateral breast cancer: the other side. Journal of the National Cancer Institute, 2001, Jul-04, Volume: 93, Issue:13 Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Immunohistochemistry; Ligands; Middle Aged; Models, Statistical; Placebos; Raloxifene Hydrochloride; Receptors, Estrogen; Retrospective Studies; Risk; Tamoxifen; Time Factors	2001
Estrogenic and antiestrogenic effects of raloxifene on collagen metabolism in breast cancer MCF-7 cells. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2001, Volume: 15, Issue:3 Topics: Breast Neoplasms; Cell Division; Collagen; Dipeptidases; Estradiol; Estrogen Antagonists; Gelatin; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tumor Cells, Cultured	2001
Raloxifene and prevention of vertebral fracture (cont'd): mainly when oestrogen is contraindicated. Prescrire international, 2000, Volume: 9, Issue:50 Topics: Breast Neoplasms; Clinical Trials as Topic; Contraindications; Diabetes Mellitus; Estrogen Replacement Therapy; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Spinal Fractures; Thromboembolism; Uterine Neoplasms	2000
Raloxifene: handle with care. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2001, Jul-24, Volume: 165, Issue:2 Topics: Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2001
Raloxifene: new preparation. Not better than oestrogen. Prescrire international, 1999, Volume: 8, Issue:44 Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Uterine Neoplasms	1999
Update in general internal medicine. Annals of internal medicine, 2001, Aug-21, Volume: 135, Issue:4 Topics: Breast Neoplasms; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2001
Design and methods of the Raloxifene Use for The Heart (RUTH) study. The American journal of cardiology, 2001, Aug-15, Volume: 88, Issue:4 Topics: Angina, Unstable; Breast Neoplasms; Coronary Disease; Double-Blind Method; Female; Humans; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Selective Estrogen Receptor Modulators	2001
Selective estrogen-receptor modulators in 2001. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:9 Topics: Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Pilot Projects; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Venous Thrombosis	2001
Patterns of physician-reported diagnoses for women receiving raloxifene prescriptions. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2001, Oct-01, Volume: 58, Issue:19 Topics: Aged; Breast Neoplasms; Climacteric; Drug Approval; Drug Labeling; Drug Utilization Review; Estrogen Antagonists; Female; Humans; Medicine; Menopause; Middle Aged; Osteoporosis; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Specialization; United States	2001
Raloxifene and breast cancer. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2001, Oct-02, Volume: 165, Issue:7 Topics: Animals; Breast Neoplasms; Disease Models, Animal; Estrogen Antagonists; Female; Humans; Mice; Raloxifene Hydrochloride; Tamoxifen; Tumor Cells, Cultured	2001
[Antiestrogens--benefits of estrogens without their disadvantages?]. Duodecim; laaketieteellinen aikakauskirja, 1998, Volume: 114, Issue:19 Topics: Alzheimer Disease; Bone Density; Breast Neoplasms; Cholesterol; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Estrogens; Female; Finland; Humans; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators	1998
Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells. The Journal of biological chemistry, 2002, Mar-15, Volume: 277, Issue:11 Topics: Breast Neoplasms; Estrogen Antagonists; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Nuclear Receptor Coactivator 2; Proteins; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen; Transcription Factors; Transfection; Transforming Growth Factor alpha; Trefoil Factor-1; Tumor Cells, Cultured; Tumor Suppressor Proteins	2002
Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstetrics and gynecology, 2001, Volume: 98, Issue:6 Topics: Breast Neoplasms; Coronary Disease; Cost-Benefit Analysis; Decision Support Techniques; Estrogen Antagonists; Female; Health Promotion; Hormone Replacement Therapy; Humans; Life Expectancy; Markov Chains; Middle Aged; Postmenopause; Quality-Adjusted Life Years; Raloxifene Hydrochloride; United States	2001
New strategies for the treatment of breast cancer. Breast cancer (Tokyo, Japan), 2001, Volume: 8, Issue:4 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Estrogen Receptor Modulators; Female; Humans; Mastectomy, Segmental; Prognosis; Raloxifene Hydrochloride; Survival Analysis; Tamoxifen; Treatment Outcome	2001
[What do we think about selective estrogen receptor modulators?]. La Revue de medecine interne, 2001, Volume: 22, Issue:12 Topics: Age Factors; Breast Neoplasms; Clinical Trials as Topic; Cohort Studies; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Placebos; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Sex Factors; Time Factors	2001
The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention. Annals of the New York Academy of Sciences, 2001, Volume: 949 Topics: Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Incidence; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; White People	2001
Chemoprevention with antiestrogens: the beginning of the end for breast cancer. Daniel G. Miller Lecture. Annals of the New York Academy of Sciences, 2001, Volume: 952 Topics: Amino Acid Substitution; Animals; Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Design; Estrogen Receptor alpha; Estrogen Receptor Modulators; Estrogens; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Ovariectomy; Raloxifene Hydrochloride; Rats; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen; Tumor Cells, Cultured	2001
Recruitment of women into trials. Lancet (London, England), 2002, Jan-12, Volume: 359, Issue:9301 Topics: Anticarcinogenic Agents; Bias; Breast Neoplasms; Control Groups; Female; Humans; Patient Selection; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Research Subjects; Selective Estrogen Receptor Modulators; Sex Characteristics; Sex Factors; Tamoxifen; Women	2002
Hobson's choice and the need for combinations of new agents for the prevention and treatment of breast cancer. Journal of the National Cancer Institute, 2002, Feb-20, Volume: 94, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Tamoxifen	2002
Breast cancer prevention. The oncologist, 2002, Volume: 7, Issue:1 Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Middle Aged; Multicenter Studies as Topic; Raloxifene Hydrochloride; Tamoxifen	2002
Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7. The Journal of steroid biochemistry and molecular biology, 2002, Volume: 80, Issue:1 Topics: Apoptosis; Benzhydryl Compounds; Breast Neoplasms; Cell Division; Coumestrol; DDT; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens, Non-Steroidal; Female; Fulvestrant; Humans; Molecular Structure; Phenols; Raloxifene Hydrochloride; Receptors, Androgen; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Surface-Active Agents; Tumor Cells, Cultured	2002
Tamoxifen: a personal retrospective. The Lancet. Oncology, 2000, Volume: 1, Issue:1 Topics: Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; History, 20th Century; History, 21st Century; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2000
Hormone may be key to raloxifene's breast cancer benefits. Health news (Waltham, Mass.), 2002, Volume: 8, Issue:3 Topics: Breast Neoplasms; Estradiol; Estrogen Receptor Modulators; Female; Humans; Raloxifene Hydrochloride; United States	2002
Measurement of serum estradiol. JAMA, 2002, Mar-27, Volume: 287, Issue:12 Topics: Breast Neoplasms; Estradiol; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Reference Values; Selective Estrogen Receptor Modulators	2002
[Hormone replacement therapy in peri- and postmenopause. Routine use is not indicated]. MMW Fortschritte der Medizin, 2002, Feb-28, Volume: 144, Issue:9 Topics: Alzheimer Disease; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Endometrial Neoplasms; Estrogen Replacement Therapy; Female; Hormone Replacement Therapy; Humans; Middle Aged; Osteoporosis, Postmenopausal; Ovarian Neoplasms; Primary Prevention; Progestins; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Thrombosis; Time Factors	2002
Biomedicine. Defining the "S" in SERMs. Science (New York, N.Y.), 2002, Mar-29, Volume: 295, Issue:5564 Topics: Breast; Breast Neoplasms; DNA; Drug Resistance, Neoplasm; Estradiol; Estrogen Replacement Therapy; Female; Histone Acetyltransferases; Humans; Ligands; Macromolecular Substances; Nuclear Receptor Coactivator 1; Organ Specificity; Protein Conformation; Raloxifene Hydrochloride; Receptors, Estrogen; Response Elements; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription Factors; Uterine Neoplasms; Uterus	2002
Molecular determinants for the tissue specificity of SERMs. Science (New York, N.Y.), 2002, Mar-29, Volume: 295, Issue:5564 Topics: Breast; Breast Neoplasms; Cell Cycle; DNA-Binding Proteins; Endometrial Neoplasms; Endometrium; Estradiol; Female; Gene Expression Regulation; Gene Silencing; Genes, myc; Histone Acetyltransferases; Histone Deacetylases; Humans; Insulin-Like Growth Factor I; Nuclear Receptor Coactivator 1; Organ Specificity; Promoter Regions, Genetic; Raloxifene Hydrochloride; Receptors, Estrogen; Repressor Proteins; Response Elements; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured	2002
Upstaging tamoxifen? New classes of drugs emerging for breast cancer. Journal of the National Cancer Institute, 2002, Apr-03, Volume: 94, Issue:7 Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase II as Topic; Double-Blind Method; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen	2002
A 60-year-old woman trying to discontinue hormone replacement therapy. JAMA, 2002, Apr-24, Volume: 287, Issue:16 Topics: Alendronate; Breast Neoplasms; Contraindications; Coronary Disease; Decision Making; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fibrocystic Breast Disease; Hot Flashes; Humans; Hysterectomy; Middle Aged; Osteoporosis, Postmenopausal; Ovariectomy; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Venous Thrombosis	2002
Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. International journal of cancer, 2002, May-10, Volume: 99, Issue:2 Topics: Animals; Breast Neoplasms; Cell Division; Cell Size; Cinnamates; Endometrium; Epithelial Cells; Estrogen Antagonists; Estrone; Female; Humans; Kinetics; Mice; Mice, Nude; Neoplasm Transplantation; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Stilbenes; Tamoxifen; Toremifene; Tumor Cells, Cultured	2002
Raloxifene is associated with less side effects than tamoxifen in women with early breast cancer: a questionnaire study from one physician's practice. Journal of women's health & gender-based medicine, 2002, Volume: 11, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Estrogen Antagonists; Female; Hot Flashes; Humans; Libido; Middle Aged; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Retrospective Studies; Selective Estrogen Receptor Modulators; Surveys and Questionnaires; Tamoxifen; Time Factors; Vaginal Discharge; Weight Gain	2002
Menopause. HRT: looking for something better. Harvard health letter, 2002, Volume: 27, Issue:7 Topics: Breast Neoplasms; Estrogen Replacement Therapy; Female; Humans; Myocardial Infarction; Norpregnenes; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2002
[Can serum estradiol predict the effect of raloxifene on breast cancer risk?]. Lakartidningen, 2002, May-02, Volume: 99, Issue:18 Topics: Biomarkers, Tumor; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Humans; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators	2002
Chemoprevention of breast cancer: recommendations and rationale. Annals of internal medicine, 2002, Jul-02, Volume: 137, Issue:1 Topics: Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Evidence-Based Medicine; Female; Humans; Primary Prevention; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2002
Summaries for patients. Using medication to prevent breast cancer: recommendations from the United States Preventive Services Task Force. Annals of internal medicine, 2002, Jul-02, Volume: 137, Issue:1 Topics: Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Evidence-Based Medicine; Female; Humans; Primary Prevention; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2002
Estrogen-stimulation of postconfluent cell accumulation and foci formation of human MCF-7 breast cancer cells. Journal of cellular biochemistry, 1991, Volume: 45, Issue:2 Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cattle; Cell Division; Contact Inhibition; Culture Media; Estradiol; Estrogens; Humans; Male; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Phenotype; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Tumor Cells, Cultured	1991
Interactions between estrogens, androgens, progestins, and glucocorticoids in ZR-75-1 human breast cancer cells. Annals of the New York Academy of Sciences, 1990, Volume: 595 Topics: Androgens; Androstenediol; Apolipoproteins; Apolipoproteins D; Breast Neoplasms; Carrier Proteins; Cell Division; Dihydrotestosterone; Estrogens; Gene Expression; Glucocorticoids; Glycoproteins; Humans; In Vitro Techniques; Insulin; Medroxyprogesterone; Medroxyprogesterone Acetate; Membrane Transport Proteins; Neoplasm Proteins; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Tumor Cells, Cultured	1990
Potent antagonism between estrogens and androgens on GCDFP-15 expression and cell growth in the ZR-75-1 human breast cancer cells. Annals of the New York Academy of Sciences, 1990, Volume: 586 Topics: Apolipoproteins; Apolipoproteins D; Biomarkers, Tumor; Breast Neoplasms; Carrier Proteins; Cell Division; Dexamethasone; Dihydrotestosterone; Drug Interactions; Estradiol; Estrogen Antagonists; Female; Glycoproteins; Humans; Membrane Transport Proteins; Neoplasm Proteins; Piperidines; Raloxifene Hydrochloride; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured	1990
Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells. Breast cancer research and treatment, 1989, Volume: 14, Issue:1 Topics: Binding, Competitive; Breast Neoplasms; Cell Division; Dexamethasone; Dihydrotestosterone; Dose-Response Relationship, Drug; Drug Interactions; Estradiol; Estrogen Antagonists; Humans; Piperidines; Polyunsaturated Alkamides; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Time Factors; Tumor Cells, Cultured	1989
Inhibitory effect of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells. Molecular endocrinology (Baltimore, Md.), 1989, Volume: 3, Issue:4 Topics: Apolipoproteins; Apolipoproteins D; Blotting, Northern; Breast Neoplasms; Carrier Proteins; Cell Division; Dexamethasone; Dihydrotestosterone; DNA Probes; Estradiol; Estrogen Antagonists; Estrogens; Female; Gene Expression Regulation; Glycoproteins; Humans; Membrane Transport Proteins; Neoplasm Proteins; Piperidines; Raloxifene Hydrochloride; RNA, Messenger	1989
Adrenal C19-5-ene steroids induce full estrogenic responses in rat pituitary gonadotrophs. Journal of steroid biochemistry, 1987, Volume: 26, Issue:5 Topics: Androstenediol; Androstenediols; Animals; Breast Neoplasms; Cells, Cultured; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estradiol; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Piperidines; Pituitary Gland, Anterior; Raloxifene Hydrochloride; Rats; Rats, Inbred Strains; Receptors, Estrogen	1987
Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast cancer research and treatment, 1988, Volume: 12, Issue:2 Topics: Androgen Antagonists; Androstenedione; Breast Neoplasms; Cell Division; Cell Line; Dihydrotestosterone; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Flutamide; Humans; Piperidines; Raloxifene Hydrochloride; Receptors, Androgen; Receptors, Estrogen; Testosterone	1988
The lack of effect of phenol red or estradiol on the growth response of human, rat, and mouse mammary cells in primary culture. Endocrinology, 1988, Volume: 123, Issue:3 Topics: Animals; Breast; Breast Neoplasms; Cell Division; Cells, Cultured; Epidermal Growth Factor; Estradiol; Estrogen Antagonists; Female; Humans; Kinetics; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Phenolphthaleins; Phenolsulfonphthalein; Piperidines; Prolactin; Raloxifene Hydrochloride; Rats; Rats, Inbred Lew; Receptors, Progesterone; Species Specificity; Tumor Cells, Cultured	1988
Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology, 1988, Volume: 45, Issue:5 Topics: Breast Neoplasms; Drug Evaluation; Estrogen Antagonists; Female; Humans; Neoplasm Metastasis; Piperidines; Raloxifene Hydrochloride	1988
An estrogen-dependent esterase activity in MCF-7 cells. Journal of steroid biochemistry, 1987, Volume: 26, Issue:6 Topics: Breast Neoplasms; Cell Line; Esterases; Estradiol; Estrogens; Humans; Kinetics; Piperidines; Raloxifene Hydrochloride; Substrate Specificity	1987
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer research, 1985, Volume: 45, Issue:2 Topics: Animals; Breast Neoplasms; Castration; Cell Division; Cell Line; Estradiol; Estrogen Antagonists; Estrogens; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Piperidines; Progesterone; Raloxifene Hydrochloride; Tamoxifen	1985